




PHARMACEUTICAL 2023

Karyopharm Therapeutics Inc.
Rank 341 of 446





PHARMACEUTICAL 2023

Karyopharm Therapeutics Inc.
Rank 341 of 446




The relative strengths and weaknesses of Karyopharm Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 29% points. The greatest weakness of Karyopharm Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 152% points.

The company's Economic Capital Ratio, given in the ranking table, is -53%, being 96% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	350,162
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	65,908
Liabilities, Non-Current	6,097
Other Assets	6,871
Other Compr. Net Income	-829
Other Expenses	5,582
Other Liabilities	302,823
Other Net Income	-22,720
Other Revenues	157,074
Property and Equipment	1,139
Research and Development	148,662
Selling, General and Administrative Expense	145,401

Output Variable	Value in 1000 USD
Assets	358,172
Liabilities	374,828
Expenses	299,645
Revenues	157,074
Stockholders Equity	-16,656
Net Income	-165,291
Comprehensive Net Income	-165,706
Economic Capital Ratio	-53%





RealRate

PHARMACEUTICAL 2023

ELI LILLY & Co
Rank 249 of 446



The relative strengths and weaknesses of ELI LILLY & Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI LILLY & Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 85% points. The greatest weakness of ELI LILLY & Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is 57%, being 14% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	18,034,500
Cost of Goods Sold	6,629,800
Intangible Assets	11,279,600
Liabilities, Current	17,138,200
Liabilities, Non-Current	21,576,200
Other Assets	10,031,700
Other Compr. Net Income	498,500
Other Expenses	2,035,600
Other Liabilities	0
Other Net Income	0
Other Revenues	28,541,400
Property and Equipment	10,144,000
Research and Development	7,190,800
Selling, General and Administrative Expense	6,440,400


Output Variable	Value in 1000 USD
Assets	49,489,800
Liabilities	38,714,400
Expenses	22,296,600
Revenues	28,541,400
Stockholders Equity	10,775,400
Net Income	6,244,800
Comprehensive Net Income	6,494,050
Economic Capital Ratio	57%



RealRate

PHARMACEUTICAL 2023

CHEMBIO DIAGNOSTICS INC. Rank 287 of 446





RealRate

PHARMACEUTICAL 2023

CHEMBIO DIAGNOSTICS INC. Rank 287 of 446




The relative strengths and weaknesses of CHEMBIO DIAGNOSTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHEMBIO DIAGNOSTICS INC. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 70% points. The greatest weakness of CHEMBIO DIAGNOSTICS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is 14%, being 29% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	48,452
Cost of Goods Sold	38,578
Intangible Assets	0
Liabilities, Current	39,300
Liabilities, Non-Current	5,426
Other Assets	6,005
Other Compr. Net Income	255
Other Expenses	3,271
Other Liabilities	87
Other Net Income	-2,813
Other Revenues	52,716
Property and Equipment	8,155
Research and Development	7,068
Selling, General and Administrative Expense	24,278

Output Variable	Value in 1000 USD
Assets	62,611
Liabilities	44,813
Expenses	73,194
Revenues	52,716
Stockholders Equity	17,798
Net Income	-23,291
Comprehensive Net Income	-23,163
Economic Capital Ratio	14%



The relative strengths and weaknesses of Astria Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Astria Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Astria Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 274%, being 231% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	227,690
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,060
Liabilities, Non-Current	357
Other Assets	2,943
Other Compr. Net Income	-79
Other Expenses	0
Other Liabilities	0
Other Net Income	1,669
Other Revenues	0
Property and Equipment	0
Research and Development	34,264
Selling, General and Administrative Expense	19,239

Output Variable	Value in 1000 USD
Assets	230,633
Liabilities	9,417
Expenses	53,503
Revenues	0
Stockholders Equity	221,216
Net Income	-51,834
Comprehensive Net Income	-51,874
Economic Capital Ratio	274%



PHARMACEUTICAL 2023

Blueprint Medicines Corp
Rank 270 of 446





PHARMACEUTICAL 2023

Blueprint Medicines Corp
Rank 270 of 446




The relative strengths and weaknesses of Blueprint Medicines Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Blueprint Medicines Corp compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Blueprint Medicines Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is 30%, being 13% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,046,651
Cost of Goods Sold	17,813
Intangible Assets	0
Liabilities, Current	183,234
Liabilities, Non-Current	116,714
Other Assets	269,907
Other Compr. Net Income	-6,310
Other Expenses	14,184
Other Liabilities	535,277
Other Net Income	-14,763
Other Revenues	204,036
Property and Equipment	33,344
Research and Development	477,419
Selling, General and Administrative Expense	237,374

Output Variable	Value in 1000 USD
Assets	1,349,902
Liabilities	835,225
Expenses	746,790
Revenues	204,036
Stockholders Equity	514,677
Net Income	-557,517
Comprehensive Net Income	-560,672
Economic Capital Ratio	30%



**Greenwich LifeSciences Inc.
Rank 81 of 446**


The relative strengths and weaknesses of Greenwich LifeSciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Greenwich LifeSciences Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 1,199% points. The greatest weakness of Greenwich LifeSciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 217%, being 174% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	9.0
Liabilities, Current	263
Liabilities, Non-Current	0
Other Assets	13,468
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	215
Other Revenues	0
Property and Equipment	0
Research and Development	6,476
Selling, General and Administrative Expense	1,565

Output Variable	Value in 1000 USD
Assets	13,477
Liabilities	263
Expenses	8,040
Revenues	0
Stockholders Equity	13,214
Net Income	-7,825
Comprehensive Net Income	-7,825
Economic Capital Ratio	217%



The relative strengths and weaknesses of Janux Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Janux Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Janux Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 240%, being 196% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	332,439
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,507
Liabilities, Non-Current	26,763
Other Assets	24,485
Other Compr. Net Income	-1,265
Other Expenses	0
Other Liabilities	0
Other Net Income	4,032
Other Revenues	8,612
Property and Equipment	7,086
Research and Development	53,441
Selling, General and Administrative Expense	22,262

Output Variable	Value in 1000 USD
Assets	364,010
Liabilities	43,270
Expenses	75,703
Revenues	8,612
Stockholders Equity	320,740
Net Income	-63,059
Comprehensive Net Income	-63,692
Economic Capital Ratio	240%



PHARMACEUTICAL 2023

ProtoKinetix Inc.
Rank 439 of 446





PHARMACEUTICAL 2023

ProtoKinetix Inc.
Rank 439 of 446

The relative strengths and weaknesses of ProtoKinetix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ProtoKinetix Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 2,129% points. The greatest weakness of ProtoKinetix Inc. is the variable Net Income, reducing the Economic Capital Ratio by 542% points.

The company's Economic Capital Ratio, given in the ranking table, is -469%, being 512% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	27
Cost of Goods Sold	0
Intangible Assets	436
Liabilities, Current	42
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,296
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property and Equipment	0
Research and Development	449
Selling, General and Administrative Expense	163

Output Variable	Value in 1000 USD
Assets	463
Liabilities	42
Expenses	1,907
Revenues	0
Stockholders Equity	421
Net Income	-1,907
Comprehensive Net Income	-1,907
Economic Capital Ratio	-469%




RealRate

PHARMACEUTICAL 2023

ImmunoGen Inc.
Rank 283 of 446

immu·gen





PHARMACEUTICAL 2023

ImmunoGen Inc.
Rank 283 of 446




The relative strengths and weaknesses of ImmunoGen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ImmunoGen Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 17% points. The greatest weakness of ImmunoGen Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 17%, being 27% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	304,121
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	121,858
Liabilities, Non-Current	47,803
Other Assets	40,438
Other Compr. Net Income	0
Other Expenses	5,559
Other Liabilities	23,449
Other Net Income	3,347
Other Revenues	108,782
Property and Equipment	4,377
Research and Development	213,370
Selling, General and Administrative Expense	116,129

Output Variable	Value in 1000 USD
Assets	348,936
Liabilities	193,110
Expenses	335,058
Revenues	108,782
Stockholders Equity	155,826
Net Income	-222,929
Comprehensive Net Income	-222,929
Economic Capital Ratio	17%





PHARMACEUTICAL 2023

Goodness Growth Holdings Inc.
Rank 318 of 446




The relative strengths and weaknesses of Goodness Growth Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Goodness Growth Holdings Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 124% points. The greatest weakness of Goodness Growth Holdings Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is -23%, being 66% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	46,729
Cost of Goods Sold	39,424
Intangible Assets	8,961
Liabilities, Current	29,709
Liabilities, Non-Current	46,249
Other Assets	103,467
Other Compr. Net Income	0
Other Expenses	14,403
Other Liabilities	79,758
Other Net Income	-29,433
Other Revenues	74,626
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	33,824

Output Variable	Value in 1000 USD
Assets	159,156
Liabilities	155,716
Expenses	87,650
Revenues	74,626
Stockholders Equity	3,441
Net Income	-42,457
Comprehensive Net Income	-42,457
Economic Capital Ratio	-23%





PHARMACEUTICAL 2023

IMPEL PHARMACEUTICALS INC Rank 383 of 446



The relative strengths and weaknesses of IMPEL PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMPEL PHARMACEUTICALS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 34% points. The greatest weakness of IMPEL PHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is -165%, being 208% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	79,809
Cost of Goods Sold	6,495
Intangible Assets	0
Liabilities, Current	22,163
Liabilities, Non-Current	49,645
Other Assets	4,878
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	60,899
Other Net Income	-23,128
Other Revenues	12,652
Property and Equipment	3,863
Research and Development	11,456
Selling, General and Administrative Expense	77,885

Output Variable	Value in 1000 USD
Assets	88,550
Liabilities	132,707
Expenses	95,836
Revenues	12,652
Stockholders Equity	-44,157
Net Income	-106,312
Comprehensive Net Income	-106,312
Economic Capital Ratio	-165%



PHARMACEUTICAL 2023

Kintara Therapeutics Inc.
Rank 319 of 446





PHARMACEUTICAL 2023

Kintara Therapeutics Inc.
Rank 319 of 446


The relative strengths and weaknesses of Kintara Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kintara Therapeutics Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Kintara Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 130% points.

The company's Economic Capital Ratio, given in the ranking table, is -24%, being 67% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	13,258
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,990
Liabilities, Non-Current	0
Other Assets	2,600
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	163
Other Net Income	21
Other Revenues	0
Property and Equipment	90
Research and Development	15,173
Selling, General and Administrative Expense	7,509

Output Variable	Value in 1000 USD
Assets	15,948
Liabilities	4,153
Expenses	22,682
Revenues	0
Stockholders Equity	11,795
Net Income	-22,661
Comprehensive Net Income	-22,661
Economic Capital Ratio	-24%





PHARMACEUTICAL 2023

First Wave BioPharma Inc.
Rank 398 of 446

The relative strengths and weaknesses of First Wave BioPharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of First Wave BioPharma Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 217% points. The greatest weakness of First Wave BioPharma Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 231% points.

The company's Economic Capital Ratio, given in the ranking table, is -229%, being 272% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	3,413
Cost of Goods Sold	0
Intangible Assets	1,684
Liabilities, Current	2,483
Liabilities, Non-Current	214
Other Assets	299
Other Compr. Net Income	1,224
Other Expenses	-8,085
Other Liabilities	0
Other Net Income	-1,952
Other Revenues	0
Property and Equipment	44
Research and Development	8,776
Selling, General and Administrative Expense	11,987

Output Variable	Value in 1000 USD
Assets	5,440
Liabilities	2,698
Expenses	12,678
Revenues	0
Stockholders Equity	2,742
Net Income	-14,630
Comprehensive Net Income	-14,018
Economic Capital Ratio	-229%



PHARMACEUTICAL 2023

Rebus Holdings Inc.
Rank 426 of 446





PHARMACEUTICAL 2023

Rebus Holdings Inc.
Rank 426 of 446

The relative strengths and weaknesses of Rebus Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rebus Holdings Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 261% points. The greatest weakness of Rebus Holdings Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 206% points.

The company's Economic Capital Ratio, given in the ranking table, is -382%, being 425% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	5.0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,242
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-356
Other Revenues	0
Property and Equipment	0
Research and Development	239
Selling, General and Administrative Expense	425

Output Variable	Value in 1000 USD
Assets	5.0
Liabilities	5,242
Expenses	664
Revenues	0
Stockholders Equity	-5,237
Net Income	-1,020
Comprehensive Net Income	-1,020
Economic Capital Ratio	-382%



PHARMACEUTICAL 2023

Foghorn Therapeutics Inc.
Rank 325 of 446





PHARMACEUTICAL 2023

Foghorn Therapeutics Inc.
Rank 325 of 446




The relative strengths and weaknesses of Foghorn Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Foghorn Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Foghorn Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 198% points.

The company's Economic Capital Ratio, given in the ranking table, is -27%, being 70% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	351,399
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	55,205
Liabilities, Non-Current	349,566
Other Assets	53,484
Other Compr. Net Income	-3,976
Other Expenses	0
Other Liabilities	0
Other Net Income	8,255
Other Revenues	19,228
Property and Equipment	0
Research and Development	105,618
Selling, General and Administrative Expense	30,747

Output Variable	Value in 1000 USD
Assets	404,883
Liabilities	404,771
Expenses	136,365
Revenues	19,228
Stockholders Equity	112
Net Income	-108,882
Comprehensive Net Income	-110,870
Economic Capital Ratio	-27%





PHARMACEUTICAL 2023

ABVC BIOPHARMA INC.
Rank 372 of 446




The relative strengths and weaknesses of ABVC BIOPHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ABVC BIOPHARMA INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 186% points. The greatest weakness of ABVC BIOPHARMA INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 162% points.

The company's Economic Capital Ratio, given in the ranking table, is -131%, being 174% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,987
Cost of Goods Sold	286
Intangible Assets	0
Liabilities, Current	5,820
Liabilities, Non-Current	792
Other Assets	6,294
Other Compr. Net Income	-133
Other Expenses	7,835
Other Liabilities	8.0
Other Net Income	-400
Other Revenues	970
Property and Equipment	574
Research and Development	2,693
Selling, General and Administrative Expense	6,068

Output Variable	Value in 1000 USD
Assets	9,855
Liabilities	6,619
Expenses	16,882
Revenues	970
Stockholders Equity	3,236
Net Income	-16,312
Comprehensive Net Income	-16,379
Economic Capital Ratio	-131%



The relative strengths and weaknesses of ATOSSA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ATOSSA THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 75% points. The greatest weakness of ATOSSA THERAPEUTICS INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 273%, being 229% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	118,197
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,568
Liabilities, Non-Current	0
Other Assets	5,335
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	731
Other Revenues	0
Property and Equipment	0
Research and Development	15,083
Selling, General and Administrative Expense	12,608

Output Variable	Value in 1000 USD
Assets	123,532
Liabilities	5,568
Expenses	27,691
Revenues	0
Stockholders Equity	117,964
Net Income	-26,960
Comprehensive Net Income	-26,960
Economic Capital Ratio	273%



PHARMACEUTICAL 2023

Applied Therapeutics Inc.
Rank 394 of 446





PHARMACEUTICAL 2023

Applied Therapeutics Inc.
Rank 394 of 446


The relative strengths and weaknesses of Applied Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Applied Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 14% points. The greatest weakness of Applied Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is -208%, being 251% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	37,308
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	33,424
Liabilities, Non-Current	878
Other Assets	1,055
Other Compr. Net Income	158
Other Expenses	0
Other Liabilities	0
Other Net Income	442
Other Revenues	0
Property and Equipment	0
Research and Development	55,634
Selling, General and Administrative Expense	27,316

Output Variable	Value in 1000 USD
Assets	38,363
Liabilities	34,302
Expenses	82,950
Revenues	0
Stockholders Equity	4,061
Net Income	-82,508
Comprehensive Net Income	-82,429
Economic Capital Ratio	-208%





PHARMACEUTICAL 2023

Mersana Therapeutics Inc.
Rank 312 of 446




The relative strengths and weaknesses of Mersana Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mersana Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 29% points. The greatest weakness of Mersana Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 85% points.

The company's Economic Capital Ratio, given in the ranking table, is -16%, being 59% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	319,219
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	91,533
Liabilities, Non-Current	150,750
Other Assets	11,136
Other Compr. Net Income	-152
Other Expenses	0
Other Liabilities	0
Other Net Income	-445
Other Revenues	26,581
Property and Equipment	3,985
Research and Development	173,385
Selling, General and Administrative Expense	56,963

Output Variable	Value in 1000 USD
Assets	334,340
Liabilities	242,283
Expenses	230,348
Revenues	26,581
Stockholders Equity	92,057
Net Income	-204,212
Comprehensive Net Income	-204,288
Economic Capital Ratio	-16%





RealRate

PHARMACEUTICAL 2023

GALECTIN THERAPEUTICS INC Rank 403 of 446




The relative strengths and weaknesses of GALECTIN THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GALECTIN THERAPEUTICS INC compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 15% points. The greatest weakness of GALECTIN THERAPEUTICS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is -252%, being 295% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	20,552
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,012
Liabilities, Non-Current	66
Other Assets	733
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	40,401
Other Net Income	-424
Other Revenues	0
Property and Equipment	0
Research and Development	31,737
Selling, General and Administrative Expense	6,615

Output Variable	Value in 1000 USD
Assets	21,285
Liabilities	53,479
Expenses	38,352
Revenues	0
Stockholders Equity	-32,194
Net Income	-38,776
Comprehensive Net Income	-38,776
Economic Capital Ratio	-252%



The relative strengths and weaknesses of PARDES BIOSCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PARDES BIOSCIENCES INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 110% points. The greatest weakness of PARDES BIOSCIENCES INC. is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 193%, being 150% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	200,402
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,425
Liabilities, Non-Current	0
Other Assets	219
Other Compr. Net Income	-24
Other Expenses	0
Other Liabilities	0
Other Net Income	3,183
Other Revenues	0
Property and Equipment	0
Research and Development	70,350
Selling, General and Administrative Expense	29,467

Output Variable	Value in 1000 USD
Assets	200,621
Liabilities	20,425
Expenses	99,817
Revenues	0
Stockholders Equity	180,196
Net Income	-96,634
Comprehensive Net Income	-96,646
Economic Capital Ratio	193%



PHARMACEUTICAL 2023

BIOVIE INC.
Rank 364 of 446





PHARMACEUTICAL 2023

BIOVIE INC.
Rank 364 of 446


The relative strengths and weaknesses of BIOVIE INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOVIE INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 16% points. The greatest weakness of BIOVIE INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is -108%, being 151% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	18,780
Cost of Goods Sold	0
Intangible Assets	1,212
Liabilities, Current	4,169
Liabilities, Non-Current	136
Other Assets	123
Other Compr. Net Income	0
Other Expenses	-939
Other Liabilities	12,139
Other Net Income	0
Other Revenues	0
Property and Equipment	0
Research and Development	17,258
Selling, General and Administrative Expense	9,765

Output Variable	Value in 1000 USD
Assets	20,115
Liabilities	16,444
Expenses	26,084
Revenues	0
Stockholders Equity	3,671
Net Income	-26,084
Comprehensive Net Income	-26,084
Economic Capital Ratio	-108%






The relative strengths and weaknesses of CYTOKINETICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CYTOKINETICS INC compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 30% points. The greatest weakness of CYTOKINETICS INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 151% points.

The company's Economic Capital Ratio, given in the ranking table, is -54%, being 97% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	795,186
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	84,617
Liabilities, Non-Current	191,749
Other Assets	139,136
Other Compr. Net Income	-2,721
Other Expenses	51,156
Other Liabilities	846,309
Other Net Income	-13,597
Other Revenues	94,588
Property and Equipment	80,453
Research and Development	240,813
Selling, General and Administrative Expense	177,977

Output Variable	Value in 1000 USD
Assets	1,014,775
Liabilities	1,122,675
Expenses	469,946
Revenues	94,588
Stockholders Equity	-107,900
Net Income	-388,955
Comprehensive Net Income	-390,316
Economic Capital Ratio	-54%



The relative strengths and weaknesses of CorMedix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CorMedix Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 98% points. The greatest weakness of CorMedix Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 188%, being 145% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	59,551
Cost of Goods Sold	3.7
Intangible Assets	0
Liabilities, Current	6,311
Liabilities, Non-Current	668
Other Assets	877
Other Compr. Net Income	-4.4
Other Expenses	-586
Other Liabilities	0
Other Net Income	337
Other Revenues	65
Property and Equipment	1,610
Research and Development	10,680
Selling, General and Administrative Expense	20,006

Output Variable	Value in 1000 USD
Assets	62,038
Liabilities	6,979
Expenses	30,104
Revenues	65
Stockholders Equity	55,060
Net Income	-29,702
Comprehensive Net Income	-29,704
Economic Capital Ratio	188%



PHARMACEUTICAL 2023

Aeglea BioTherapeutics Inc.
Rank 296 of 446





RealRate

PHARMACEUTICAL 2023

Aeglea BioTherapeutics Inc.
Rank 296 of 446




The relative strengths and weaknesses of Aeglea BioTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.


The greatest strength of Aeglea BioTherapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Aeglea BioTherapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 93% points.

The company's Economic Capital Ratio, given in the ranking table, is 5.9%, being 37% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	62,258
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,656
Liabilities, Non-Current	4,004
Other Assets	5,666
Other Compr. Net Income	-28
Other Expenses	-136
Other Liabilities	2,179
Other Net Income	830
Other Revenues	2,329
Property and Equipment	3,220
Research and Development	58,579
Selling, General and Administrative Expense	28,531

Output Variable	Value in 1000 USD
Assets	71,144
Liabilities	20,839
Expenses	86,974
Revenues	2,329
Stockholders Equity	50,305
Net Income	-83,815
Comprehensive Net Income	-83,829
Economic Capital Ratio	5.9%





The relative strengths and weaknesses of Ainos Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ainos Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 413% points. The greatest weakness of Ainos Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 230%, being 186% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	2,846
Cost of Goods Sold	2,114
Intangible Assets	32,807
Liabilities, Current	2,473
Liabilities, Non-Current	8.1
Other Assets	81
Other Compr. Net Income	-207
Other Expenses	0
Other Liabilities	0
Other Net Income	-30
Other Revenues	3,520
Property and Equipment	1,376
Research and Development	6,846
Selling, General and Administrative Expense	8,536

Output Variable	Value in 1000 USD
Assets	37,109
Liabilities	2,481
Expenses	17,496
Revenues	3,520
Stockholders Equity	34,628
Net Income	-14,007
Comprehensive Net Income	-14,110
Economic Capital Ratio	230%



PHARMACEUTICAL 2023

Cell Source Inc.
Rank 430 of 446





PHARMACEUTICAL 2023

Cell Source Inc.
Rank 430 of 446

The relative strengths and weaknesses of Cell Source Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cell Source Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 344% points. The greatest weakness of Cell Source Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 234% points.

The company's Economic Capital Ratio, given in the ranking table, is -400%, being 443% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	680
Liabilities, Non-Current	0
Other Assets	410
Other Compr. Net Income	0
Other Expenses	58
Other Liabilities	12,363
Other Net Income	-992
Other Revenues	0
Property and Equipment	0
Research and Development	1,938
Selling, General and Administrative Expense	2,179


Output Variable	Value in 1000 USD
Assets	410
Liabilities	13,044
Expenses	4,175
Revenues	0
Stockholders Equity	-12,634
Net Income	-5,168
Comprehensive Net Income	-5,168
Economic Capital Ratio	-400%



RealRate

PHARMACEUTICAL 2023

INFINITY PHARMACEUTICALS INC. Rank 379 of 446





RealRate

PHARMACEUTICAL 2023

INFINITY PHARMACEUTICALS INC. Rank 379 of 446



The relative strengths and weaknesses of INFINITY PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INFINITY PHARMACEUTICALS INC. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 10% points. The greatest weakness of INFINITY PHARMACEUTICALS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is -149%, being 192% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	40,302
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,628
Liabilities, Non-Current	361
Other Assets	1,049
Other Compr. Net Income	0
Other Expenses	1,563
Other Liabilities	47,213
Other Net Income	475
Other Revenues	2,593
Property and Equipment	800
Research and Development	32,411
Selling, General and Administrative Expense	13,463

Output Variable	Value in 1000 USD
Assets	42,151
Liabilities	61,202
Expenses	47,437
Revenues	2,593
Stockholders Equity	-19,051
Net Income	-44,369
Comprehensive Net Income	-44,369
Economic Capital Ratio	-149%



PHARMACEUTICAL 2023

INTERCEPT PHARMACEUTICALS INC. Rank 231 of 446





PHARMACEUTICAL 2023

INTERCEPT PHARMACEUTICALS INC. Rank 231 of 446



The relative strengths and weaknesses of INTERCEPT PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTERCEPT PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 130% points. The greatest weakness of INTERCEPT PHARMACEUTICALS INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is 75%, being 32% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	540,127
Cost of Goods Sold	984
Intangible Assets	0
Liabilities, Current	230,077
Liabilities, Non-Current	230,557
Other Assets	12,597
Other Compr. Net Income	-5,383
Other Expenses	0
Other Liabilities	0
Other Net Income	290,032
Other Revenues	285,710
Property and Equipment	987
Research and Development	176,639
Selling, General and Administrative Expense	176,303

Output Variable	Value in 1000 USD
Assets	553,711
Liabilities	460,634
Expenses	353,926
Revenues	285,710
Stockholders Equity	93,077
Net Income	221,816
Comprehensive Net Income	219,124
Economic Capital Ratio	75%



PHARMACEUTICAL 2023

ENDONOVO THERAPEUTICS INC.
Rank 435 of 446





RealRate

PHARMACEUTICAL 2023

ENDONOVO THERAPEUTICS INC. Rank 435 of 446


The relative strengths and weaknesses of ENDONOVO THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENDONOVO THERAPEUTICS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 318% points. The greatest weakness of ENDONOVO THERAPEUTICS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 260% points.

The company's Economic Capital Ratio, given in the ranking table, is -425%, being 468% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	16
Cost of Goods Sold	10.0
Intangible Assets	1,265
Liabilities, Current	33,382
Liabilities, Non-Current	80
Other Assets	0
Other Compr. Net Income	0
Other Expenses	3,390
Other Liabilities	0
Other Net Income	-15,210
Other Revenues	135
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	1,281
Liabilities	33,462
Expenses	3,400
Revenues	135
Stockholders Equity	-32,180
Net Income	-18,475
Comprehensive Net Income	-18,475
Economic Capital Ratio	-425%





PHARMACEUTICAL 2023

OPKO HEALTH INC.
Rank 133 of 446



The relative strengths and weaknesses of OPKO HEALTH INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OPKO HEALTH INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 147% points. The greatest weakness of OPKO HEALTH INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is 170%, being 126% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	394,525
Cost of Goods Sold	0
Intangible Assets	1,419,371
Liabilities, Current	213,480
Liabilities, Non-Current	392,131
Other Assets	353,363
Other Compr. Net Income	-13,211
Other Expenses	720,391
Other Liabilities	0
Other Net Income	-165,268
Other Revenues	1,004,196
Property and Equipment	0
Research and Development	73,887
Selling, General and Administrative Expense	372,672

Output Variable	Value in 1000 USD
Assets	2,167,259
Liabilities	605,611
Expenses	1,166,950
Revenues	1,004,196
Stockholders Equity	1,561,648
Net Income	-328,022
Comprehensive Net Income	-334,628
Economic Capital Ratio	170%




RealRate

PHARMACEUTICAL 2023

uniQure N.V.
Rank 160 of 446

uniQure





PHARMACEUTICAL 2023

uniQure N.V.
Rank 160 of 446

uniQure

The relative strengths and weaknesses of uniQure N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of uniQure N.V. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 39% points. The greatest weakness of uniQure N.V. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 145%, being 102% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	476,774
Cost of Goods Sold	1,254
Intangible Assets	84,359
Liabilities, Current	75,919
Liabilities, Non-Current	153,036
Other Assets	93,299
Other Compr. Net Income	-29,435
Other Expenses	13,143
Other Liabilities	0
Other Net Income	26,604
Other Revenues	113,654
Property and Equipment	50,532
Research and Development	197,591
Selling, General and Administrative Expense	55,059


Output Variable	Value in 1000 USD
Assets	704,964
Liabilities	228,955
Expenses	267,047
Revenues	113,654
Stockholders Equity	476,009
Net Income	-126,789
Comprehensive Net Income	-141,506
Economic Capital Ratio	145%



RealRate

PHARMACEUTICAL 2023

Emmaus Life Sciences Inc.
Rank 363 of 446





RealRate

PHARMACEUTICAL 2023

Emmaus Life Sciences Inc.
Rank 363 of 446




The relative strengths and weaknesses of Emmaus Life Sciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Emmaus Life Sciences Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 155% points. The greatest weakness of Emmaus Life Sciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is -108%, being 151% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	6,289
Cost of Goods Sold	2,588
Intangible Assets	0
Liabilities, Current	54,323
Liabilities, Non-Current	24,267
Other Assets	41,861
Other Compr. Net Income	-2,364
Other Expenses	7,553
Other Liabilities	3,726
Other Net Income	-3,979
Other Revenues	18,390
Property and Equipment	75
Research and Development	1,725
Selling, General and Administrative Expense	13,170

Output Variable	Value in 1000 USD
Assets	48,225
Liabilities	82,316
Expenses	25,036
Revenues	18,390
Stockholders Equity	-34,091
Net Income	-10,625
Comprehensive Net Income	-11,807
Economic Capital Ratio	-108%





PHARMACEUTICAL 2023

TFF Pharmaceuticals Inc.
Rank 246 of 446




The relative strengths and weaknesses of TFF Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of TFF Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 67% points. The greatest weakness of TFF Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 148% points.

The company's Economic Capital Ratio, given in the ranking table, is 60%, being 17% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	19,025
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,131
Liabilities, Non-Current	110
Other Assets	2,017
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	27
Other Revenues	496
Property and Equipment	3,078
Research and Development	18,496
Selling, General and Administrative Expense	13,796

Output Variable	Value in 1000 USD
Assets	24,120
Liabilities	1,241
Expenses	32,293
Revenues	496
Stockholders Equity	22,879
Net Income	-31,770
Comprehensive Net Income	-31,770
Economic Capital Ratio	60%





PHARMACEUTICAL 2023

G1 Therapeutics Inc.
Rank 313 of 446



The relative strengths and weaknesses of G1 Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of G1 Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 23% points. The greatest weakness of G1 Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is -19%, being 62% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	179,500
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	35,588
Liabilities, Non-Current	5,615
Other Assets	6,476
Other Compr. Net Income	0
Other Expenses	5,448
Other Liabilities	78,015
Other Net Income	-9,681
Other Revenues	51,301
Property and Equipment	1,989
Research and Development	83,316
Selling, General and Administrative Expense	100,415


Output Variable	Value in 1000 USD
Assets	187,965
Liabilities	119,218
Expenses	189,179
Revenues	51,301
Stockholders Equity	68,747
Net Income	-147,559
Comprehensive Net Income	-147,559
Economic Capital Ratio	-19%



RealRate

PHARMACEUTICAL 2023

Sonnet BioTherapeutics Holdings Inc.
Rank 441 of 446





RealRate

PHARMACEUTICAL 2023

Sonnet BioTherapeutics Holdings Inc. Rank 441 of 446




The relative strengths and weaknesses of Sonnet BioTherapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet BioTherapeutics Holdings Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 43% points. The greatest weakness of Sonnet BioTherapeutics Holdings Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 328% points.

The company's Economic Capital Ratio, given in the ranking table, is -480%, being 523% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	5,414
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,165
Liabilities, Non-Current	204
Other Assets	370
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-52
Other Revenues	350
Property and Equipment	46
Research and Development	21,444
Selling, General and Administrative Expense	8,575

Output Variable	Value in 1000 USD
Assets	5,830
Liabilities	8,369
Expenses	30,019
Revenues	350
Stockholders Equity	-2,539
Net Income	-29,722
Comprehensive Net Income	-29,722
Economic Capital Ratio	-480%





RealRate

PHARMACEUTICAL 2023

Ensysce Biosciences Inc. Rank 428 of 446



The relative strengths and weaknesses of Ensysce Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ensysce Biosciences Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 21% points. The greatest weakness of Ensysce Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 280% points.

The company's Economic Capital Ratio, given in the ranking table, is -394%, being 437% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	5,299
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,464
Liabilities, Non-Current	450
Other Assets	586
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	14
Other Revenues	2,523
Property and Equipment	0
Research and Development	19,836
Selling, General and Administrative Expense	6,910

Output Variable	Value in 1000 USD
Assets	5,885
Liabilities	9,915
Expenses	26,745
Revenues	2,523
Stockholders Equity	-4,030
Net Income	-24,208
Comprehensive Net Income	-24,208
Economic Capital Ratio	-394%



PHARMACEUTICAL 2023

Verrica Pharmaceuticals Inc.
Rank 118 of 446





PHARMACEUTICAL 2023

Verrica Pharmaceuticals Inc.
Rank 118 of 446




The relative strengths and weaknesses of Verrica Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verrica Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 59% points. The greatest weakness of Verrica Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 180%, being 137% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	39,115
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,459
Liabilities, Non-Current	1,229
Other Assets	1,719
Other Compr. Net Income	29
Other Expenses	725
Other Liabilities	0
Other Net Income	-3,191
Other Revenues	9,032
Property and Equipment	3,887
Research and Development	12,198
Selling, General and Administrative Expense	17,405

Output Variable	Value in 1000 USD
Assets	44,721
Liabilities	4,688
Expenses	30,328
Revenues	9,032
Stockholders Equity	40,033
Net Income	-24,487
Comprehensive Net Income	-24,472
Economic Capital Ratio	180%




The relative strengths and weaknesses of Kinnate Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kinnate Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Kinnate Biopharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 219%, being 176% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	230,837
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,167
Liabilities, Non-Current	3,191
Other Assets	44,918
Other Compr. Net Income	-886
Other Expenses	0
Other Liabilities	0
Other Net Income	2,250
Other Revenues	0
Property and Equipment	3,071
Research and Development	88,150
Selling, General and Administrative Expense	30,371

Output Variable	Value in 1000 USD
Assets	278,826
Liabilities	20,358
Expenses	118,521
Revenues	0
Stockholders Equity	258,468
Net Income	-116,271
Comprehensive Net Income	-116,714
Economic Capital Ratio	219%



The relative strengths and weaknesses of Viking Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viking Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 110% points. The greatest weakness of Viking Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 189%, being 145% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	167,040
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,947
Liabilities, Non-Current	1,260
Other Assets	1,489
Other Compr. Net Income	-553
Other Expenses	0
Other Liabilities	0
Other Net Income	1,488
Other Revenues	0
Property and Equipment	0
Research and Development	54,234
Selling, General and Administrative Expense	16,121

Output Variable	Value in 1000 USD
Assets	168,529
Liabilities	23,207
Expenses	70,355
Revenues	0
Stockholders Equity	145,322
Net Income	-68,867
Comprehensive Net Income	-69,144
Economic Capital Ratio	189%



PHARMACEUTICAL 2023

Seres Therapeutics Inc.
Rank 350 of 446





PHARMACEUTICAL 2023

Seres Therapeutics Inc.
Rank 350 of 446



The relative strengths and weaknesses of Seres Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Seres Therapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 59% points. The greatest weakness of Seres Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is -67%, being 111% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	194,764
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	85,596
Liabilities, Non-Current	109,384
Other Assets	131,035
Other Compr. Net Income	48
Other Expenses	1,004
Other Liabilities	143,021
Other Net Income	-3,667
Other Revenues	7,128
Property and Equipment	22,985
Research and Development	172,920
Selling, General and Administrative Expense	79,694

Output Variable	Value in 1000 USD
Assets	348,784
Liabilities	338,001
Expenses	253,618
Revenues	7,128
Stockholders Equity	10,783
Net Income	-250,157
Comprehensive Net Income	-250,133
Economic Capital Ratio	-67%



PHARMACEUTICAL 2023

RHYTHM PHARMACEUTICALS INC. Rank 196 of 446





RealRate

PHARMACEUTICAL 2023

RHYTHM PHARMACEUTICALS INC. Rank 196 of 446



The relative strengths and weaknesses of RHYTHM PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RHYTHM PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 68% points. The greatest weakness of RHYTHM PHARMACEUTICALS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 109%, being 66% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	354,236
Cost of Goods Sold	2,133
Intangible Assets	7,883
Liabilities, Current	39,809
Liabilities, Non-Current	1,260
Other Assets	18,165
Other Compr. Net Income	-91
Other Expenses	0
Other Liabilities	77,150
Other Net Income	-1,962
Other Revenues	23,638
Property and Equipment	2,197
Research and Development	108,630
Selling, General and Administrative Expense	92,032

Output Variable	Value in 1000 USD
Assets	382,481
Liabilities	118,219
Expenses	202,795
Revenues	23,638
Stockholders Equity	264,262
Net Income	-181,119
Comprehensive Net Income	-181,164
Economic Capital Ratio	109%



PHARMACEUTICAL 2023

NATURES SUNSHINE PRODUCTS
INC
Rank 142 of 446





PHARMACEUTICAL 2023

NATURES SUNSHINE PRODUCTS INC Rank 142 of 446




The relative strengths and weaknesses of NATURES SUNSHINE PRODUCTS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NATURES SUNSHINE PRODUCTS INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 223% points. The greatest weakness of NATURES SUNSHINE PRODUCTS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 161%, being 118% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	149,507
Cost of Goods Sold	122,150
Intangible Assets	0
Liabilities, Current	65,582
Liabilities, Non-Current	14,799
Other Assets	34,109
Other Compr. Net Income	-4,048
Other Expenses	145,042
Other Liabilities	2,350
Other Net Income	-1,043
Other Revenues	421,910
Property and Equipment	46,162
Research and Development	0
Selling, General and Administrative Expense	153,125

Output Variable	Value in 1000 USD
Assets	229,778
Liabilities	82,731
Expenses	420,317
Revenues	421,910
Stockholders Equity	147,047
Net Income	550
Comprehensive Net Income	-1,474
Economic Capital Ratio	161%





RealRate

PHARMACEUTICAL 2023

AMARIN CORP PLC\UK Rank 148 of 446




The relative strengths and weaknesses of AMARIN CORP PLC\UK are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AMARIN CORP PLC\UK compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 59% points. The greatest weakness of AMARIN CORP PLC\UK is the variable Liabilities, Current, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 156%, being 113% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	689,098
Cost of Goods Sold	0
Intangible Assets	21,780
Liabilities, Current	259,479
Liabilities, Non-Current	31,367
Other Assets	174,427
Other Compr. Net Income	0
Other Expenses	142,248
Other Liabilities	0
Other Net Income	2,079
Other Revenues	369,193
Property and Equipment	874
Research and Development	30,411
Selling, General and Administrative Expense	304,416

Output Variable	Value in 1000 USD
Assets	886,179
Liabilities	290,846
Expenses	477,075
Revenues	369,193
Stockholders Equity	595,333
Net Income	-105,803
Comprehensive Net Income	-105,803
Economic Capital Ratio	156%



The relative strengths and weaknesses of AGIOS PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGIOS PHARMACEUTICALS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 56% points. The greatest weakness of AGIOS PHARMACEUTICALS INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 241%, being 197% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	832,772
Cost of Goods Sold	1,704
Intangible Assets	0
Liabilities, Current	62,629
Liabilities, Non-Current	75,275
Other Assets	382,959
Other Compr. Net Income	-11,337
Other Expenses	0
Other Liabilities	0
Other Net Income	157,246
Other Revenues	14,240
Property and Equipment	22,987
Research and Development	279,910
Selling, General and Administrative Expense	121,673

Output Variable	Value in 1000 USD
Assets	1,238,718
Liabilities	137,904
Expenses	403,287
Revenues	14,240
Stockholders Equity	1,100,814
Net Income	-231,801
Comprehensive Net Income	-237,470
Economic Capital Ratio	241%



PHARMACEUTICAL 2023

PROVECTUS
BIOPHARMACEUTICALS INC.
Rank 408 of 446





PHARMACEUTICAL 2023

PROVECTUS BIOPHARMACEUTICALS INC. Rank 408 of 446

The relative strengths and weaknesses of PROVECTUS BIOPHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PROVECTUS BIOPHARMACEUTICALS INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 9.7% points. The greatest weakness of PROVECTUS BIOPHARMACEUTICALS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 152% points.

The company's Economic Capital Ratio, given in the ranking table, is -277%, being 320% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	1,899
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,192
Liabilities, Non-Current	73
Other Assets	117
Other Compr. Net Income	-1.2
Other Expenses	0
Other Liabilities	0
Other Net Income	-127
Other Revenues	989
Property and Equipment	21
Research and Development	2,389
Selling, General and Administrative Expense	2,028

Output Variable	Value in 1000 USD
Assets	2,037
Liabilities	8,266
Expenses	4,417
Revenues	989
Stockholders Equity	-6,229
Net Income	-3,555
Comprehensive Net Income	-3,555
Economic Capital Ratio	-277%



PHARMACEUTICAL 2023

Tharimmune Inc.
Rank 275 of 446





PHARMACEUTICAL 2023

Tharimmune Inc.
Rank 275 of 446

The relative strengths and weaknesses of Tharimmune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tharimmune Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Tharimmune Inc. is the variable Net Income, reducing the Economic Capital Ratio by 123% points.

The company's Economic Capital Ratio, given in the ranking table, is 27%, being 16% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	6,689
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,145
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,591
Other Revenues	0
Property and Equipment	0
Research and Development	2,278
Selling, General and Administrative Expense	4,604

Output Variable	Value in 1000 USD
Assets	6,689
Liabilities	1,145
Expenses	6,882
Revenues	0
Stockholders Equity	5,544
Net Income	-8,473
Comprehensive Net Income	-8,473
Economic Capital Ratio	27%



PHARMACEUTICAL 2023

LIFECORE BIOMEDICAL INC. \DE\
Rank 262 of 446





RealRate

PHARMACEUTICAL 2023

LIFECORE BIOMEDICAL INC. \DE\ Rank 262 of 446

LANDEC


The relative strengths and weaknesses of LIFECORE BIOMEDICAL INC. \DE\ are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIFECORE BIOMEDICAL INC. \DE\ compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 95% points. The greatest weakness of LIFECORE BIOMEDICAL INC. \DE\ is the variable Assets, Current, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is 37%, being 6.4% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	123,712
Cost of Goods Sold	135,416
Intangible Assets	13,881
Liabilities, Current	79,231
Liabilities, Non-Current	97,769
Other Assets	27,132
Other Compr. Net Income	772
Other Expenses	49,214
Other Liabilities	10,215
Other Net Income	-50,433
Other Revenues	191,600
Property and Equipment	130,435
Research and Development	7,841
Selling, General and Administrative Expense	46,127

Output Variable	Value in 1000 USD
Assets	295,160
Liabilities	187,215
Expenses	238,598
Revenues	191,600
Stockholders Equity	107,945
Net Income	-97,431
Comprehensive Net Income	-97,045
Economic Capital Ratio	37%





PHARMACEUTICAL 2023

Vistagen Therapeutics Inc.
Rank 155 of 446




The relative strengths and weaknesses of Vistagen Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vistagen Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 88% points. The greatest weakness of Vistagen Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 150%, being 107% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	70,998
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,765
Liabilities, Non-Current	4,163
Other Assets	3,231
Other Compr. Net Income	0
Other Expenses	3.4
Other Liabilities	0
Other Net Income	20
Other Revenues	1,109
Property and Equipment	414
Research and Development	35,408
Selling, General and Administrative Expense	13,480

Output Variable	Value in 1000 USD
Assets	74,643
Liabilities	9,928
Expenses	48,891
Revenues	1,109
Stockholders Equity	64,715
Net Income	-47,762
Comprehensive Net Income	-47,762
Economic Capital Ratio	150%



The relative strengths and weaknesses of Moleculin Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moleculin Biotech Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Moleculin Biotech Inc. is the variable Net Income, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 193%, being 150% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	45,596
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,819
Liabilities, Non-Current	335
Other Assets	11,551
Other Compr. Net Income	-29
Other Expenses	-1,075
Other Liabilities	77
Other Net Income	280
Other Revenues	0
Property and Equipment	275
Research and Development	18,968
Selling, General and Administrative Expense	11,542

Output Variable	Value in 1000 USD
Assets	57,422
Liabilities	5,231
Expenses	29,435
Revenues	0
Stockholders Equity	52,191
Net Income	-29,155
Comprehensive Net Income	-29,170
Economic Capital Ratio	193%



PHARMACEUTICAL 2023

Evolus Inc.
Rank 322 of 446





RealRate

PHARMACEUTICAL 2023

Evolus Inc.
Rank 322 of 446




The relative strengths and weaknesses of Evolus Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evolus Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Evolus Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is -25%, being 68% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	100,802
Cost of Goods Sold	55,887
Intangible Assets	69,805
Liabilities, Current	46,509
Liabilities, Non-Current	1,224
Other Assets	4,760
Other Compr. Net Income	-337
Other Expenses	20,669
Other Liabilities	111,751
Other Net Income	110
Other Revenues	148,616
Property and Equipment	2,616
Research and Development	4,742
Selling, General and Administrative Expense	141,840

Output Variable	Value in 1000 USD
Assets	177,983
Liabilities	159,484
Expenses	223,138
Revenues	148,616
Stockholders Equity	18,499
Net Income	-74,412
Comprehensive Net Income	-74,580
Economic Capital Ratio	-25%



The relative strengths and weaknesses of Aadi Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aadi Bioscience Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Aadi Bioscience Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 7.0% points.

The company's Economic Capital Ratio, given in the ranking table, is 202%, being 159% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	180,029
Cost of Goods Sold	1,335
Intangible Assets	0
Liabilities, Current	18,835
Liabilities, Non-Current	1,267
Other Assets	3,700
Other Compr. Net Income	-115
Other Expenses	3,724
Other Liabilities	5,757
Other Net Income	2,168
Other Revenues	15,216
Property and Equipment	508
Research and Development	32,662
Selling, General and Administrative Expense	40,176

Output Variable	Value in 1000 USD
Assets	184,237
Liabilities	25,859
Expenses	77,897
Revenues	15,216
Stockholders Equity	158,378
Net Income	-60,513
Comprehensive Net Income	-60,570
Economic Capital Ratio	202%



PHARMACEUTICAL 2023

Praxis Precision Medicines Inc.
Rank 362 of 446





RealRate

PHARMACEUTICAL 2023

Praxis Precision Medicines Inc.
Rank 362 of 446



The relative strengths and weaknesses of Praxis Precision Medicines Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Praxis Precision Medicines Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 22% points. The greatest weakness of Praxis Precision Medicines Inc. is the variable Net Income, reducing the Economic Capital Ratio by 170% points.

The company's Economic Capital Ratio, given in the ranking table, is -108%, being 151% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	110,840
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	34,345
Liabilities, Non-Current	4,677
Other Assets	3,317
Other Compr. Net Income	3.0
Other Expenses	0
Other Liabilities	0
Other Net Income	957
Other Revenues	0
Property and Equipment	971
Research and Development	155,040
Selling, General and Administrative Expense	59,946

Output Variable	Value in 1000 USD
Assets	115,128
Liabilities	39,022
Expenses	214,986
Revenues	0
Stockholders Equity	76,106
Net Income	-214,029
Comprehensive Net Income	-214,028
Economic Capital Ratio	-108%



PHARMACEUTICAL 2023

Nkarta Inc.
Rank 116 of 446





PHARMACEUTICAL 2023

Nkarta Inc.
Rank 116 of 446


The relative strengths and weaknesses of Nkarta Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nkarta Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Nkarta Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 183%, being 140% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	360,688
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,046
Liabilities, Non-Current	78,685
Other Assets	50,342
Other Compr. Net Income	-529
Other Expenses	0
Other Liabilities	0
Other Net Income	5,118
Other Revenues	0
Property and Equipment	61,908
Research and Development	90,897
Selling, General and Administrative Expense	28,058

Output Variable	Value in 1000 USD
Assets	472,938
Liabilities	100,731
Expenses	118,955
Revenues	0
Stockholders Equity	372,207
Net Income	-113,837
Comprehensive Net Income	-114,102
Economic Capital Ratio	183%





RealRate

PHARMACEUTICAL 2023

UroGen Pharma Ltd.
Rank 378 of 446




The relative strengths and weaknesses of UroGen Pharma Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UroGen Pharma Ltd. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 20% points. The greatest weakness of UroGen Pharma Ltd. is the variable Assets, Current, reducing the Economic Capital Ratio by 80% points.

The company's Economic Capital Ratio, given in the ranking table, is -146%, being 189% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	128,907
Cost of Goods Sold	7,654
Intangible Assets	0
Liabilities, Current	23,916
Liabilities, Non-Current	99,123
Other Assets	5,415
Other Compr. Net Income	-82
Other Expenses	31,752
Other Liabilities	101,941
Other Net Income	0
Other Revenues	65,367
Property and Equipment	1,297
Research and Development	52,906
Selling, General and Administrative Expense	82,838

Output Variable	Value in 1000 USD
Assets	135,619
Liabilities	224,980
Expenses	175,150
Revenues	65,367
Stockholders Equity	-89,361
Net Income	-109,783
Comprehensive Net Income	-109,824
Economic Capital Ratio	-146%





RealRate

PHARMACEUTICAL 2023

MUSTANG BIO INC. Rank 298 of 446




The relative strengths and weaknesses of MUSTANG BIO INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MUSTANG BIO INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 19% points. The greatest weakness of MUSTANG BIO INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 3.0%, being 40% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	78,852
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,109
Liabilities, Non-Current	3,334
Other Assets	13,570
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	27,706
Other Net Income	-1,366
Other Revenues	0
Property and Equipment	0
Research and Development	63,949
Selling, General and Administrative Expense	12,210

Output Variable	Value in 1000 USD
Assets	92,422
Liabilities	46,149
Expenses	76,159
Revenues	0
Stockholders Equity	46,273
Net Income	-77,525
Comprehensive Net Income	-77,525
Economic Capital Ratio	3.0%





PHARMACEUTICAL 2023

HARROW INC.
Rank 278 of 446




The relative strengths and weaknesses of HARROW INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HARROW INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 65% points. The greatest weakness of HARROW INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 151% points.

The company's Economic Capital Ratio, given in the ranking table, is 23%, being 20% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	118,260
Cost of Goods Sold	25,383
Intangible Assets	24,057
Liabilities, Current	18,632
Liabilities, Non-Current	7,332
Other Assets	11,575
Other Compr. Net Income	0
Other Expenses	75
Other Liabilities	104,174
Other Net Income	-15,930
Other Revenues	88,595
Property and Equipment	3,486
Research and Development	3,050
Selling, General and Administrative Expense	58,243

Output Variable	Value in 1000 USD
Assets	157,378
Liabilities	130,138
Expenses	86,751
Revenues	88,595
Stockholders Equity	27,240
Net Income	-14,086
Comprehensive Net Income	-14,086
Economic Capital Ratio	23%




The relative strengths and weaknesses of XBiotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XBiotech Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 63% points. The greatest weakness of XBiotech Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 302%, being 259% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	219,843
Cost of Goods Sold	651
Intangible Assets	0
Liabilities, Current	4,066
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-1,145
Other Expenses	-688
Other Liabilities	1,635
Other Net Income	902
Other Revenues	4,010
Property and Equipment	26,260
Research and Development	31,544
Selling, General and Administrative Expense	6,305

Output Variable	Value in 1000 USD
Assets	246,103
Liabilities	5,701
Expenses	37,812
Revenues	4,010
Stockholders Equity	240,402
Net Income	-32,900
Comprehensive Net Income	-33,472
Economic Capital Ratio	302%



The relative strengths and weaknesses of Reneo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Reneo Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Reneo Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 206%, being 163% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	106,353
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,124
Liabilities, Non-Current	1,059
Other Assets	1,376
Other Compr. Net Income	-77
Other Expenses	0
Other Liabilities	29
Other Net Income	1,893
Other Revenues	0
Property and Equipment	453
Research and Development	37,705
Selling, General and Administrative Expense	16,143


Output Variable	Value in 1000 USD
Assets	108,182
Liabilities	8,212
Expenses	53,848
Revenues	0
Stockholders Equity	99,970
Net Income	-51,955
Comprehensive Net Income	-51,994
Economic Capital Ratio	206%



RealRate

PHARMACEUTICAL 2023

9 METERS BIOPHARMA INC. Rank 370 of 446





RealRate

PHARMACEUTICAL 2023

9 METERS BIOPHARMA INC. Rank 370 of 446



The relative strengths and weaknesses of 9 METERS BIOPHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of 9 METERS BIOPHARMA INC. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 15% points. The greatest weakness of 9 METERS BIOPHARMA INC. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is -124%, being 167% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	33,018
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	30,696
Liabilities, Non-Current	51
Other Assets	120
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,749
Other Revenues	0
Property and Equipment	10
Research and Development	31,008
Selling, General and Administrative Expense	11,009


Output Variable	Value in 1000 USD
Assets	33,148
Liabilities	30,747
Expenses	42,017
Revenues	0
Stockholders Equity	2,401
Net Income	-43,766
Comprehensive Net Income	-43,766
Economic Capital Ratio	-124%



RealRate

PHARMACEUTICAL 2023

CHINA PHARMA HOLDINGS INC. Rank 280 of 446





RealRate

PHARMACEUTICAL 2023

CHINA PHARMA HOLDINGS INC. Rank 280 of 446




The relative strengths and weaknesses of CHINA PHARMA HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHINA PHARMA HOLDINGS INC. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 133% points. The greatest weakness of CHINA PHARMA HOLDINGS INC. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is 19%, being 25% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	5,965
Cost of Goods Sold	8,598
Intangible Assets	1,807
Liabilities, Current	12,739
Liabilities, Non-Current	0
Other Assets	39
Other Compr. Net Income	-991
Other Expenses	976
Other Liabilities	755
Other Net Income	-424
Other Revenues	8,104
Property and Equipment	9,973
Research and Development	186
Selling, General and Administrative Expense	1,893

Output Variable	Value in 1000 USD
Assets	17,784
Liabilities	13,494
Expenses	11,653
Revenues	8,104
Stockholders Equity	4,290
Net Income	-3,973
Comprehensive Net Income	-4,468
Economic Capital Ratio	19%





RealRate

PHARMACEUTICAL 2023

Hepion Pharmaceuticals Inc. Rank 181 of 446



The relative strengths and weaknesses of Hepion Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hepion Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Hepion Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 123%, being 80% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	56,496
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,886
Liabilities, Non-Current	0
Other Assets	3,667
Other Compr. Net Income	-90
Other Expenses	-1,003
Other Liabilities	2,503
Other Net Income	415
Other Revenues	0
Property and Equipment	82
Research and Development	33,269
Selling, General and Administrative Expense	10,348

Output Variable	Value in 1000 USD
Assets	60,244
Liabilities	10,389
Expenses	42,615
Revenues	0
Stockholders Equity	49,856
Net Income	-42,200
Comprehensive Net Income	-42,245
Economic Capital Ratio	123%



PHARMACEUTICAL 2023

REGENEREX PHARMA INC.
Rank 424 of 446





PHARMACEUTICAL 2023

REGENEREX PHARMA INC. Rank 424 of 446


The relative strengths and weaknesses of REGENEREX PHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENEREX PHARMA INC. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 45% points. The greatest weakness of REGENEREX PHARMA INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 199% points.

The company's Economic Capital Ratio, given in the ranking table, is -371%, being 414% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	7.9
Cost of Goods Sold	0
Intangible Assets	7.4
Liabilities, Current	660
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	340
Other Net Income	-64
Other Revenues	0
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	126

Output Variable	Value in 1000 USD
Assets	15
Liabilities	1,001
Expenses	126
Revenues	0
Stockholders Equity	-986
Net Income	-190
Comprehensive Net Income	-190
Economic Capital Ratio	-371%





PHARMACEUTICAL 2023

ALIMERA SCIENCES INC Rank 332 of 446




The relative strengths and weaknesses of ALIMERA SCIENCES INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALIMERA SCIENCES INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 99% points. The greatest weakness of ALIMERA SCIENCES INC is the variable Assets, Current, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is -33%, being 76% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	29,413
Cost of Goods Sold	0
Intangible Assets	8,957
Liabilities, Current	39,732
Liabilities, Non-Current	0
Other Assets	1,707
Other Compr. Net Income	-1,106
Other Expenses	42,579
Other Liabilities	0
Other Net Income	-558
Other Revenues	54,129
Property and Equipment	2,525
Research and Development	16,228
Selling, General and Administrative Expense	12,871

Output Variable	Value in 1000 USD
Assets	42,602
Liabilities	39,732
Expenses	71,678
Revenues	54,129
Stockholders Equity	2,870
Net Income	-18,107
Comprehensive Net Income	-18,660
Economic Capital Ratio	-33%





PHARMACEUTICAL 2023

SYBLEU Inc
Rank 415 of 446


The relative strengths and weaknesses of SYBLEU Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SYBLEU Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 64% points. The greatest weakness of SYBLEU Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 189% points.

The company's Economic Capital Ratio, given in the ranking table, is -335%, being 379% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	67
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	165
Liabilities, Non-Current	0
Other Assets	9.5
Other Compr. Net Income	0
Other Expenses	47
Other Liabilities	162
Other Net Income	-189
Other Revenues	12
Property and Equipment	0
Research and Development	5.1
Selling, General and Administrative Expense	16

Output Variable	Value in 1000 USD
Assets	76
Liabilities	326
Expenses	68
Revenues	12
Stockholders Equity	-250
Net Income	-245
Comprehensive Net Income	-245
Economic Capital Ratio	-335%





PHARMACEUTICAL 2023

Cyclerion Therapeutics Inc.
Rank 391 of 446




The relative strengths and weaknesses of Cyclerion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cyclerion Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 18% points. The greatest weakness of Cyclerion Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 214% points.

The company's Economic Capital Ratio, given in the ranking table, is -203%, being 246% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	14,820
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,627
Liabilities, Non-Current	0
Other Assets	3,259
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	294
Other Revenues	1,625
Property and Equipment	0
Research and Development	31,493
Selling, General and Administrative Expense	14,504

Output Variable	Value in 1000 USD
Assets	18,079
Liabilities	7,627
Expenses	45,997
Revenues	1,625
Stockholders Equity	10,452
Net Income	-44,078
Comprehensive Net Income	-44,078
Economic Capital Ratio	-203%





RealRate

PHARMACEUTICAL 2023

IONIS PHARMACEUTICALS INC

Rank 269 of 446



The relative strengths and weaknesses of IONIS PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IONIS PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 51% points. The greatest weakness of IONIS PHARMACEUTICALS INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is 31%, being 12% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	2,202,694
Cost of Goods Sold	14,116
Intangible Assets	0
Liabilities, Current	311,561
Liabilities, Non-Current	473,835
Other Assets	256,888
Other Compr. Net Income	-24,812
Other Expenses	853,006
Other Liabilities	1,175,593
Other Net Income	160,328
Other Revenues	587,367
Property and Equipment	74,294
Research and Development	0
Selling, General and Administrative Expense	150,295

Output Variable	Value in 1000 USD
Assets	2,533,876
Liabilities	1,960,989
Expenses	1,017,417
Revenues	587,367
Stockholders Equity	572,887
Net Income	-269,722
Comprehensive Net Income	-282,128
Economic Capital Ratio	31%



PHARMACEUTICAL 2023

BIOADAPTIVES INC. Rank 437 of 446





PHARMACEUTICAL 2023

BIOADAPTIVES INC. Rank 437 of 446


The relative strengths and weaknesses of BIOADAPTIVES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOADAPTIVES INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 414% points. The greatest weakness of BIOADAPTIVES INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 267% points.

The company's Economic Capital Ratio, given in the ranking table, is -445%, being 488% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	34
Cost of Goods Sold	10
Intangible Assets	0
Liabilities, Current	1,489
Liabilities, Non-Current	0
Other Assets	3.0
Other Compr. Net Income	0
Other Expenses	175
Other Liabilities	0
Other Net Income	-474
Other Revenues	17
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	254

Output Variable	Value in 1000 USD
Assets	37
Liabilities	1,489
Expenses	439
Revenues	17
Stockholders Equity	-1,452
Net Income	-896
Comprehensive Net Income	-896
Economic Capital Ratio	-445%




The relative strengths and weaknesses of Ayala Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ayala Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Ayala Pharmaceuticals Inc. is the variable Expenses, reducing the Economic Capital Ratio by 29% points.

The company's Economic Capital Ratio, given in the ranking table, is 186%, being 143% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	25,759
Cost of Goods Sold	0
Intangible Assets	110
Liabilities, Current	2,303
Liabilities, Non-Current	0
Other Assets	23
Other Compr. Net Income	0
Other Expenses	3,103
Other Liabilities	0
Other Net Income	5,001
Other Revenues	250
Property and Equipment	38
Research and Development	7,616
Selling, General and Administrative Expense	8,891

Output Variable	Value in 1000 USD
Assets	25,930
Liabilities	2,303
Expenses	19,610
Revenues	250
Stockholders Equity	23,627
Net Income	-14,359
Comprehensive Net Income	-14,359
Economic Capital Ratio	186%




The relative strengths and weaknesses of Nuvalent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nuvalent Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Nuvalent Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 285%, being 241% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	477,991
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,481
Liabilities, Non-Current	0
Other Assets	4,468
Other Compr. Net Income	-266
Other Expenses	0
Other Liabilities	0
Other Net Income	4,254
Other Revenues	0
Property and Equipment	0
Research and Development	63,731
Selling, General and Administrative Expense	22,377

Output Variable	Value in 1000 USD
Assets	482,459
Liabilities	19,481
Expenses	86,108
Revenues	0
Stockholders Equity	462,978
Net Income	-81,854
Comprehensive Net Income	-81,987
Economic Capital Ratio	285%





RealRate

PHARMACEUTICAL 2023

PUMA BIOTECHNOLOGY INC. Rank 274 of 446




The relative strengths and weaknesses of PUMA BIOTECHNOLOGY INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA BIOTECHNOLOGY INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 102% points. The greatest weakness of PUMA BIOTECHNOLOGY INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is 29%, being 15% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	134,281
Cost of Goods Sold	55,093
Intangible Assets	0
Liabilities, Current	77,484
Liabilities, Non-Current	110,141
Other Assets	86,632
Other Compr. Net Income	2.0
Other Expenses	7,455
Other Liabilities	12,826
Other Net Income	0
Other Revenues	228,031
Property and Equipment	1,146
Research and Development	52,240
Selling, General and Administrative Expense	89,978

Output Variable	Value in 1000 USD
Assets	222,059
Liabilities	200,451
Expenses	204,766
Revenues	228,031
Stockholders Equity	21,608
Net Income	23,265
Comprehensive Net Income	23,266
Economic Capital Ratio	29%





PHARMACEUTICAL 2023

Eledon Pharmaceuticals Inc.
Rank 194 of 446




The relative strengths and weaknesses of Eledon Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eledon Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Eledon Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is 112%, being 69% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	59,518
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,475
Liabilities, Non-Current	383
Other Assets	33,275
Other Compr. Net Income	0
Other Expenses	48,648
Other Liabilities	1,752
Other Net Income	462
Other Revenues	0
Property and Equipment	0
Research and Development	27,080
Selling, General and Administrative Expense	12,700

Output Variable	Value in 1000 USD
Assets	92,793
Liabilities	8,610
Expenses	88,428
Revenues	0
Stockholders Equity	84,183
Net Income	-87,966
Comprehensive Net Income	-87,966
Economic Capital Ratio	112%




The relative strengths and weaknesses of ABBOTT LABORATORIES are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ABBOTT LABORATORIES compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 101% points. The greatest weakness of ABBOTT LABORATORIES is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 241%, being 198% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	25,224,000
Cost of Goods Sold	19,142,000
Intangible Assets	33,253,000
Liabilities, Current	15,489,000
Liabilities, Non-Current	0
Other Assets	6,799,000
Other Compr. Net Income	323,000
Other Expenses	3,944,000
Other Liabilities	0
Other Net Income	502,000
Other Revenues	43,653,000
Property and Equipment	9,162,000
Research and Development	2,888,000
Selling, General and Administrative Expense	11,248,000

Output Variable	Value in 1000 USD
Assets	74,438,000
Liabilities	15,489,000
Expenses	37,222,000
Revenues	43,653,000
Stockholders Equity	58,949,000
Net Income	6,933,000
Comprehensive Net Income	7,094,500
Economic Capital Ratio	241%





RealRate

PHARMACEUTICAL 2023

Vaxxinity Inc.
Rank 259 of 446



The relative strengths and weaknesses of Vaxxinity Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vaxxinity Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 42% points. The greatest weakness of Vaxxinity Inc. is the variable Net Income, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 42%, being 1.0% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	93,887
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	30,941
Liabilities, Non-Current	236
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	13,045
Other Net Income	757
Other Revenues	0
Property and Equipment	12,512
Research and Development	47,627
Selling, General and Administrative Expense	28,352

Output Variable	Value in 1000 USD
Assets	106,399
Liabilities	44,222
Expenses	75,979
Revenues	0
Stockholders Equity	62,177
Net Income	-75,222
Comprehensive Net Income	-75,222
Economic Capital Ratio	42%



PHARMACEUTICAL 2023

Harmony Biosciences Holdings Inc.
Rank 114 of 446





RealRate

PHARMACEUTICAL 2023

Harmony Biosciences Holdings Inc. Rank 114 of 446




The relative strengths and weaknesses of Harmony Biosciences Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Harmony Biosciences Holdings Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 116% points. The greatest weakness of Harmony Biosciences Holdings Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is 185%, being 142% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	400,285
Cost of Goods Sold	83,481
Intangible Assets	160,953
Liabilities, Current	78,884
Liabilities, Non-Current	192,148
Other Assets	112,059
Other Compr. Net Income	-151
Other Expenses	2,503
Other Liabilities	0
Other Net Income	-15,500
Other Revenues	437,855
Property and Equipment	573
Research and Development	70,886
Selling, General and Administrative Expense	84,017

Output Variable	Value in 1000 USD
Assets	673,870
Liabilities	271,032
Expenses	240,887
Revenues	437,855
Stockholders Equity	402,838
Net Income	181,468
Comprehensive Net Income	181,392
Economic Capital Ratio	185%



The relative strengths and weaknesses of DICE Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DICE Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of DICE Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 287%, being 244% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	577,762
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,149
Liabilities, Non-Current	11,841
Other Assets	13,295
Other Compr. Net Income	-539
Other Expenses	679
Other Liabilities	0
Other Net Income	5,013
Other Revenues	0
Property and Equipment	2,921
Research and Development	62,559
Selling, General and Administrative Expense	25,662

Output Variable	Value in 1000 USD
Assets	593,978
Liabilities	26,990
Expenses	88,900
Revenues	0
Stockholders Equity	566,988
Net Income	-83,887
Comprehensive Net Income	-84,156
Economic Capital Ratio	287%



PHARMACEUTICAL 2023

Hoth Therapeutics Inc.
Rank 346 of 446





PHARMACEUTICAL 2023

Hoth Therapeutics Inc.
Rank 346 of 446


The relative strengths and weaknesses of Hoth Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hoth Therapeutics Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Hoth Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 165% points.

The company's Economic Capital Ratio, given in the ranking table, is -61%, being 104% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	6,726
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,388
Liabilities, Non-Current	0
Other Assets	33
Other Compr. Net Income	4.4
Other Expenses	6,221
Other Liabilities	250
Other Net Income	-306
Other Revenues	0
Property and Equipment	0
Research and Development	4,845
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	6,759
Liabilities	1,638
Expenses	11,066
Revenues	0
Stockholders Equity	5,122
Net Income	-11,372
Comprehensive Net Income	-11,370
Economic Capital Ratio	-61%





PHARMACEUTICAL 2023

PFIZER INC
Rank 175 of 446




The relative strengths and weaknesses of PFIZER INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PFIZER INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 92% points. The greatest weakness of PFIZER INC is the variable Assets, Current, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 131%, being 88% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	51,259,000
Cost of Goods Sold	34,344,000
Intangible Assets	94,745,000
Liabilities, Current	42,138,000
Liabilities, Non-Current	46,064,000
Other Assets	34,927,000
Other Compr. Net Income	-2,442,000
Other Expenses	8,312,000
Other Liabilities	13,086,000
Other Net Income	-211,000
Other Revenues	100,330,000
Property and Equipment	16,274,000
Research and Development	12,381,000
Selling, General and Administrative Expense	13,677,000

Output Variable	Value in 1000 USD
Assets	197,205,000
Liabilities	101,288,000
Expenses	68,714,000
Revenues	100,330,000
Stockholders Equity	95,917,000
Net Income	31,405,000
Comprehensive Net Income	30,184,000
Economic Capital Ratio	131%





RealRate

PHARMACEUTICAL 2023

SELLAS Life Sciences Group Inc. Rank 386 of 446



The relative strengths and weaknesses of SELLAS Life Sciences Group Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SELLAS Life Sciences Group Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 14% points. The greatest weakness of SELLAS Life Sciences Group Inc. is the variable Net Income, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is -178%, being 221% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	17,756
Cost of Goods Sold	100
Intangible Assets	1,914
Liabilities, Current	15,515
Liabilities, Non-Current	573
Other Assets	1,273
Other Compr. Net Income	0
Other Expenses	10,000
Other Liabilities	4.0
Other Net Income	649
Other Revenues	1,000
Property and Equipment	0
Research and Development	20,268
Selling, General and Administrative Expense	12,582


Output Variable	Value in 1000 USD
Assets	20,943
Liabilities	16,092
Expenses	42,950
Revenues	1,000
Stockholders Equity	4,851
Net Income	-41,301
Comprehensive Net Income	-41,301
Economic Capital Ratio	-178%



RealRate

PHARMACEUTICAL 2023

Xeris Biopharma Holdings Inc. Rank 305 of 446





RealRate

PHARMACEUTICAL 2023

Xeris Biopharma Holdings Inc. Rank 305 of 446




The relative strengths and weaknesses of Xeris Biopharma Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xeris Biopharma Holdings Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Xeris Biopharma Holdings Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 127% points.

The company's Economic Capital Ratio, given in the ranking table, is -5.3%, being 48% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	186,818
Cost of Goods Sold	0
Intangible Assets	143,466
Liabilities, Current	73,621
Liabilities, Non-Current	9,433
Other Assets	8,722
Other Compr. Net Income	8.0
Other Expenses	32,053
Other Liabilities	216,281
Other Net Income	-14,144
Other Revenues	110,248
Property and Equipment	5,516
Research and Development	20,966
Selling, General and Administrative Expense	137,745

Output Variable	Value in 1000 USD
Assets	344,522
Liabilities	299,335
Expenses	190,764
Revenues	110,248
Stockholders Equity	45,187
Net Income	-94,660
Comprehensive Net Income	-94,656
Economic Capital Ratio	-5.3%



The relative strengths and weaknesses of Carisma Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Carisma Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 68% points. The greatest weakness of Carisma Therapeutics Inc. is the variable Other Assets, reducing the Economic Capital Ratio by 7.5% points.

The company's Economic Capital Ratio, given in the ranking table, is 229%, being 186% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	189,144
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	30,984
Liabilities, Non-Current	0
Other Assets	30
Other Compr. Net Income	-546
Other Expenses	-16,347
Other Liabilities	0
Other Net Income	2,150
Other Revenues	40,000
Property and Equipment	0
Research and Development	38,594
Selling, General and Administrative Expense	39,787

Output Variable	Value in 1000 USD
Assets	189,174
Liabilities	30,984
Expenses	62,034
Revenues	40,000
Stockholders Equity	158,190
Net Income	-19,884
Comprehensive Net Income	-20,157
Economic Capital Ratio	229%



PHARMACEUTICAL 2023

BICYCLE THERAPEUTICS plc
Rank 177 of 446





RealRate

PHARMACEUTICAL 2023

BICYCLE THERAPEUTICS plc Rank 177 of 446



The relative strengths and weaknesses of BICYCLE THERAPEUTICS plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BICYCLE THERAPEUTICS plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 71% points. The greatest weakness of BICYCLE THERAPEUTICS plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 129%, being 86% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	369,383
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	53,342
Liabilities, Non-Current	45,029
Other Assets	22,116
Other Compr. Net Income	3,775
Other Expenses	-1,524
Other Liabilities	41,455
Other Net Income	2,412
Other Revenues	14,463
Property and Equipment	19,110
Research and Development	81,609
Selling, General and Administrative Expense	49,507

Output Variable	Value in 1000 USD
Assets	410,609
Liabilities	139,826
Expenses	129,592
Revenues	14,463
Stockholders Equity	270,783
Net Income	-112,717
Comprehensive Net Income	-110,830
Economic Capital Ratio	129%



PHARMACEUTICAL 2023

Oncotelic Therapeutics Inc.
Rank 163 of 446





RealRate

PHARMACEUTICAL 2023

Oncotelic Therapeutics Inc. Rank 163 of 446




The relative strengths and weaknesses of Oncotelic Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncotelic Therapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 123% points. The greatest weakness of Oncotelic Therapeutics Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is 142%, being 99% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	303
Cost of Goods Sold	0
Intangible Assets	12,071
Liabilities, Current	16,923
Liabilities, Non-Current	0
Other Assets	23,742
Other Compr. Net Income	0
Other Expenses	4,111
Other Liabilities	0
Other Net Income	14,398
Other Revenues	0
Property and Equipment	0
Research and Development	757
Selling, General and Administrative Expense	4,854

Output Variable	Value in 1000 USD
Assets	36,117
Liabilities	16,923
Expenses	9,722
Revenues	0
Stockholders Equity	19,193
Net Income	4,677
Comprehensive Net Income	4,677
Economic Capital Ratio	142%





PHARMACEUTICAL 2023

Wave Life Sciences Ltd.
Rank 375 of 446



The relative strengths and weaknesses of Wave Life Sciences Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Wave Life Sciences Ltd. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 13% points. The greatest weakness of Wave Life Sciences Ltd. is the variable Assets, Current, reducing the Economic Capital Ratio by 82% points.

The company's Economic Capital Ratio, given in the ranking table, is -137%, being 180% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	98,537
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	71,521
Liabilities, Non-Current	112,082
Other Assets	30,565
Other Compr. Net Income	-210
Other Expenses	681
Other Liabilities	0
Other Net Income	1,578
Other Revenues	3,649
Property and Equipment	17,284
Research and Development	115,856
Selling, General and Administrative Expense	50,513

Output Variable	Value in 1000 USD
Assets	146,386
Liabilities	183,603
Expenses	167,050
Revenues	3,649
Stockholders Equity	-37,217
Net Income	-161,823
Comprehensive Net Income	-161,928
Economic Capital Ratio	-137%



PHARMACEUTICAL 2023

RIGEL PHARMACEUTICALS INC
Rank 343 of 446





PHARMACEUTICAL 2023

RIGEL PHARMACEUTICALS INC

Rank 343 of 446




The relative strengths and weaknesses of RIGEL PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RIGEL PHARMACEUTICALS INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 59% points. The greatest weakness of RIGEL PHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is -58%, being 101% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	115,903
Cost of Goods Sold	1,749
Intangible Assets	0
Liabilities, Current	65,211
Liabilities, Non-Current	43,236
Other Assets	17,519
Other Compr. Net Income	-51
Other Expenses	5,027
Other Liabilities	39,448
Other Net Income	684
Other Revenues	120,242
Property and Equipment	857
Research and Development	60,272
Selling, General and Administrative Expense	112,451

Output Variable	Value in 1000 USD
Assets	134,279
Liabilities	147,895
Expenses	179,499
Revenues	120,242
Stockholders Equity	-13,616
Net Income	-58,573
Comprehensive Net Income	-58,598
Economic Capital Ratio	-58%




The relative strengths and weaknesses of Kiniksa Pharmaceuticals Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kiniksa Pharmaceuticals Ltd. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 137% points. The greatest weakness of Kiniksa Pharmaceuticals Ltd. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 5.3% points.

The company's Economic Capital Ratio, given in the ranking table, is 331%, being 287% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	243,060
Cost of Goods Sold	0
Intangible Assets	18,250
Liabilities, Current	47,066
Liabilities, Non-Current	16,457
Other Assets	196,704
Other Compr. Net Income	110
Other Expenses	-125,371
Other Liabilities	0
Other Net Income	0
Other Revenues	221,433
Property and Equipment	1,658
Research and Development	65,490
Selling, General and Administrative Expense	97,951

Output Variable	Value in 1000 USD
Assets	459,672
Liabilities	63,523
Expenses	38,070
Revenues	221,433
Stockholders Equity	396,149
Net Income	183,363
Comprehensive Net Income	183,418
Economic Capital Ratio	331%



The relative strengths and weaknesses of CATALYST PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CATALYST PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 117% points. The greatest weakness of CATALYST PHARMACEUTICALS INC. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 9.8% points.

The company's Economic Capital Ratio, given in the ranking table, is 266%, being 223% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	320,797
Cost of Goods Sold	34,393
Intangible Assets	32,471
Liabilities, Current	57,588
Liabilities, Non-Current	17,621
Other Assets	21,515
Other Compr. Net Income	172
Other Expenses	21,640
Other Liabilities	0
Other Net Income	2,881
Other Revenues	214,203
Property and Equipment	847
Research and Development	19,789
Selling, General and Administrative Expense	58,183

Output Variable	Value in 1000 USD
Assets	375,630
Liabilities	75,209
Expenses	134,005
Revenues	214,203
Stockholders Equity	300,421
Net Income	83,079
Comprehensive Net Income	83,165
Economic Capital Ratio	266%



PHARMACEUTICAL 2023

Virios Therapeutics Inc.
Rank 291 of 446





PHARMACEUTICAL 2023

Virios Therapeutics Inc.
Rank 291 of 446


The relative strengths and weaknesses of Virios Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Virios Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Virios Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 156% points.

The company's Economic Capital Ratio, given in the ranking table, is 7.5%, being 36% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	8,370
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,043
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	67
Other Revenues	0
Property and Equipment	0
Research and Development	8,070
Selling, General and Administrative Expense	4,246

Output Variable	Value in 1000 USD
Assets	8,370
Liabilities	1,043
Expenses	12,315
Revenues	0
Stockholders Equity	7,326
Net Income	-12,248
Comprehensive Net Income	-12,248
Economic Capital Ratio	7.5%





PHARMACEUTICAL 2023

Arbutus Biopharma Corp
Rank 176 of 446




The relative strengths and weaknesses of Arbutus Biopharma Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arbutus Biopharma Corp compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 25% points. The greatest weakness of Arbutus Biopharma Corp is the variable Research and Development, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 130%, being 87% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	151,139
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	32,857
Liabilities, Non-Current	1,815
Other Assets	39,210
Other Compr. Net Income	-2,153
Other Expenses	6,677
Other Liabilities	23,895
Other Net Income	444
Other Revenues	39,019
Property and Equipment	5,070
Research and Development	84,408
Selling, General and Administrative Expense	17,834

Output Variable	Value in 1000 USD
Assets	195,419
Liabilities	58,567
Expenses	108,919
Revenues	39,019
Stockholders Equity	136,852
Net Income	-69,456
Comprehensive Net Income	-70,532
Economic Capital Ratio	130%



The relative strengths and weaknesses of Ovid Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ovid Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Ovid Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 194%, being 151% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	131,381
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,992
Liabilities, Non-Current	16,002
Other Assets	22,737
Other Compr. Net Income	-42
Other Expenses	0
Other Liabilities	0
Other Net Income	1,379
Other Revenues	1,503
Property and Equipment	1,148
Research and Development	24,618
Selling, General and Administrative Expense	32,433


Output Variable	Value in 1000 USD
Assets	155,266
Liabilities	22,993
Expenses	57,051
Revenues	1,503
Stockholders Equity	132,273
Net Income	-54,169
Comprehensive Net Income	-54,190
Economic Capital Ratio	194%



RealRate

PHARMACEUTICAL 2023

Verastem Inc.
Rank 288 of 446





RealRate

PHARMACEUTICAL 2023

Verastem Inc.
Rank 288 of 446



The relative strengths and weaknesses of Verastem Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verastem Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Verastem Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 11%, being 32% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	92,870
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,663
Liabilities, Non-Current	1,470
Other Assets	2,088
Other Compr. Net Income	-34
Other Expenses	2,137
Other Liabilities	24,526
Other Net Income	1,262
Other Revenues	2,596
Property and Equipment	92
Research and Development	50,558
Selling, General and Administrative Expense	24,975

Output Variable	Value in 1000 USD
Assets	95,050
Liabilities	47,659
Expenses	77,670
Revenues	2,596
Stockholders Equity	47,391
Net Income	-73,812
Comprehensive Net Income	-73,829
Economic Capital Ratio	11%



PHARMACEUTICAL 2023

Alzamend Neuro Inc.
Rank 170 of 446





PHARMACEUTICAL 2023

Alzamend Neuro Inc.
Rank 170 of 446

The relative strengths and weaknesses of Alzamend Neuro Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alzamend Neuro Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Alzamend Neuro Inc. is the variable Net Income, reducing the Economic Capital Ratio by 77% points.

The company's Economic Capital Ratio, given in the ranking table, is 135%, being 92% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	14,414
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,165
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-43
Other Revenues	0
Property and Equipment	103
Research and Development	5,201
Selling, General and Administrative Expense	7,118

Output Variable	Value in 1000 USD
Assets	14,516
Liabilities	1,165
Expenses	12,320
Revenues	0
Stockholders Equity	13,352
Net Income	-12,362
Comprehensive Net Income	-12,362
Economic Capital Ratio	135%



PHARMACEUTICAL 2023

America Great Health
Rank 443 of 446





PHARMACEUTICAL 2023

America Great Health
Rank 443 of 446

The relative strengths and weaknesses of America Great Health are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of America Great Health compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of America Great Health is the variable Assets, Current, reducing the Economic Capital Ratio by 341% points.

The company's Economic Capital Ratio, given in the ranking table, is -509%, being 552% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	197
Cost of Goods Sold	1,588
Intangible Assets	0
Liabilities, Current	2,757
Liabilities, Non-Current	1,055
Other Assets	116
Other Compr. Net Income	59
Other Expenses	0
Other Liabilities	384
Other Net Income	-191
Other Revenues	105
Property and Equipment	24
Research and Development	0
Selling, General and Administrative Expense	3,250

Output Variable	Value in 1000 USD
Assets	336
Liabilities	4,197
Expenses	4,839
Revenues	105
Stockholders Equity	-3,860
Net Income	-4,925
Comprehensive Net Income	-4,896
Economic Capital Ratio	-509%



PHARMACEUTICAL 2023

AMERICAN BIO MEDICA CORP Rank 397 of 446





PHARMACEUTICAL 2023

AMERICAN BIO MEDICA CORP Rank 397 of 446




The relative strengths and weaknesses of AMERICAN BIO MEDICA CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AMERICAN BIO MEDICA CORP compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 43% points. The greatest weakness of AMERICAN BIO MEDICA CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 163% points.

The company's Economic Capital Ratio, given in the ranking table, is -226%, being 270% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	769
Cost of Goods Sold	1,106
Intangible Assets	0
Liabilities, Current	3,602
Liabilities, Non-Current	6.0
Other Assets	34
Other Compr. Net Income	0
Other Expenses	139
Other Liabilities	0
Other Net Income	-166
Other Revenues	913
Property and Equipment	466
Research and Development	85
Selling, General and Administrative Expense	917

Output Variable	Value in 1000 USD
Assets	1,269
Liabilities	3,608
Expenses	2,247
Revenues	913
Stockholders Equity	-2,339
Net Income	-1,500
Comprehensive Net Income	-1,500
Economic Capital Ratio	-226%





PHARMACEUTICAL 2023

Endo International plc
Rank 119 of 446




The relative strengths and weaknesses of Endo International plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Endo International plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 116% points. The greatest weakness of Endo International plc is the variable Other Expenses, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is 180%, being 136% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,076,768
Cost of Goods Sold	1,092,499
Intangible Assets	3,084,946
Liabilities, Current	689,627
Liabilities, Non-Current	0
Other Assets	596,223
Other Compr. Net Income	-10,496
Other Expenses	2,786,124
Other Liabilities	0
Other Net Income	-458,155
Other Revenues	2,318,875
Property and Equipment	0
Research and Development	128,033
Selling, General and Administrative Expense	777,169

Output Variable	Value in 1000 USD
Assets	5,757,937
Liabilities	689,627
Expenses	4,783,825
Revenues	2,318,875
Stockholders Equity	5,068,310
Net Income	-2,923,105
Comprehensive Net Income	-2,928,353
Economic Capital Ratio	180%



The relative strengths and weaknesses of Olema Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Olema Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 98% points. The greatest weakness of Olema Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 200%, being 157% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	208,899
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,549
Liabilities, Non-Current	1,550
Other Assets	5,266
Other Compr. Net Income	-1,664
Other Expenses	0
Other Liabilities	0
Other Net Income	2,201
Other Revenues	0
Property and Equipment	1,480
Research and Development	82,274
Selling, General and Administrative Expense	24,714

Output Variable	Value in 1000 USD
Assets	215,645
Liabilities	18,099
Expenses	106,988
Revenues	0
Stockholders Equity	197,546
Net Income	-104,787
Comprehensive Net Income	-105,619
Economic Capital Ratio	200%



PHARMACEUTICAL 2023

Vincerx Pharma Inc.
Rank 256 of 446





RealRate

PHARMACEUTICAL 2023

Vincerx Pharma Inc.
Rank 256 of 446




The relative strengths and weaknesses of Vincerx Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vincerx Pharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 35% points. The greatest weakness of Vincerx Pharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 88% points.

The company's Economic Capital Ratio, given in the ranking table, is 47%, being 3.7% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	55,964
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,156
Liabilities, Non-Current	2,462
Other Assets	3,145
Other Compr. Net Income	-5.0
Other Expenses	2,469
Other Liabilities	0
Other Net Income	8,207
Other Revenues	0
Property and Equipment	177
Research and Development	52,152
Selling, General and Administrative Expense	18,953

Output Variable	Value in 1000 USD
Assets	59,286
Liabilities	11,618
Expenses	73,574
Revenues	0
Stockholders Equity	47,668
Net Income	-65,367
Comprehensive Net Income	-65,370
Economic Capital Ratio	47%



The relative strengths and weaknesses of Morphic Holding Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Morphic Holding Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 67% points. The greatest weakness of Morphic Holding Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 9.8% points.

The company's Economic Capital Ratio, given in the ranking table, is 278%, being 235% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	362,182
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,126
Liabilities, Non-Current	2,344
Other Assets	4,288
Other Compr. Net Income	-2,857
Other Expenses	67
Other Liabilities	0
Other Net Income	4,422
Other Revenues	70,808
Property and Equipment	2,119
Research and Development	102,062
Selling, General and Administrative Expense	32,142

Output Variable	Value in 1000 USD
Assets	368,589
Liabilities	19,470
Expenses	134,271
Revenues	70,808
Stockholders Equity	349,119
Net Income	-59,041
Comprehensive Net Income	-60,470
Economic Capital Ratio	278%



PHARMACEUTICAL 2023

RenovoRx Inc.
Rank 282 of 446





PHARMACEUTICAL 2023

RenovoRx Inc.
Rank 282 of 446


The relative strengths and weaknesses of RenovoRx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RenovoRx Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 53% points. The greatest weakness of RenovoRx Inc. is the variable Net Income, reducing the Economic Capital Ratio by 138% points.

The company's Economic Capital Ratio, given in the ranking table, is 17%, being 26% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	7,265
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	534
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	17
Other Expenses	0
Other Liabilities	568
Other Net Income	61
Other Revenues	0
Property and Equipment	0
Research and Development	4,301
Selling, General and Administrative Expense	5,649

Output Variable	Value in 1000 USD
Assets	7,265
Liabilities	1,102
Expenses	9,950
Revenues	0
Stockholders Equity	6,163
Net Income	-9,889
Comprehensive Net Income	-9,880
Economic Capital Ratio	17%





PHARMACEUTICAL 2023

CTI BIOPHARMA CORP
Rank 356 of 446




The relative strengths and weaknesses of CTI BIOPHARMA CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CTI BIOPHARMA CORP compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 21% points. The greatest weakness of CTI BIOPHARMA CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is -91%, being 135% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	99,396
Cost of Goods Sold	3,514
Intangible Assets	23,226
Liabilities, Current	81,134
Liabilities, Non-Current	1,234
Other Assets	3,303
Other Compr. Net Income	-35
Other Expenses	8,510
Other Liabilities	61,134
Other Net Income	-13,195
Other Revenues	53,948
Property and Equipment	0
Research and Development	36,895
Selling, General and Administrative Expense	84,826

Output Variable	Value in 1000 USD
Assets	125,925
Liabilities	143,502
Expenses	133,745
Revenues	53,948
Stockholders Equity	-17,577
Net Income	-92,992
Comprehensive Net Income	-93,010
Economic Capital Ratio	-91%





PHARMACEUTICAL 2023

EYENOVIA INC.
Rank 292 of 446





The relative strengths and weaknesses of EYENOVIA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of EYENOVIA INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 27% points. The greatest weakness of EYENOVIA INC. is the variable Net Income, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 7.3%, being 36% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	27,643
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,512
Liabilities, Non-Current	908
Other Assets	2,099
Other Compr. Net Income	0
Other Expenses	1,380
Other Liabilities	8,382
Other Net Income	280
Other Revenues	0
Property and Equipment	1,295
Research and Development	13,379
Selling, General and Administrative Expense	13,533


Output Variable	Value in 1000 USD
Assets	31,036
Liabilities	13,802
Expenses	28,292
Revenues	0
Stockholders Equity	17,235
Net Income	-28,011
Comprehensive Net Income	-28,011
Economic Capital Ratio	7.3%





PHARMACEUTICAL 2023

Cue Biopharma Inc.
Rank 209 of 446




The relative strengths and weaknesses of Cue Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cue Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Cue Biopharma Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 103%, being 59% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	77,187
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,549
Liabilities, Non-Current	14,052
Other Assets	12,597
Other Compr. Net Income	-96
Other Expenses	-277
Other Liabilities	0
Other Net Income	214
Other Revenues	1,245
Property and Equipment	1,499
Research and Development	38,578
Selling, General and Administrative Expense	16,169

Output Variable	Value in 1000 USD
Assets	91,283
Liabilities	25,601
Expenses	54,470
Revenues	1,245
Stockholders Equity	65,683
Net Income	-53,010
Comprehensive Net Income	-53,058
Economic Capital Ratio	103%



The relative strengths and weaknesses of Xenon Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenon Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Xenon Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 283%, being 240% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	600,298
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,702
Liabilities, Non-Current	9,947
Other Assets	147,348
Other Compr. Net Income	-2,010
Other Expenses	118
Other Liabilities	0
Other Net Income	3,888
Other Revenues	9,434
Property and Equipment	6,500
Research and Development	105,767
Selling, General and Administrative Expense	32,810

Output Variable	Value in 1000 USD
Assets	754,146
Liabilities	32,649
Expenses	138,695
Revenues	9,434
Stockholders Equity	721,497
Net Income	-125,373
Comprehensive Net Income	-126,378
Economic Capital Ratio	283%



PHARMACEUTICAL 2023

Zoetis Inc.
Rank 229 of 446





RealRate

PHARMACEUTICAL 2023

Zoetis Inc.
Rank 229 of 446



The relative strengths and weaknesses of Zoetis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zoetis Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Zoetis Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is 76%, being 33% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	7,506,000
Cost of Goods Sold	2,454,000
Intangible Assets	4,126,000
Liabilities, Current	3,167,000
Liabilities, Non-Current	6,955,000
Other Assets	540,000
Other Compr. Net Income	-50,000
Other Expenses	927,000
Other Liabilities	400,000
Other Net Income	-40,000
Other Revenues	8,080,000
Property and Equipment	2,753,000
Research and Development	539,000
Selling, General and Administrative Expense	2,009,000

Output Variable	Value in 1000 USD
Assets	14,925,000
Liabilities	10,522,000
Expenses	5,929,000
Revenues	8,080,000
Stockholders Equity	4,403,000
Net Income	2,111,000
Comprehensive Net Income	2,086,000
Economic Capital Ratio	76%



PHARMACEUTICAL 2023

Fulcrum Therapeutics Inc.
Rank 117 of 446





RealRate

PHARMACEUTICAL 2023

Fulcrum Therapeutics Inc. Rank 117 of 446



The relative strengths and weaknesses of Fulcrum Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Fulcrum Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Fulcrum Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 182%, being 139% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	207,519
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,725
Liabilities, Non-Current	11,018
Other Assets	12,260
Other Compr. Net Income	-400
Other Expenses	427
Other Liabilities	0
Other Net Income	2,690
Other Revenues	6,342
Property and Equipment	6,906
Research and Development	76,782
Selling, General and Administrative Expense	41,694

Output Variable	Value in 1000 USD
Assets	226,685
Liabilities	27,743
Expenses	118,903
Revenues	6,342
Stockholders Equity	198,942
Net Income	-109,871
Comprehensive Net Income	-110,071
Economic Capital Ratio	182%



PHARMACEUTICAL 2023

TENAX THERAPEUTICS INC. Rank 412 of 446





PHARMACEUTICAL 2023

TENAX THERAPEUTICS INC. Rank 412 of 446


The relative strengths and weaknesses of TENAX THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of TENAX THERAPEUTICS INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 19% points. The greatest weakness of TENAX THERAPEUTICS INC. is the variable Net Income, reducing the Economic Capital Ratio by 277% points.

The company's Economic Capital Ratio, given in the ranking table, is -319%, being 362% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	3,208
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,848
Liabilities, Non-Current	64
Other Assets	189
Other Compr. Net Income	0
Other Expenses	4.4
Other Liabilities	0
Other Net Income	0
Other Revenues	9.2
Property and Equipment	7.2
Research and Development	5,377
Selling, General and Administrative Expense	5,675

Output Variable	Value in 1000 USD
Assets	3,405
Liabilities	1,912
Expenses	11,057
Revenues	9.2
Stockholders Equity	1,493
Net Income	-11,048
Comprehensive Net Income	-11,048
Economic Capital Ratio	-319%





PHARMACEUTICAL 2023

Acer Therapeutics Inc.
Rank 407 of 446




The relative strengths and weaknesses of Acer Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acer Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 103% points. The greatest weakness of Acer Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 195% points.

The company's Economic Capital Ratio, given in the ranking table, is -275%, being 318% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	3,517
Cost of Goods Sold	0
Intangible Assets	7,647
Liabilities, Current	18,952
Liabilities, Non-Current	146
Other Assets	246
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	9,288
Other Net Income	-1,623
Other Revenues	0
Property and Equipment	215
Research and Development	11,925
Selling, General and Administrative Expense	12,689

Output Variable	Value in 1000 USD
Assets	11,624
Liabilities	28,385
Expenses	24,614
Revenues	0
Stockholders Equity	-16,761
Net Income	-26,237
Comprehensive Net Income	-26,237
Economic Capital Ratio	-275%




The relative strengths and weaknesses of Avidity Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avidity Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Avidity Biosciences Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 234%, being 191% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	622,942
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	51,908
Liabilities, Non-Current	8,817
Other Assets	9,604
Other Compr. Net Income	-2,511
Other Expenses	0
Other Liabilities	0
Other Net Income	4,918
Other Revenues	9,224
Property and Equipment	6,254
Research and Development	150,404
Selling, General and Administrative Expense	37,733

Output Variable	Value in 1000 USD
Assets	638,800
Liabilities	60,725
Expenses	188,137
Revenues	9,224
Stockholders Equity	578,075
Net Income	-173,995
Comprehensive Net Income	-175,250
Economic Capital Ratio	234%



The relative strengths and weaknesses of AbbVie Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AbbVie Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 127% points. The greatest weakness of AbbVie Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 29% points.


The company's Economic Capital Ratio, given in the ranking table, is 238%, being 195% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	28,463,000
Cost of Goods Sold	17,414,000
Intangible Assets	99,595,000
Liabilities, Current	29,538,000
Liabilities, Non-Current	0
Other Assets	5,812,000
Other Compr. Net Income	691,000
Other Expenses	1,688,000
Other Liabilities	0
Other Net Income	-4,640,000
Other Revenues	58,054,000
Property and Equipment	4,935,000
Research and Development	7,207,000
Selling, General and Administrative Expense	15,260,000

Output Variable	Value in 1000 USD
Assets	138,805,000
Liabilities	29,538,000
Expenses	41,569,000
Revenues	58,054,000
Stockholders Equity	109,267,000
Net Income	11,845,000
Comprehensive Net Income	12,190,500
Economic Capital Ratio	238%



PHARMACEUTICAL 2023

CUMBERLAND PHARMACEUTICALS 
INC
 Rank 230 of 446





PHARMACEUTICAL 2023

CUMBERLAND PHARMACEUTICALS INC

Rank 230 of 446



The relative strengths and weaknesses of CUMBERLAND PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CUMBERLAND PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 65% points. The greatest weakness of CUMBERLAND PHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 75%, being 32% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	45,870
Cost of Goods Sold	9,119
Intangible Assets	31,505
Liabilities, Current	28,580
Liabilities, Non-Current	12,171
Other Assets	15,266
Other Compr. Net Income	0
Other Expenses	22,383
Other Liabilities	16,200
Other Net Income	710
Other Revenues	42,011
Property and Equipment	284
Research and Development	6,689
Selling, General and Administrative Expense	10,180

Output Variable	Value in 1000 USD
Assets	92,925
Liabilities	56,951
Expenses	48,371
Revenues	42,011
Stockholders Equity	35,974
Net Income	-5,650
Comprehensive Net Income	-5,650
Economic Capital Ratio	75%



PHARMACEUTICAL 2023

Avenir Wellness Solutions Inc.
Rank 420 of 446





PHARMACEUTICAL 2023

Avenir Wellness Solutions Inc.
Rank 420 of 446




The relative strengths and weaknesses of Avenir Wellness Solutions Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avenir Wellness Solutions Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Avenir Wellness Solutions Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 267% points.

The company's Economic Capital Ratio, given in the ranking table, is -363%, being 406% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	5,928
Cost of Goods Sold	1,557
Intangible Assets	244
Liabilities, Current	13,913
Liabilities, Non-Current	46
Other Assets	678
Other Compr. Net Income	0
Other Expenses	9,926
Other Liabilities	0
Other Net Income	-7,197
Other Revenues	4,896
Property and Equipment	4.0
Research and Development	0
Selling, General and Administrative Expense	11,725

Output Variable	Value in 1000 USD
Assets	6,854
Liabilities	13,959
Expenses	23,208
Revenues	4,896
Stockholders Equity	-7,105
Net Income	-25,509
Comprehensive Net Income	-25,509
Economic Capital Ratio	-363%





The relative strengths and weaknesses of ARDELYX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARDELYX INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 25% points. The greatest weakness of ARDELYX INC. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 72%, being 29% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	153,603
Cost of Goods Sold	4,117
Intangible Assets	0
Liabilities, Current	65,603
Liabilities, Non-Current	14,880
Other Assets	35,240
Other Compr. Net Income	-48
Other Expenses	5,081
Other Liabilities	11,254
Other Net Income	1,633
Other Revenues	52,158
Property and Equipment	1,223
Research and Development	35,201
Selling, General and Administrative Expense	76,599

Output Variable	Value in 1000 USD
Assets	190,066
Liabilities	91,737
Expenses	120,998
Revenues	52,158
Stockholders Equity	98,329
Net Income	-67,207
Comprehensive Net Income	-67,231
Economic Capital Ratio	72%



PHARMACEUTICAL 2023

Decibel Therapeutics Inc.
Rank 220 of 446





RealRate

PHARMACEUTICAL 2023

Decibel Therapeutics Inc. Rank 220 of 446




The relative strengths and weaknesses of Decibel Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Decibel Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 59% points. The greatest weakness of Decibel Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 94%, being 51% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	108,030
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,442
Liabilities, Non-Current	12,373
Other Assets	10,817
Other Compr. Net Income	-91
Other Expenses	240
Other Liabilities	6,765
Other Net Income	1,192
Other Revenues	0
Property and Equipment	4,526
Research and Development	40,330
Selling, General and Administrative Expense	23,627

Output Variable	Value in 1000 USD
Assets	123,373
Liabilities	41,580
Expenses	64,197
Revenues	0
Stockholders Equity	81,793
Net Income	-63,005
Comprehensive Net Income	-63,050
Economic Capital Ratio	94%





PHARMACEUTICAL 2023

Societal CDMO Inc.
Rank 241 of 446



The relative strengths and weaknesses of Societal CDMO Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Societal CDMO Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Societal CDMO Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is 65%, being 22% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	55,586
Cost of Goods Sold	67,076
Intangible Assets	44,005
Liabilities, Current	22,808
Liabilities, Non-Current	35,551
Other Assets	7,487
Other Compr. Net Income	0
Other Expenses	16,069
Other Liabilities	39,225
Other Net Income	-4,996
Other Revenues	90,214
Property and Equipment	50,365
Research and Development	0
Selling, General and Administrative Expense	21,954

Output Variable	Value in 1000 USD
Assets	157,443
Liabilities	97,584
Expenses	105,099
Revenues	90,214
Stockholders Equity	59,859
Net Income	-19,881
Comprehensive Net Income	-19,881
Economic Capital Ratio	65%



PHARMACEUTICAL 2023

Alaunos Therapeutics Inc.
Rank 242 of 446





RealRate

PHARMACEUTICAL 2023

Alaunos Therapeutics Inc. Rank 242 of 446




The relative strengths and weaknesses of Alaunos Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alaunos Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Alaunos Therapeutics Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 63%, being 19% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	53,799
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,166
Liabilities, Non-Current	28
Other Assets	2,678
Other Compr. Net Income	0
Other Expenses	-133
Other Liabilities	2,188
Other Net Income	-2,625
Other Revenues	2,922
Property and Equipment	8,460
Research and Development	25,018
Selling, General and Administrative Expense	13,142

Output Variable	Value in 1000 USD
Assets	64,937
Liabilities	26,382
Expenses	38,027
Revenues	2,922
Stockholders Equity	38,555
Net Income	-37,730
Comprehensive Net Income	-37,730
Economic Capital Ratio	63%





PHARMACEUTICAL 2023

Regulus Therapeutics Inc.
Rank 217 of 446



The relative strengths and weaknesses of Regulus Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regulus Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Regulus Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 96%, being 53% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	44,079
Cost of Goods Sold	0
Intangible Assets	62
Liabilities, Current	11,657
Liabilities, Non-Current	1,768
Other Assets	2,575
Other Compr. Net Income	-12
Other Expenses	689
Other Liabilities	0
Other Net Income	0
Other Revenues	605
Property and Equipment	0
Research and Development	18,410
Selling, General and Administrative Expense	9,829


Output Variable	Value in 1000 USD
Assets	46,716
Liabilities	13,425
Expenses	28,928
Revenues	605
Stockholders Equity	33,291
Net Income	-28,323
Comprehensive Net Income	-28,329
Economic Capital Ratio	96%



PHARMACEUTICAL 2023

Esperion Therapeutics Inc.
Rank 389 of 446

ESPERION





PHARMACEUTICAL 2023

Esperion Therapeutics Inc.
Rank 389 of 446

ESPERION


The relative strengths and weaknesses of Esperion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Esperion Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 12% points. The greatest weakness of Esperion Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 165% points.

The company's Economic Capital Ratio, given in the ranking table, is -193%, being 236% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	246,683
Cost of Goods Sold	0
Intangible Assets	56
Liabilities, Current	92,308
Liabilities, Non-Current	665
Other Assets	1,036
Other Compr. Net Income	29
Other Expenses	83,777
Other Liabilities	478,744
Other Net Income	2,652
Other Revenues	75,475
Property and Equipment	164
Research and Development	118,927
Selling, General and Administrative Expense	109,082

Output Variable	Value in 1000 USD
Assets	247,939
Liabilities	571,717
Expenses	311,786
Revenues	75,475
Stockholders Equity	-323,778
Net Income	-233,659
Comprehensive Net Income	-233,644
Economic Capital Ratio	-193%




The relative strengths and weaknesses of Organon & Co. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Organon & Co. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Organon & Co. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 229%, being 186% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	3,931,000
Cost of Goods Sold	2,294,000
Intangible Assets	5,252,000
Liabilities, Current	2,512,000
Liabilities, Non-Current	0
Other Assets	754,000
Other Compr. Net Income	-51,000
Other Expenses	788,000
Other Liabilities	0
Other Net Income	0
Other Revenues	6,174,000
Property and Equipment	1,018,000
Research and Development	471,000
Selling, General and Administrative Expense	1,704,000

Output Variable	Value in 1000 USD
Assets	10,955,000
Liabilities	2,512,000
Expenses	5,257,000
Revenues	6,174,000
Stockholders Equity	8,443,000
Net Income	917,000
Comprehensive Net Income	891,500
Economic Capital Ratio	229%




The relative strengths and weaknesses of Zomedica Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zomedica Corp. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 60% points. The greatest weakness of Zomedica Corp. is the variable Other Revenues, reducing the Economic Capital Ratio by 2.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 303%, being 260% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	123,501
Cost of Goods Sold	5,278
Intangible Assets	105,778
Liabilities, Current	7,811
Liabilities, Non-Current	3,162
Other Assets	43,522
Other Compr. Net Income	-845
Other Expenses	-2,365
Other Liabilities	1,245
Other Net Income	2,543
Other Revenues	18,930
Property and Equipment	6,809
Research and Development	2,578
Selling, General and Administrative Expense	32,997

Output Variable	Value in 1000 USD
Assets	279,610
Liabilities	12,218
Expenses	38,488
Revenues	18,930
Stockholders Equity	267,392
Net Income	-17,015
Comprehensive Net Income	-17,438
Economic Capital Ratio	303%




The relative strengths and weaknesses of Viracta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viracta Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Viracta Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 186%, being 143% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	93,747
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,011
Liabilities, Non-Current	0
Other Assets	2,096
Other Compr. Net Income	-178
Other Expenses	0
Other Liabilities	0
Other Net Income	1,392
Other Revenues	0
Property and Equipment	148
Research and Development	26,262
Selling, General and Administrative Expense	24,327

Output Variable	Value in 1000 USD
Assets	95,991
Liabilities	10,011
Expenses	50,589
Revenues	0
Stockholders Equity	85,980
Net Income	-49,197
Comprehensive Net Income	-49,286
Economic Capital Ratio	186%





PHARMACEUTICAL 2023

Mirum Pharmaceuticals Inc.
Rank 260 of 446




The relative strengths and weaknesses of Mirum Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirum Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Mirum Pharmaceuticals Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is 39%, being 4.6% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	190,225
Cost of Goods Sold	0
Intangible Assets	58,954
Liabilities, Current	64,729
Liabilities, Non-Current	5,789
Other Assets	102,813
Other Compr. Net Income	-182
Other Expenses	21,041
Other Liabilities	140,351
Other Net Income	4,222
Other Revenues	77,062
Property and Equipment	914
Research and Development	106,842
Selling, General and Administrative Expense	89,066

Output Variable	Value in 1000 USD
Assets	352,906
Liabilities	210,869
Expenses	216,949
Revenues	77,062
Stockholders Equity	142,037
Net Income	-135,665
Comprehensive Net Income	-135,756
Economic Capital Ratio	39%



The relative strengths and weaknesses of OMEROS CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OMEROS CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 84% points. The greatest weakness of OMEROS CORP is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 228%, being 185% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	443,236
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	136,383
Liabilities, Non-Current	0
Other Assets	147,733
Other Compr. Net Income	0
Other Expenses	22,702
Other Liabilities	0
Other Net Income	229,446
Other Revenues	4,062
Property and Equipment	0
Research and Development	112,721
Selling, General and Administrative Expense	50,668

Output Variable	Value in 1000 USD
Assets	590,969
Liabilities	136,383
Expenses	186,091
Revenues	4,062
Stockholders Equity	454,586
Net Income	47,417
Comprehensive Net Income	47,417
Economic Capital Ratio	228%



PHARMACEUTICAL 2023

Axsome Therapeutics Inc.
Rank 300 of 446





PHARMACEUTICAL 2023

Axsome Therapeutics Inc.
Rank 300 of 446


The relative strengths and weaknesses of Axsome Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Axsome Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Axsome Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 0.47%, being 43% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	245,641
Cost of Goods Sold	0
Intangible Assets	69,971
Liabilities, Current	96,561
Liabilities, Non-Current	94,259
Other Assets	15,141
Other Compr. Net Income	0
Other Expenses	12,635
Other Liabilities	31,100
Other Net Income	-7,335
Other Revenues	50,037
Property and Equipment	723
Research and Development	57,947
Selling, General and Administrative Expense	159,254

Output Variable	Value in 1000 USD
Assets	331,476
Liabilities	221,920
Expenses	229,836
Revenues	50,037
Stockholders Equity	109,556
Net Income	-187,134
Comprehensive Net Income	-187,134
Economic Capital Ratio	0.47%





PHARMACEUTICAL 2023

DYNAVAX TECHNOLOGIES CORP Rank 112 of 446




The relative strengths and weaknesses of DYNAVAX TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DYNAVAX TECHNOLOGIES CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 125% points. The greatest weakness of DYNAVAX TECHNOLOGIES CORP is the variable Other Liabilities, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 186%, being 143% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	916,985
Cost of Goods Sold	0
Intangible Assets	2,006
Liabilities, Current	150,074
Liabilities, Non-Current	33,185
Other Assets	29,263
Other Compr. Net Income	-3,172
Other Expenses	267,227
Other Liabilities	221,578
Other Net Income	8,023
Other Revenues	730,368
Property and Equipment	37,596
Research and Development	46,600
Selling, General and Administrative Expense	131,408

Output Variable	Value in 1000 USD
Assets	985,850
Liabilities	404,837
Expenses	445,235
Revenues	730,368
Stockholders Equity	581,013
Net Income	293,156
Comprehensive Net Income	291,570
Economic Capital Ratio	186%



The relative strengths and weaknesses of Altimmune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Altimmune Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Altimmune Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 205%, being 162% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	192,813
Cost of Goods Sold	0
Intangible Assets	12,419
Liabilities, Current	17,054
Liabilities, Non-Current	0
Other Assets	615
Other Compr. Net Income	-187
Other Expenses	-197
Other Liabilities	4,581
Other Net Income	2,830
Other Revenues	-68
Property and Equipment	1,081
Research and Development	70,538
Selling, General and Administrative Expense	17,134

Output Variable	Value in 1000 USD
Assets	206,928
Liabilities	21,635
Expenses	87,475
Revenues	-68
Stockholders Equity	185,293
Net Income	-84,713
Comprehensive Net Income	-84,806
Economic Capital Ratio	205%



PHARMACEUTICAL 2023

Paratek Pharmaceuticals Inc.
Rank 376 of 446





PHARMACEUTICAL 2023

Paratek Pharmaceuticals Inc.
Rank 376 of 446




The relative strengths and weaknesses of Paratek Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Paratek Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Paratek Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 160% points.

The company's Economic Capital Ratio, given in the ranking table, is -139%, being 182% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	136,842
Cost of Goods Sold	23,056
Intangible Assets	829
Liabilities, Current	37,388
Liabilities, Non-Current	260,867
Other Assets	34,251
Other Compr. Net Income	9.0
Other Expenses	18,176
Other Liabilities	45,325
Other Net Income	819
Other Revenues	160,268
Property and Equipment	616
Research and Development	37,823
Selling, General and Administrative Expense	145,598

Output Variable	Value in 1000 USD
Assets	172,538
Liabilities	343,580
Expenses	224,653
Revenues	160,268
Stockholders Equity	-171,042
Net Income	-63,566
Comprehensive Net Income	-63,562
Economic Capital Ratio	-139%



The relative strengths and weaknesses of SIGA TECHNOLOGIES INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SIGA TECHNOLOGIES INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 115% points. The greatest weakness of SIGA TECHNOLOGIES INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 3.8% points.

The company's Economic Capital Ratio, given in the ranking table, is 297%, being 254% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	185,786
Cost of Goods Sold	10,433
Intangible Assets	898
Liabilities, Current	21,518
Liabilities, Non-Current	0
Other Assets	6,503
Other Compr. Net Income	0
Other Expenses	10,228
Other Liabilities	3,358
Other Net Income	1,433
Other Revenues	110,776
Property and Equipment	1,848
Research and Development	22,526
Selling, General and Administrative Expense	35,117

Output Variable	Value in 1000 USD
Assets	195,036
Liabilities	24,876
Expenses	78,303
Revenues	110,776
Stockholders Equity	170,160
Net Income	33,905
Comprehensive Net Income	33,905
Economic Capital Ratio	297%



PHARMACEUTICAL 2023

MARINUS PHARMACEUTICALS INC.
Rank 222 of 446





RealRate

PHARMACEUTICAL 2023

MARINUS PHARMACEUTICALS INC. Rank 222 of 446




The relative strengths and weaknesses of MARINUS PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MARINUS PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 67% points. The greatest weakness of MARINUS PHARMACEUTICALS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 123% points.

The company's Economic Capital Ratio, given in the ranking table, is 89%, being 46% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	252,378
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	25,017
Liabilities, Non-Current	0
Other Assets	2,904
Other Compr. Net Income	0
Other Expenses	15,570
Other Liabilities	118,501
Other Net Income	107,033
Other Revenues	25,478
Property and Equipment	4,236
Research and Development	79,912
Selling, General and Administrative Expense	56,845

Output Variable	Value in 1000 USD
Assets	259,518
Liabilities	143,518
Expenses	152,327
Revenues	25,478
Stockholders Equity	116,000
Net Income	-19,816
Comprehensive Net Income	-19,816
Economic Capital Ratio	89%





PHARMACEUTICAL 2023

CANNAPHARMARX INC. Rank 405 of 446

The relative strengths and weaknesses of CANNAPHARMARX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CANNAPHARMARX INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 85% points. The greatest weakness of CANNAPHARMARX INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 186% points.

The company's Economic Capital Ratio, given in the ranking table, is -270%, being 313% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	100
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,165
Liabilities, Non-Current	0
Other Assets	5,206
Other Compr. Net Income	612
Other Expenses	2,985
Other Liabilities	5,593
Other Net Income	-3,319
Other Revenues	0
Property and Equipment	108
Research and Development	0
Selling, General and Administrative Expense	2,227

Output Variable	Value in 1000 USD
Assets	5,414
Liabilities	22,759
Expenses	5,212
Revenues	0
Stockholders Equity	-17,344
Net Income	-8,531
Comprehensive Net Income	-8,225
Economic Capital Ratio	-270%



PHARMACEUTICAL 2023

Stoke Therapeutics Inc.
Rank 173 of 446





PHARMACEUTICAL 2023

Stoke Therapeutics Inc.
Rank 173 of 446

The relative strengths and weaknesses of Stoke Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Stoke Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 82% points. The greatest weakness of Stoke Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 132%, being 89% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	244,070
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,394
Liabilities, Non-Current	39,824
Other Assets	5,322
Other Compr. Net Income	-1,007
Other Expenses	0
Other Liabilities	0
Other Net Income	3,289
Other Revenues	12,405
Property and Equipment	6,675
Research and Development	77,837
Selling, General and Administrative Expense	38,924


Output Variable	Value in 1000 USD
Assets	256,067
Liabilities	71,218
Expenses	116,761
Revenues	12,405
Stockholders Equity	184,849
Net Income	-101,067
Comprehensive Net Income	-101,570
Economic Capital Ratio	132%



PHARMACEUTICAL 2023

Bausch Health Companies Inc.
Rank 301 of 446

BAUSCH Health





PHARMACEUTICAL 2023

Bausch Health Companies Inc.
Rank 301 of 446

BAUSCH Health

The relative strengths and weaknesses of Bausch Health Companies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bausch Health Companies Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 147% points. The greatest weakness of Bausch Health Companies Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 193% points.

The company's Economic Capital Ratio, given in the ranking table, is 0.37%, being 43% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	4,247,000
Cost of Goods Sold	0
Intangible Assets	17,347,000
Liabilities, Current	3,941,000
Liabilities, Non-Current	21,075,000
Other Assets	2,492,000
Other Compr. Net Income	-282,000
Other Expenses	6,063,000
Other Liabilities	410,000
Other Net Income	881,000
Other Revenues	8,124,000
Property and Equipment	1,600,000
Research and Development	529,000
Selling, General and Administrative Expense	2,625,000

Output Variable	Value in 1000 USD
Assets	25,686,000
Liabilities	25,426,000
Expenses	9,217,000
Revenues	8,124,000
Stockholders Equity	260,000
Net Income	-212,000
Comprehensive Net Income	-353,000
Economic Capital Ratio	0.37%



PHARMACEUTICAL 2023

Orgenesis Inc.
Rank 161 of 446





PHARMACEUTICAL 2023

Orgenesis Inc.
Rank 161 of 446



The relative strengths and weaknesses of Orgenesis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Orgenesis Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Orgenesis Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 145%, being 102% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	46,318
Cost of Goods Sold	27,066
Intangible Assets	17,881
Liabilities, Current	15,910
Liabilities, Non-Current	15,744
Other Assets	3,895
Other Compr. Net Income	-2,243
Other Expenses	2,181
Other Liabilities	0
Other Net Income	-3,358
Other Revenues	36,025
Property and Equipment	22,834
Research and Development	0
Selling, General and Administrative Expense	15,589

Output Variable	Value in 1000 USD
Assets	90,928
Liabilities	31,654
Expenses	44,836
Revenues	36,025
Stockholders Equity	59,274
Net Income	-12,169
Comprehensive Net Income	-13,290
Economic Capital Ratio	145%



PHARMACEUTICAL 2023

Aravive Inc.
Rank 359 of 446





RealRate

PHARMACEUTICAL 2023

Aravive Inc.
Rank 359 of 446




The relative strengths and weaknesses of Aravive Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aravive Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 18% points. The greatest weakness of Aravive Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is -102%, being 145% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	57,970
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,112
Liabilities, Non-Current	2,503
Other Assets	3,913
Other Compr. Net Income	0
Other Expenses	8,981
Other Liabilities	26,881
Other Net Income	3,496
Other Revenues	9,137
Property and Equipment	270
Research and Development	66,938
Selling, General and Administrative Expense	13,036

Output Variable	Value in 1000 USD
Assets	62,153
Liabilities	51,496
Expenses	88,955
Revenues	9,137
Stockholders Equity	10,657
Net Income	-76,322
Comprehensive Net Income	-76,322
Economic Capital Ratio	-102%





RealRate

PHARMACEUTICAL 2023

BridgeBio Pharma Inc.
Rank 395 of 446



The relative strengths and weaknesses of BridgeBio Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BridgeBio Pharma Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 28% points. The greatest weakness of BridgeBio Pharma Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is -211%, being 254% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	548,853
Cost of Goods Sold	0
Intangible Assets	28,712
Liabilities, Current	121,428
Liabilities, Non-Current	469,910
Other Assets	30,902
Other Compr. Net Income	3,273
Other Expenses	47,199
Other Liabilities	1,276,622
Other Net Income	27,550
Other Revenues	77,648
Property and Equipment	14,569
Research and Development	399,462
Selling, General and Administrative Expense	143,189

Output Variable	Value in 1000 USD
Assets	623,036
Liabilities	1,867,960
Expenses	589,850
Revenues	77,648
Stockholders Equity	-1,244,924
Net Income	-484,652
Comprehensive Net Income	-483,016
Economic Capital Ratio	-211%



PHARMACEUTICAL 2023

Marker Therapeutics Inc.
Rank 284 of 446





PHARMACEUTICAL 2023

Marker Therapeutics Inc.
Rank 284 of 446

The relative strengths and weaknesses of Marker Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Marker Therapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 120% points. The greatest weakness of Marker Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 15%, being 28% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	16,619
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,782
Liabilities, Non-Current	7,039
Other Assets	17,803
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	15
Other Revenues	9,014
Property and Equipment	0
Research and Development	26,139
Selling, General and Administrative Expense	12,820

Output Variable	Value in 1000 USD
Assets	34,422
Liabilities	14,821
Expenses	38,959
Revenues	9,014
Stockholders Equity	19,601
Net Income	-29,931
Comprehensive Net Income	-29,931
Economic Capital Ratio	15%



PHARMACEUTICAL 2023

Elicio Therapeutics Inc.
Rank 187 of 446





PHARMACEUTICAL 2023

Elicio Therapeutics Inc.
Rank 187 of 446




The relative strengths and weaknesses of Elicio Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Elicio Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Elicio Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 118%, being 75% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	51,430
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,369
Liabilities, Non-Current	2,481
Other Assets	1,087
Other Compr. Net Income	189
Other Expenses	9,185
Other Liabilities	168
Other Net Income	814
Other Revenues	2,301
Property and Equipment	273
Research and Development	18,100
Selling, General and Administrative Expense	14,637

Output Variable	Value in 1000 USD
Assets	52,790
Liabilities	9,018
Expenses	41,922
Revenues	2,301
Stockholders Equity	43,772
Net Income	-38,807
Comprehensive Net Income	-38,712
Economic Capital Ratio	118%





PHARMACEUTICAL 2023

ATHERSYS INC NEW
Rank 406 of 446




The relative strengths and weaknesses of ATHERSYS INC NEW are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ATHERSYS INC NEW compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 28% points. The greatest weakness of ATHERSYS INC NEW is the variable Assets, Current, reducing the Economic Capital Ratio by 219% points.

The company's Economic Capital Ratio, given in the ranking table, is -275%, being 318% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	13,535
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	38,444
Liabilities, Non-Current	0
Other Assets	9,982
Other Compr. Net Income	0
Other Expenses	-2,777
Other Liabilities	0
Other Net Income	278
Other Revenues	5,325
Property and Equipment	4,214
Research and Development	65,031
Selling, General and Administrative Expense	15,883

Output Variable	Value in 1000 USD
Assets	27,731
Liabilities	38,444
Expenses	78,137
Revenues	5,325
Stockholders Equity	-10,713
Net Income	-72,534
Comprehensive Net Income	-72,534
Economic Capital Ratio	-275%





PHARMACEUTICAL 2023

Cogent Biosciences Inc.
Rank 126 of 446



The relative strengths and weaknesses of Cogent Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cogent Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 68% points. The greatest weakness of Cogent Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 173%, being 130% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	264,966
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,849
Liabilities, Non-Current	18,226
Other Assets	28,061
Other Compr. Net Income	-104
Other Expenses	0
Other Liabilities	0
Other Net Income	7,598
Other Revenues	0
Property and Equipment	7,783
Research and Development	121,627
Selling, General and Administrative Expense	26,212


Output Variable	Value in 1000 USD
Assets	300,810
Liabilities	45,075
Expenses	147,839
Revenues	0
Stockholders Equity	255,735
Net Income	-140,241
Comprehensive Net Income	-140,293
Economic Capital Ratio	173%



PHARMACEUTICAL 2023

SPECTRUM PHARMACEUTICALS INC

Rank 328 of 446





PHARMACEUTICAL 2023

SPECTRUM PHARMACEUTICALS INC Rank 328 of 446




The relative strengths and weaknesses of SPECTRUM PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SPECTRUM PHARMACEUTICALS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 22% points. The greatest weakness of SPECTRUM PHARMACEUTICALS INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is -31%, being 74% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	101,011
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	42,685
Liabilities, Non-Current	4,099
Other Assets	1,851
Other Compr. Net Income	125
Other Expenses	1,838
Other Liabilities	28,666
Other Net Income	-2,658
Other Revenues	10,114
Property and Equipment	476
Research and Development	42,203
Selling, General and Administrative Expense	38,816

Output Variable	Value in 1000 USD
Assets	103,338
Liabilities	75,450
Expenses	82,857
Revenues	10,114
Stockholders Equity	27,888
Net Income	-75,401
Comprehensive Net Income	-75,338
Economic Capital Ratio	-31%




The relative strengths and weaknesses of ROCKET PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ROCKET PHARMACEUTICALS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 42% points. The greatest weakness of ROCKET PHARMACEUTICALS INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 202%, being 159% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	364,060
Cost of Goods Sold	0
Intangible Assets	64,878
Liabilities, Current	39,169
Liabilities, Non-Current	3,683
Other Assets	93,860
Other Compr. Net Income	-196
Other Expenses	1,862
Other Liabilities	19,269
Other Net Income	453
Other Revenues	3,889
Property and Equipment	29,009
Research and Development	165,570
Selling, General and Administrative Expense	58,773

Output Variable	Value in 1000 USD
Assets	551,807
Liabilities	62,121
Expenses	226,205
Revenues	3,889
Stockholders Equity	489,686
Net Income	-221,863
Comprehensive Net Income	-221,961
Economic Capital Ratio	202%



The relative strengths and weaknesses of LIGAND PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIGAND PHARMACEUTICALS INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 102% points. The greatest weakness of LIGAND PHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 214%, being 171% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	263,601
Cost of Goods Sold	0
Intangible Assets	448,128
Liabilities, Current	98,810
Liabilities, Non-Current	32,302
Other Assets	38,457
Other Compr. Net Income	-67
Other Expenses	128,294
Other Liabilities	34,071
Other Net Income	4,832
Other Revenues	196,245
Property and Equipment	12,482
Research and Development	36,082
Selling, General and Administrative Expense	70,062

Output Variable	Value in 1000 USD
Assets	762,668
Liabilities	165,183
Expenses	234,438
Revenues	196,245
Stockholders Equity	597,485
Net Income	-33,361
Comprehensive Net Income	-33,394
Economic Capital Ratio	214%



PHARMACEUTICAL 2023

PHIBRO ANIMAL HEALTH CORP Rank 243 of 446





PHARMACEUTICAL 2023

PHIBRO ANIMAL HEALTH CORP Rank 243 of 446




The relative strengths and weaknesses of PHIBRO ANIMAL HEALTH CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PHIBRO ANIMAL HEALTH CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 103% points. The greatest weakness of PHIBRO ANIMAL HEALTH CORP is the variable Other Liabilities, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is 62%, being 19% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	566,232
Cost of Goods Sold	656,861
Intangible Assets	117,087
Liabilities, Current	190,832
Liabilities, Non-Current	60,500
Other Assets	82,890
Other Compr. Net Income	-5,820
Other Expenses	23,152
Other Liabilities	417,925
Other Net Income	-6,659
Other Revenues	942,261
Property and Equipment	165,490
Research and Development	0
Selling, General and Administrative Expense	206,414

Output Variable	Value in 1000 USD
Assets	931,699
Liabilities	669,257
Expenses	886,427
Revenues	942,261
Stockholders Equity	262,442
Net Income	49,175
Comprehensive Net Income	46,265
Economic Capital Ratio	62%






The relative strengths and weaknesses of REGENERON PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENERON PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 95% points. The greatest weakness of REGENERON PHARMACEUTICALS INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 8.5% points.

The company's Economic Capital Ratio, given in the ranking table, is 242%, being 199% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	15,884,100
Cost of Goods Sold	0
Intangible Assets	915,500
Liabilities, Current	3,141,300
Liabilities, Non-Current	2,689,200
Other Assets	12,414,900
Other Compr. Net Income	-212,600
Other Expenses	2,246,000
Other Liabilities	720,000
Other Net Income	119,900
Other Revenues	12,172,900
Property and Equipment	0
Research and Development	3,592,500
Selling, General and Administrative Expense	2,115,900

Output Variable	Value in 1000 USD
Assets	29,214,500
Liabilities	6,550,500
Expenses	7,954,400
Revenues	12,172,900
Stockholders Equity	22,664,000
Net Income	4,338,400
Comprehensive Net Income	4,232,100
Economic Capital Ratio	242%





PHARMACEUTICAL 2023

AGILE THERAPEUTICS INC Rank 393 of 446




The relative strengths and weaknesses of AGILE THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGILE THERAPEUTICS INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 128% points. The greatest weakness of AGILE THERAPEUTICS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 259% points.

The company's Economic Capital Ratio, given in the ranking table, is -205%, being 249% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	11,358
Cost of Goods Sold	6,836
Intangible Assets	0
Liabilities, Current	13,387
Liabilities, Non-Current	466
Other Assets	2,707
Other Compr. Net Income	0
Other Expenses	36,816
Other Liabilities	5,934
Other Net Income	22,469
Other Revenues	10,884
Property and Equipment	177
Research and Development	3,253
Selling, General and Administrative Expense	11,860

Output Variable	Value in 1000 USD
Assets	14,242
Liabilities	19,787
Expenses	58,765
Revenues	10,884
Stockholders Equity	-5,545
Net Income	-25,412
Comprehensive Net Income	-25,412
Economic Capital Ratio	-205%





PHARMACEUTICAL 2023

Liquidia Corp
Rank 169 of 446



The relative strengths and weaknesses of Liquidia Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Liquidia Corp compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Liquidia Corp is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 136%, being 93% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	99,811
Cost of Goods Sold	2,859
Intangible Assets	7,629
Liabilities, Current	8,800
Liabilities, Non-Current	23,211
Other Assets	17,607
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	6,765
Other Net Income	-2,245
Other Revenues	15,935
Property and Equipment	4,151
Research and Development	19,435
Selling, General and Administrative Expense	32,411

Output Variable	Value in 1000 USD
Assets	129,198
Liabilities	38,776
Expenses	54,705
Revenues	15,935
Stockholders Equity	90,422
Net Income	-41,015
Comprehensive Net Income	-41,015
Economic Capital Ratio	136%



PHARMACEUTICAL 2023

Transcode Therapeutics Inc.
Rank 390 of 446





PHARMACEUTICAL 2023

Transcode Therapeutics Inc.
Rank 390 of 446


The relative strengths and weaknesses of Transcode Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Transcode Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 17% points. The greatest weakness of Transcode Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 175% points.

The company's Economic Capital Ratio, given in the ranking table, is -201%, being 244% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	7,379
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,347
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1,101
Other Revenues	0
Property and Equipment	209
Research and Development	10,232
Selling, General and Administrative Expense	8,433

Output Variable	Value in 1000 USD
Assets	7,588
Liabilities	4,347
Expenses	18,666
Revenues	0
Stockholders Equity	3,241
Net Income	-17,565
Comprehensive Net Income	-17,565
Economic Capital Ratio	-201%





PHARMACEUTICAL 2023

Innovation1 Biotech Inc.
Rank 355 of 446




The relative strengths and weaknesses of Innovation1 Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Innovation1 Biotech Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 341% points. The greatest weakness of Innovation1 Biotech Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 141% points.

The company's Economic Capital Ratio, given in the ranking table, is -85%, being 128% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	287
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	29,812
Liabilities, Non-Current	11,298
Other Assets	43,674
Other Compr. Net Income	0
Other Expenses	40,466
Other Liabilities	0
Other Net Income	-152
Other Revenues	0
Property and Equipment	2.6
Research and Development	201
Selling, General and Administrative Expense	362

Output Variable	Value in 1000 USD
Assets	43,963
Liabilities	41,111
Expenses	41,030
Revenues	0
Stockholders Equity	2,853
Net Income	-41,182
Comprehensive Net Income	-41,182
Economic Capital Ratio	-85%





PHARMACEUTICAL 2023

CohBar Inc.
Rank 139 of 446




The relative strengths and weaknesses of CohBar Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CohBar Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 102% points. The greatest weakness of CohBar Inc. is the variable Net Income, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is 163%, being 120% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	16,219
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	180
Liabilities, Non-Current	0
Other Assets	82
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	854
Other Net Income	213
Other Revenues	0
Property and Equipment	66
Research and Development	5,936
Selling, General and Administrative Expense	6,453

Output Variable	Value in 1000 USD
Assets	16,366
Liabilities	1,034
Expenses	12,388
Revenues	0
Stockholders Equity	15,332
Net Income	-12,175
Comprehensive Net Income	-12,175
Economic Capital Ratio	163%




The relative strengths and weaknesses of PROCYON CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PROCYON CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 158% points. The greatest weakness of PROCYON CORP is the variable Other Expenses, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is 177%, being 134% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,585
Cost of Goods Sold	1,357
Intangible Assets	17
Liabilities, Current	643
Liabilities, Non-Current	491
Other Assets	1,047
Other Compr. Net Income	0
Other Expenses	1,987
Other Liabilities	0
Other Net Income	1.8
Other Revenues	4,842
Property and Equipment	154
Research and Development	0
Selling, General and Administrative Expense	1,711

Output Variable	Value in 1000 USD
Assets	3,802
Liabilities	1,135
Expenses	5,054
Revenues	4,842
Stockholders Equity	2,668
Net Income	-210
Comprehensive Net Income	-210
Economic Capital Ratio	177%




The relative strengths and weaknesses of MEDICINOVA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MEDICINOVA INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 49% points. The greatest weakness of MEDICINOVA INC is the variable Other Expenses, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 273%, being 230% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	58,987
Cost of Goods Sold	0
Intangible Assets	9,600
Liabilities, Current	3,187
Liabilities, Non-Current	524
Other Assets	5,522
Other Compr. Net Income	-16
Other Expenses	9,147
Other Liabilities	202
Other Net Income	562
Other Revenues	0
Property and Equipment	45
Research and Development	0
Selling, General and Administrative Expense	5,485

Output Variable	Value in 1000 USD
Assets	74,155
Liabilities	3,913
Expenses	14,631
Revenues	0
Stockholders Equity	70,242
Net Income	-14,069
Comprehensive Net Income	-14,077
Economic Capital Ratio	273%





PHARMACEUTICAL 2023

VERU INC.
Rank 248 of 446



The relative strengths and weaknesses of VERU INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VERU INC. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 19% points. The greatest weakness of VERU INC. is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 58%, being 15% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	104,769
Cost of Goods Sold	8,763
Intangible Assets	10,856
Liabilities, Current	41,438
Liabilities, Non-Current	4,112
Other Assets	19,314
Other Compr. Net Income	0
Other Expenses	236
Other Liabilities	9,738
Other Net Income	-316
Other Revenues	39,354
Property and Equipment	1,186
Research and Development	70,646
Selling, General and Administrative Expense	43,169

Output Variable	Value in 1000 USD
Assets	136,126
Liabilities	55,287
Expenses	122,814
Revenues	39,354
Stockholders Equity	80,839
Net Income	-83,776
Comprehensive Net Income	-83,776
Economic Capital Ratio	58%



PHARMACEUTICAL 2023

Sonoma Pharmaceuticals Inc.
Rank 239 of 446





RealRate

PHARMACEUTICAL 2023

Sonoma Pharmaceuticals Inc. Rank 239 of 446



The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Sonoma Pharmaceuticals Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 69%, being 26% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	16,430
Cost of Goods Sold	8,635
Intangible Assets	0
Liabilities, Current	5,819
Liabilities, Non-Current	309
Other Assets	2,095
Other Compr. Net Income	267
Other Expenses	-332
Other Liabilities	4,020
Other Net Income	469
Other Revenues	12,628
Property and Equipment	320
Research and Development	125
Selling, General and Administrative Expense	9,755

Output Variable	Value in 1000 USD
Assets	18,845
Liabilities	10,148
Expenses	18,183
Revenues	12,628
Stockholders Equity	8,697
Net Income	-5,086
Comprehensive Net Income	-4,952
Economic Capital Ratio	69%



PHARMACEUTICAL 2023

GT Biopharma Inc.
Rank 306 of 446





PHARMACEUTICAL 2023

GT Biopharma Inc.
Rank 306 of 446

The relative strengths and weaknesses of GT Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GT Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 39% points. The greatest weakness of GT Biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 103% points.

The company's Economic Capital Ratio, given in the ranking table, is -6.5%, being 50% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	16,562
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,938
Liabilities, Non-Current	64
Other Assets	174
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	373
Other Revenues	0
Property and Equipment	0
Research and Development	8,811
Selling, General and Administrative Expense	12,446


Output Variable	Value in 1000 USD
Assets	16,736
Liabilities	5,002
Expenses	21,257
Revenues	0
Stockholders Equity	11,734
Net Income	-20,884
Comprehensive Net Income	-20,884
Economic Capital Ratio	-6.5%



RealRate

PHARMACEUTICAL 2023

MEI Pharma Inc.
Rank 276 of 446





RealRate

PHARMACEUTICAL 2023

MEI Pharma Inc.
Rank 276 of 446




The relative strengths and weaknesses of MEI Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MEI Pharma Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 35% points. The greatest weakness of MEI Pharma Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is 24%, being 20% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	167,126
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,443
Liabilities, Non-Current	8,771
Other Assets	9,054
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	92,213
Other Net Income	21,030
Other Revenues	40,697
Property and Equipment	1,660
Research and Development	85,641
Selling, General and Administrative Expense	30,540

Output Variable	Value in 1000 USD
Assets	177,840
Liabilities	125,427
Expenses	116,181
Revenues	40,697
Stockholders Equity	52,413
Net Income	-54,454
Comprehensive Net Income	-54,454
Economic Capital Ratio	24%



The relative strengths and weaknesses of Atea Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Atea Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Atea Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 270%, being 227% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	660,922
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,478
Liabilities, Non-Current	2,403
Other Assets	4,081
Other Compr. Net Income	-684
Other Expenses	45,124
Other Liabilities	5,255
Other Net Income	0
Other Revenues	11,151
Property and Equipment	1,705
Research and Development	81,936
Selling, General and Administrative Expense	48,714

Output Variable	Value in 1000 USD
Assets	666,708
Liabilities	26,136
Expenses	175,774
Revenues	11,151
Stockholders Equity	640,572
Net Income	-164,623
Comprehensive Net Income	-164,965
Economic Capital Ratio	270%



PHARMACEUTICAL 2023

Pyxis Oncology Inc.
Rank 184 of 446





PHARMACEUTICAL 2023

Pyxis Oncology Inc.
Rank 184 of 446

The relative strengths and weaknesses of Pyxis Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pyxis Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Pyxis Oncology Inc. is the variable Net Income, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 119%, being 76% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	186,612
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,634
Liabilities, Non-Current	18,921
Other Assets	13,602
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	2,764
Other Revenues	0
Property and Equipment	11,165
Research and Development	86,129
Selling, General and Administrative Expense	37,352

Output Variable	Value in 1000 USD
Assets	211,379
Liabilities	50,555
Expenses	123,481
Revenues	0
Stockholders Equity	160,824
Net Income	-120,717
Comprehensive Net Income	-120,717
Economic Capital Ratio	119%



PHARMACEUTICAL 2023

Assertio Holdings Inc.
Rank 138 of 446





PHARMACEUTICAL 2023

Assertio Holdings Inc.
Rank 138 of 446




The relative strengths and weaknesses of Assertio Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Assertio Holdings Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 96% points. The greatest weakness of Assertio Holdings Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 165%, being 122% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	132,262
Cost of Goods Sold	0
Intangible Assets	197,996
Liabilities, Current	95,316
Liabilities, Non-Current	70,672
Other Assets	82,911
Other Compr. Net Income	0
Other Expenses	-8,416
Other Liabilities	22,200
Other Net Income	-8,239
Other Revenues	156,234
Property and Equipment	744
Research and Development	0
Selling, General and Administrative Expense	46,786

Output Variable	Value in 1000 USD
Assets	413,913
Liabilities	188,188
Expenses	38,370
Revenues	156,234
Stockholders Equity	225,725
Net Income	109,625
Comprehensive Net Income	109,625
Economic Capital Ratio	165%




The relative strengths and weaknesses of IDEAYA Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IDEAYA Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of IDEAYA Biosciences Inc. is the variable Intangible Assets, reducing the Economic Capital Ratio by 3.6% points.

The company's Economic Capital Ratio, given in the ranking table, is 254%, being 211% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	370,454
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,718
Liabilities, Non-Current	6,796
Other Assets	11,006
Other Compr. Net Income	-2,159
Other Expenses	0
Other Liabilities	0
Other Net Income	3,847
Other Revenues	50,931
Property and Equipment	6,509
Research and Development	89,536
Selling, General and Administrative Expense	23,897

Output Variable	Value in 1000 USD
Assets	387,969
Liabilities	38,514
Expenses	113,433
Revenues	50,931
Stockholders Equity	349,455
Net Income	-58,655
Comprehensive Net Income	-59,734
Economic Capital Ratio	254%





PHARMACEUTICAL 2023

EXICURE INC.
Rank 158 of 446




The relative strengths and weaknesses of EXICURE INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of EXICURE INC. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 145% points. The greatest weakness of EXICURE INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is 145%, being 102% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	10,051
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,639
Liabilities, Non-Current	6,767
Other Assets	10,747
Other Compr. Net Income	2.0
Other Expenses	209
Other Liabilities	0
Other Net Income	-542
Other Revenues	28,826
Property and Equipment	2,530
Research and Development	19,767
Selling, General and Administrative Expense	10,890

Output Variable	Value in 1000 USD
Assets	23,328
Liabilities	8,406
Expenses	30,866
Revenues	28,826
Stockholders Equity	14,922
Net Income	-2,582
Comprehensive Net Income	-2,581
Economic Capital Ratio	145%





RealRate

PHARMACEUTICAL 2023

Longboard Pharmaceuticals Inc. Rank 147 of 446



The relative strengths and weaknesses of Longboard Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Longboard Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 104% points. The greatest weakness of Longboard Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is 157%, being 114% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	69,838
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,764
Liabilities, Non-Current	0
Other Assets	769
Other Compr. Net Income	-528
Other Expenses	0
Other Liabilities	0
Other Net Income	853
Other Revenues	0
Property and Equipment	9.0
Research and Development	34,638
Selling, General and Administrative Expense	10,160

Output Variable	Value in 1000 USD
Assets	70,616
Liabilities	8,764
Expenses	44,798
Revenues	0
Stockholders Equity	61,852
Net Income	-43,945
Comprehensive Net Income	-44,209
Economic Capital Ratio	157%



PHARMACEUTICAL 2023

HERON THERAPEUTICS INC. DE Rank 347 of 446





PHARMACEUTICAL 2023

HERON THERAPEUTICS INC. DE Rank 347 of 446




The relative strengths and weaknesses of HERON THERAPEUTICS INC. DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HERON THERAPEUTICS INC. DE compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 24% points. The greatest weakness of HERON THERAPEUTICS INC. DE is the variable Other Liabilities, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is -65%, being 108% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	205,435
Cost of Goods Sold	54,874
Intangible Assets	0
Liabilities, Current	82,355
Liabilities, Non-Current	5,740
Other Assets	23,356
Other Compr. Net Income	-13
Other Expenses	82,513
Other Liabilities	149,284
Other Net Income	-7,366
Other Revenues	107,672
Property and Equipment	22,160
Research and Development	107,506
Selling, General and Administrative Expense	37,437

Output Variable	Value in 1000 USD
Assets	250,951
Liabilities	237,379
Expenses	282,330
Revenues	107,672
Stockholders Equity	13,572
Net Income	-182,024
Comprehensive Net Income	-182,030
Economic Capital Ratio	-65%





PHARMACEUTICAL 2023

Biostax Corp.
Rank 419 of 446



The relative strengths and weaknesses of Biostax Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biostax Corp. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Biostax Corp. is the variable Assets, Current, reducing the Economic Capital Ratio by 251% points.

The company's Economic Capital Ratio, given in the ranking table, is -354%, being 397% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	150
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,477
Liabilities, Non-Current	0
Other Assets	813
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-2,373
Other Revenues	0
Property and Equipment	0
Research and Development	14
Selling, General and Administrative Expense	1,149

Output Variable	Value in 1000 USD
Assets	964
Liabilities	3,477
Expenses	1,163
Revenues	0
Stockholders Equity	-2,513
Net Income	-3,536
Comprehensive Net Income	-3,536
Economic Capital Ratio	-354%



PHARMACEUTICAL 2023

Rain Oncology Inc.
Rank 152 of 446





PHARMACEUTICAL 2023

Rain Oncology Inc.
Rank 152 of 446


The relative strengths and weaknesses of Rain Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rain Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 105% points. The greatest weakness of Rain Oncology Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 151%, being 108% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	133,628
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,966
Liabilities, Non-Current	178
Other Assets	1,459
Other Compr. Net Income	-77
Other Expenses	3.0
Other Liabilities	0
Other Net Income	1,415
Other Revenues	0
Property and Equipment	93
Research and Development	61,400
Selling, General and Administrative Expense	15,736

Output Variable	Value in 1000 USD
Assets	135,180
Liabilities	22,144
Expenses	77,139
Revenues	0
Stockholders Equity	113,036
Net Income	-75,724
Comprehensive Net Income	-75,762
Economic Capital Ratio	151%




The relative strengths and weaknesses of Kura Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kura Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 96% points. The greatest weakness of Kura Oncology Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 237%, being 194% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	446,426
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,057
Liabilities, Non-Current	11,971
Other Assets	7,340
Other Compr. Net Income	-6,243
Other Expenses	0
Other Liabilities	0
Other Net Income	4,025
Other Revenues	0
Property and Equipment	2,540
Research and Development	92,812
Selling, General and Administrative Expense	47,053

Output Variable	Value in 1000 USD
Assets	456,306
Liabilities	36,028
Expenses	139,865
Revenues	0
Stockholders Equity	420,278
Net Income	-135,840
Comprehensive Net Income	-138,962
Economic Capital Ratio	237%





PHARMACEUTICAL 2023

vTv Therapeutics Inc.
Rank 339 of 446




The relative strengths and weaknesses of vTv Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of vTv Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 14% points. The greatest weakness of vTv Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is -50%, being 93% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	27,094
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,708
Liabilities, Non-Current	19,007
Other Assets	5,937
Other Compr. Net Income	0
Other Expenses	215
Other Liabilities	684
Other Net Income	-2,318
Other Revenues	2,018
Property and Equipment	207
Research and Development	12,357
Selling, General and Administrative Expense	12,201

Output Variable	Value in 1000 USD
Assets	33,238
Liabilities	27,399
Expenses	24,773
Revenues	2,018
Stockholders Equity	5,839
Net Income	-25,073
Comprehensive Net Income	-25,073
Economic Capital Ratio	-50%





RealRate

PHARMACEUTICAL 2023

DMK PHARMACEUTICALS Corp Rank 401 of 446



The relative strengths and weaknesses of DMK PHARMACEUTICALS Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DMK PHARMACEUTICALS Corp compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 16% points. The greatest weakness of DMK PHARMACEUTICALS Corp is the variable Assets, Current, reducing the Economic Capital Ratio by 183% points.

The company's Economic Capital Ratio, given in the ranking table, is -245%, being 288% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	9,272
Cost of Goods Sold	6,187
Intangible Assets	0
Liabilities, Current	11,396
Liabilities, Non-Current	0
Other Assets	370
Other Compr. Net Income	0
Other Expenses	2.0
Other Liabilities	186
Other Net Income	-1,417
Other Revenues	4,756
Property and Equipment	1,289
Research and Development	10,380
Selling, General and Administrative Expense	13,248

Output Variable	Value in 1000 USD
Assets	10,931
Liabilities	11,582
Expenses	29,817
Revenues	4,756
Stockholders Equity	-651
Net Income	-26,478
Comprehensive Net Income	-26,478
Economic Capital Ratio	-245%



PHARMACEUTICAL 2023

NORTHWEST BIOTHERAPEUTICS INC Rank 417 of 446





PHARMACEUTICAL 2023

NORTHWEST BIOTHERAPEUTICS INC Rank 417 of 446

The relative strengths and weaknesses of NORTHWEST BIOTHERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NORTHWEST BIOTHERAPEUTICS INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 38% points. The greatest weakness of NORTHWEST BIOTHERAPEUTICS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 226% points.

The company's Economic Capital Ratio, given in the ranking table, is -339%, being 382% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	9,425
Cost of Goods Sold	0
Intangible Assets	626
Liabilities, Current	126,005
Liabilities, Non-Current	10,361
Other Assets	7,854
Other Compr. Net Income	2,788
Other Expenses	0
Other Liabilities	0
Other Net Income	-37,851
Other Revenues	1,683
Property and Equipment	13,418
Research and Development	35,511
Selling, General and Administrative Expense	33,353

Output Variable	Value in 1000 USD
Assets	31,323
Liabilities	136,366
Expenses	68,864
Revenues	1,683
Stockholders Equity	-105,043
Net Income	-105,032
Comprehensive Net Income	-103,638
Economic Capital Ratio	-339%



PHARMACEUTICAL 2023

Arcutis Biotherapeutics Inc.
Rank 286 of 446





PHARMACEUTICAL 2023

Arcutis Biotherapeutics Inc.
Rank 286 of 446


The relative strengths and weaknesses of Arcutis Biotherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcutis Biotherapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Arcutis Biotherapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is 14%, being 29% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	437,406
Cost of Goods Sold	0
Intangible Assets	7,188
Liabilities, Current	37,807
Liabilities, Non-Current	201,886
Other Assets	2,799
Other Compr. Net Income	-831
Other Expenses	754
Other Liabilities	0
Other Net Income	-9,831
Other Revenues	3,686
Property and Equipment	1,881
Research and Development	182,435
Selling, General and Administrative Expense	122,124

Output Variable	Value in 1000 USD
Assets	449,274
Liabilities	239,693
Expenses	305,313
Revenues	3,686
Stockholders Equity	209,581
Net Income	-311,458
Comprehensive Net Income	-311,874
Economic Capital Ratio	14%





PHARMACEUTICAL 2023

NEKTAR THERAPEUTICS Rank 254 of 446




The relative strengths and weaknesses of NEKTAR THERAPEUTICS are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEKTAR THERAPEUTICS compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 36% points. The greatest weakness of NEKTAR THERAPEUTICS is the variable Other Liabilities, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 50%, being 6.4% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	545,968
Cost of Goods Sold	21,635
Intangible Assets	76,501
Liabilities, Current	68,204
Liabilities, Non-Current	120,380
Other Assets	55,680
Other Compr. Net Income	-2,750
Other Expenses	139,145
Other Liabilities	155,378
Other Net Income	11,183
Other Revenues	92,055
Property and Equipment	32,451
Research and Development	218,323
Selling, General and Administrative Expense	92,333

Output Variable	Value in 1000 USD
Assets	710,600
Liabilities	343,962
Expenses	471,436
Revenues	92,055
Stockholders Equity	366,638
Net Income	-368,198
Comprehensive Net Income	-369,573
Economic Capital Ratio	50%





RealRate

PHARMACEUTICAL 2023

Timber Pharmaceuticals Inc. Rank 374 of 446



The relative strengths and weaknesses of Timber Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Timber Pharmaceuticals Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 18% points. The greatest weakness of Timber Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 151% points.

The company's Economic Capital Ratio, given in the ranking table, is -135%, being 179% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	9,813
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,041
Liabilities, Non-Current	0
Other Assets	443
Other Compr. Net Income	0
Other Expenses	4,008
Other Liabilities	0
Other Net Income	-136
Other Revenues	83
Property and Equipment	19
Research and Development	9,302
Selling, General and Administrative Expense	6,017

Output Variable	Value in 1000 USD
Assets	10,276
Liabilities	5,041
Expenses	19,326
Revenues	83
Stockholders Equity	5,234
Net Income	-19,379
Comprehensive Net Income	-19,379
Economic Capital Ratio	-135%



PHARMACEUTICAL 2023

Propanc Biopharma Inc.
Rank 444 of 446





PHARMACEUTICAL 2023

Propanc Biopharma Inc.
Rank 444 of 446

The relative strengths and weaknesses of Propanc Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Propanc Biopharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 494% points. The greatest weakness of Propanc Biopharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 340% points.

The company's Economic Capital Ratio, given in the ranking table, is -510%, being 554% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	15
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,063
Liabilities, Non-Current	42
Other Assets	65
Other Compr. Net Income	-551
Other Expenses	-27
Other Liabilities	0
Other Net Income	-722
Other Revenues	0
Property and Equipment	2.0
Research and Development	256
Selling, General and Administrative Expense	1,706


Output Variable	Value in 1000 USD
Assets	82
Liabilities	3,105
Expenses	1,936
Revenues	0
Stockholders Equity	-3,024
Net Income	-2,658
Comprehensive Net Income	-2,934
Economic Capital Ratio	-510%



RealRate

PHARMACEUTICAL 2023

AMICUS THERAPEUTICS INC. Rank 304 of 446





RealRate

PHARMACEUTICAL 2023

AMICUS THERAPEUTICS INC. Rank 304 of 446




The relative strengths and weaknesses of AMICUS THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AMICUS THERAPEUTICS INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 46% points. The greatest weakness of AMICUS THERAPEUTICS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is -5.1%, being 48% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	423,816
Cost of Goods Sold	38,599
Intangible Assets	220,797
Liabilities, Current	139,018
Liabilities, Non-Current	60,517
Other Assets	48,776
Other Compr. Net Income	-17,086
Other Expenses	44,684
Other Liabilities	401,585
Other Net Income	7,200
Other Revenues	329,233
Property and Equipment	30,778
Research and Development	276,677
Selling, General and Administrative Expense	213,041

Output Variable	Value in 1000 USD
Assets	724,167
Liabilities	601,120
Expenses	573,001
Revenues	329,233
Stockholders Equity	123,047
Net Income	-236,568
Comprehensive Net Income	-245,111
Economic Capital Ratio	-5.1%





PHARMACEUTICAL 2023

Evelo Biosciences Inc.
Rank 388 of 446


The relative strengths and weaknesses of Evelo Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evelo Biosciences Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 15% points. The greatest weakness of Evelo Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 98% points.

The company's Economic Capital Ratio, given in the ranking table, is -184%, being 227% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	51,573
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,395
Liabilities, Non-Current	57,038
Other Assets	8,026
Other Compr. Net Income	0
Other Expenses	930
Other Liabilities	0
Other Net Income	-5,131
Other Revenues	0
Property and Equipment	4,842
Research and Development	78,554
Selling, General and Administrative Expense	29,912

Output Variable	Value in 1000 USD
Assets	64,441
Liabilities	69,433
Expenses	109,396
Revenues	0
Stockholders Equity	-4,992
Net Income	-114,527
Comprehensive Net Income	-114,527
Economic Capital Ratio	-184%





PHARMACEUTICAL 2023

Zentalis Pharmaceuticals Inc.
Rank 145 of 446



The relative strengths and weaknesses of Zentalis Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zentalis Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Zentalis Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 158%, being 115% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	451,933
Cost of Goods Sold	0
Intangible Assets	3,736
Liabilities, Current	56,647
Liabilities, Non-Current	47,786
Other Assets	75,936
Other Compr. Net Income	-921
Other Expenses	-469
Other Liabilities	853
Other Net Income	-10,295
Other Revenues	0
Property and Equipment	7,705
Research and Development	172,734
Selling, General and Administrative Expense	54,553

Output Variable	Value in 1000 USD
Assets	539,310
Liabilities	105,286
Expenses	226,818
Revenues	0
Stockholders Equity	434,024
Net Income	-237,113
Comprehensive Net Income	-237,574
Economic Capital Ratio	158%



PHARMACEUTICAL 2023

Q BioMed Inc.
Rank 385 of 446





PHARMACEUTICAL 2023

Q BioMed Inc.
Rank 385 of 446


The relative strengths and weaknesses of Q BioMed Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Q BioMed Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 129% points. The greatest weakness of Q BioMed Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 204% points.

The company's Economic Capital Ratio, given in the ranking table, is -172%, being 215% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	72
Cost of Goods Sold	293
Intangible Assets	300
Liabilities, Current	8,133
Liabilities, Non-Current	0
Other Assets	3,143
Other Compr. Net Income	0
Other Expenses	0.0010
Other Liabilities	0
Other Net Income	1,394
Other Revenues	284
Property and Equipment	0
Research and Development	125
Selling, General and Administrative Expense	3,311

Output Variable	Value in 1000 USD
Assets	3,516
Liabilities	8,133
Expenses	3,730
Revenues	284
Stockholders Equity	-4,617
Net Income	-2,052
Comprehensive Net Income	-2,052
Economic Capital Ratio	-172%




The relative strengths and weaknesses of KalVista Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KalVista Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points. The greatest weakness of KalVista Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 211%, being 168% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	193,647
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,576
Liabilities, Non-Current	7,211
Other Assets	8,055
Other Compr. Net Income	-2,429
Other Expenses	0
Other Liabilities	0
Other Net Income	14,274
Other Revenues	0
Property and Equipment	2,178
Research and Development	70,167
Selling, General and Administrative Expense	26,446

Output Variable	Value in 1000 USD
Assets	203,880
Liabilities	18,787
Expenses	96,613
Revenues	0
Stockholders Equity	185,093
Net Income	-82,339
Comprehensive Net Income	-83,554
Economic Capital Ratio	211%





PHARMACEUTICAL 2023

Akebia Therapeutics Inc.
Rank 316 of 446

Akebia

The relative strengths and weaknesses of Akebia Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Akebia Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Akebia Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is -22%, being 65% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	184,949
Cost of Goods Sold	84,796
Intangible Assets	55,053
Liabilities, Current	124,756
Liabilities, Non-Current	118,496
Other Assets	106,614
Other Compr. Net Income	0
Other Expenses	19,108
Other Liabilities	99,236
Other Net Income	-13,447
Other Revenues	292,602
Property and Equipment	5,214
Research and Development	129,114
Selling, General and Administrative Expense	138,699

Output Variable	Value in 1000 USD
Assets	351,830
Liabilities	342,488
Expenses	371,717
Revenues	292,602
Stockholders Equity	9,342
Net Income	-92,562
Comprehensive Net Income	-92,562
Economic Capital Ratio	-22%



PHARMACEUTICAL 2023

Vicapsys Life Sciences Inc.
Rank 440 of 446





PHARMACEUTICAL 2023


Vicapsys Life Sciences Inc.
Rank 440 of 446

The relative strengths and weaknesses of Vicapsys Life Sciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vicapsys Life Sciences Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 368% points. The greatest weakness of Vicapsys Life Sciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 296% points.

The company's Economic Capital Ratio, given in the ranking table, is -479%, being 522% points below the market average of 43%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	72	Assets	72
Cost of Goods Sold	0	Liabilities	1,023
Intangible Assets	0	Expenses	985
Liabilities, Current	1,023	Revenues	0
Liabilities, Non-Current	0	Stockholders Equity	-951
Other Assets	0	Net Income	-985
Other Compr. Net Income	0	Comprehensive Net Income	-985
Other Expenses	911	Economic Capital Ratio	-479%
Other Liabilities	0		
Other Net Income	0		
Other Revenues	0		
Property and Equipment	0		
Research and Development	13		
Selling, General and Administrative Expense	60		




The relative strengths and weaknesses of Cyteir Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cyteir Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Cyteir Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 257%, being 214% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	149,209
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,315
Liabilities, Non-Current	1,631
Other Assets	2,324
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	2,109
Other Revenues	0
Property and Equipment	1,699
Research and Development	34,624
Selling, General and Administrative Expense	13,546

Output Variable	Value in 1000 USD
Assets	153,232
Liabilities	6,946
Expenses	48,170
Revenues	0
Stockholders Equity	146,286
Net Income	-46,061
Comprehensive Net Income	-46,061
Economic Capital Ratio	257%



The relative strengths and weaknesses of ANAPTYSBIO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANAPTYSBIO INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of ANAPTYSBIO INC is the variable Other Revenues, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 275%, being 231% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	447,205
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,054
Liabilities, Non-Current	0
Other Assets	161,089
Other Compr. Net Income	-4,824
Other Expenses	24
Other Liabilities	0
Other Net Income	-13,546
Other Revenues	10,287
Property and Equipment	2,089
Research and Development	88,798
Selling, General and Administrative Expense	36,643

Output Variable	Value in 1000 USD
Assets	610,383
Liabilities	26,054
Expenses	125,465
Revenues	10,287
Stockholders Equity	584,329
Net Income	-128,724
Comprehensive Net Income	-131,136
Economic Capital Ratio	275%



PHARMACEUTICAL 2023

FIBROGEN INC
Rank 338 of 446





PHARMACEUTICAL 2023

FIBROGEN INC
Rank 338 of 446




The relative strengths and weaknesses of FIBROGEN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of FIBROGEN INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 19% points. The greatest weakness of FIBROGEN INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is -49%, being 92% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	492,826
Cost of Goods Sold	20,280
Intangible Assets	0
Liabilities, Current	273,562
Liabilities, Non-Current	271,755
Other Assets	96,656
Other Compr. Net Income	-1,557
Other Expenses	358
Other Liabilities	66,250
Other Net Income	7,729
Other Revenues	140,734
Property and Equipment	20,605
Research and Development	296,791
Selling, General and Administrative Expense	124,688

Output Variable	Value in 1000 USD
Assets	610,087
Liabilities	611,567
Expenses	442,117
Revenues	140,734
Stockholders Equity	-1,480
Net Income	-293,654
Comprehensive Net Income	-294,432
Economic Capital Ratio	-49%





PHARMACEUTICAL 2023

SYNLOGIC INC.
Rank 197 of 446



The relative strengths and weaknesses of SYNLOGIC INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SYNLOGIC INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 31% points. The greatest weakness of SYNLOGIC INC. is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 109%, being 66% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	79,782
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,122
Liabilities, Non-Current	16,133
Other Assets	23,760
Other Compr. Net Income	-116
Other Expenses	0
Other Liabilities	0
Other Net Income	1,272
Other Revenues	1,180
Property and Equipment	7,323
Research and Development	52,044
Selling, General and Administrative Expense	16,555

Output Variable	Value in 1000 USD
Assets	110,865
Liabilities	28,255
Expenses	68,599
Revenues	1,180
Stockholders Equity	82,610
Net Income	-66,147
Comprehensive Net Income	-66,205
Economic Capital Ratio	109%



PHARMACEUTICAL 2023

BRISTOL MYERS SQUIBB CO
Rank 233 of 446





PHARMACEUTICAL 2023

BRISTOL MYERS SQUIBB CO Rank 233 of 446



The relative strengths and weaknesses of BRISTOL MYERS SQUIBB CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BRISTOL MYERS SQUIBB CO compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 119% points. The greatest weakness of BRISTOL MYERS SQUIBB CO is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is 74%, being 31% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	27,273,000
Cost of Goods Sold	10,137,000
Intangible Assets	57,008,000
Liabilities, Current	21,890,000
Liabilities, Non-Current	41,646,000
Other Assets	6,284,000
Other Compr. Net Income	-31,000
Other Expenses	12,354,000
Other Liabilities	2,166,000
Other Net Income	0
Other Revenues	46,159,000
Property and Equipment	6,255,000
Research and Development	9,509,000
Selling, General and Administrative Expense	7,814,000

Output Variable	Value in 1000 USD
Assets	96,820,000
Liabilities	65,702,000
Expenses	39,814,000
Revenues	46,159,000
Stockholders Equity	31,118,000
Net Income	6,345,000
Comprehensive Net Income	6,329,500
Economic Capital Ratio	74%



PHARMACEUTICAL 2023

MARIZYME INC.
Rank 326 of 446






The relative strengths and weaknesses of MARIZYME INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MARIZYME INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 424% points. The greatest weakness of MARIZYME INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is -27%, being 70% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,955
Cost of Goods Sold	54
Intangible Assets	34,866
Liabilities, Current	2,922
Liabilities, Non-Current	18,344
Other Assets	1,854
Other Compr. Net Income	0
Other Expenses	33,524
Other Liabilities	0
Other Net Income	-842
Other Revenues	233
Property and Equipment	13
Research and Development	3,979
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	38,688
Liabilities	21,266
Expenses	37,557
Revenues	233
Stockholders Equity	17,422
Net Income	-38,166
Comprehensive Net Income	-38,166
Economic Capital Ratio	-27%





RealRate

PHARMACEUTICAL 2023

Alkermes plc.
Rank 191 of 446




The relative strengths and weaknesses of Alkermes plc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alkermes plc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Alkermes plc. is the variable Assets, Current, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 113%, being 70% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,130,306
Cost of Goods Sold	218,108
Intangible Assets	130,553
Liabilities, Current	497,742
Liabilities, Non-Current	422,483
Other Assets	377,758
Other Compr. Net Income	-7,166
Other Expenses	27,326
Other Liabilities	0
Other Net Income	-25,039
Other Revenues	1,111,795
Property and Equipment	325,361
Research and Development	393,842
Selling, General and Administrative Expense	605,747

Output Variable	Value in 1000 USD
Assets	1,963,978
Liabilities	920,225
Expenses	1,245,023
Revenues	1,111,795
Stockholders Equity	1,043,753
Net Income	-158,267
Comprehensive Net Income	-161,850
Economic Capital Ratio	113%





RealRate

PHARMACEUTICAL 2023

VYNE Therapeutics Inc. Rank 182 of 446




The relative strengths and weaknesses of VYNE Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VYNE Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 79% points. The greatest weakness of VYNE Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 123%, being 80% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	38,275
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	2,483
Other Compr. Net Income	0
Other Expenses	13
Other Liabilities	9,345
Other Net Income	11,098
Other Revenues	477
Property and Equipment	0
Research and Development	18,385
Selling, General and Administrative Expense	16,387

Output Variable	Value in 1000 USD
Assets	40,758
Liabilities	9,345
Expenses	34,785
Revenues	477
Stockholders Equity	31,413
Net Income	-23,210
Comprehensive Net Income	-23,210
Economic Capital Ratio	123%





PHARMACEUTICAL 2023

Monopar Therapeutics Rank 227 of 446



The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Monopar Therapeutics is the variable Net Income, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 84%, being 41% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	13,166
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,129
Liabilities, Non-Current	8.4
Other Assets	61
Other Compr. Net Income	12
Other Expenses	0
Other Liabilities	0
Other Net Income	21
Other Revenues	0
Property and Equipment	0
Research and Development	7,592
Selling, General and Administrative Expense	2,945

Output Variable	Value in 1000 USD
Assets	13,227
Liabilities	3,137
Expenses	10,537
Revenues	0
Stockholders Equity	10,090
Net Income	-10,516
Comprehensive Net Income	-10,510
Economic Capital Ratio	84%



PHARMACEUTICAL 2023

Cryoport Inc.
Rank 186 of 446





PHARMACEUTICAL 2023

Cryoport Inc.
Rank 186 of 446



The relative strengths and weaknesses of Cryoport Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cryoport Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Cryoport Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 128% points.

The company's Economic Capital Ratio, given in the ranking table, is 119%, being 75% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	604,176
Cost of Goods Sold	133,404
Intangible Assets	342,126
Liabilities, Current	40,851
Liabilities, Non-Current	25,172
Other Assets	28,841
Other Compr. Net Income	-33,306
Other Expenses	2,239
Other Liabilities	416,885
Other Net Income	-3,190
Other Revenues	237,277
Property and Equipment	63,603
Research and Development	15,722
Selling, General and Administrative Expense	120,055


Output Variable	Value in 1000 USD
Assets	1,038,746
Liabilities	482,908
Expenses	271,420
Revenues	237,277
Stockholders Equity	555,838
Net Income	-37,333
Comprehensive Net Income	-53,986
Economic Capital Ratio	119%



RealRate

PHARMACEUTICAL 2023

International Stem Cell CORP Rank 310 of 446





RealRate

PHARMACEUTICAL 2023

International Stem Cell CORP Rank 310 of 446




The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of International Stem Cell CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 123% points. The greatest weakness of International Stem Cell CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is -14%, being 57% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,963
Cost of Goods Sold	3,269
Intangible Assets	878
Liabilities, Current	4,635
Liabilities, Non-Current	720
Other Assets	1,046
Other Compr. Net Income	0
Other Expenses	1,245
Other Liabilities	0
Other Net Income	-148
Other Revenues	8,180
Property and Equipment	248
Research and Development	492
Selling, General and Administrative Expense	3,357

Output Variable	Value in 1000 USD
Assets	5,135
Liabilities	5,355
Expenses	8,363
Revenues	8,180
Stockholders Equity	-220
Net Income	-331
Comprehensive Net Income	-331
Economic Capital Ratio	-14%





PHARMACEUTICAL 2023

BIO-PATH HOLDINGS INC Rank 188 of 446



The relative strengths and weaknesses of BIO-PATH HOLDINGS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIO-PATH HOLDINGS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 91% points. The greatest weakness of BIO-PATH HOLDINGS INC is the variable Net Income, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is 118%, being 75% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	15,615
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,684
Liabilities, Non-Current	113
Other Assets	198
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	33
Other Revenues	0
Property and Equipment	158
Research and Development	9,165
Selling, General and Administrative Expense	4,736

Output Variable	Value in 1000 USD
Assets	15,971
Liabilities	1,797
Expenses	13,901
Revenues	0
Stockholders Equity	14,174
Net Income	-13,868
Comprehensive Net Income	-13,868
Economic Capital Ratio	118%



PHARMACEUTICAL 2023

Aptevo Therapeutics Inc.
Rank 149 of 446





PHARMACEUTICAL 2023

Aptevo Therapeutics Inc.
Rank 149 of 446



The relative strengths and weaknesses of Aptevo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aptevo Therapeutics Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 143% points. The greatest weakness of Aptevo Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 154%, being 111% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	27,450
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,706
Liabilities, Non-Current	7,535
Other Assets	5,303
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	36,668
Other Revenues	3,114
Property and Equipment	1,462
Research and Development	17,882
Selling, General and Administrative Expense	13,873

Output Variable	Value in 1000 USD
Assets	34,215
Liabilities	16,241
Expenses	31,755
Revenues	3,114
Stockholders Equity	17,974
Net Income	8,027
Comprehensive Net Income	8,027
Economic Capital Ratio	154%



PHARMACEUTICAL 2023

Collectar Biosciences Inc.
Rank 311 of 446





PHARMACEUTICAL 2023

Collectar Biosciences Inc.
Rank 311 of 446


The relative strengths and weaknesses of Collectar Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Collectar Biosciences Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Collectar Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 115% points.

The company's Economic Capital Ratio, given in the ranking table, is -14%, being 57% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	20,530
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,529
Liabilities, Non-Current	553
Other Assets	642
Other Compr. Net Income	0
Other Expenses	-60
Other Liabilities	0
Other Net Income	153
Other Revenues	0
Property and Equipment	419
Research and Development	19,220
Selling, General and Administrative Expense	9,594

Output Variable	Value in 1000 USD
Assets	21,590
Liabilities	6,082
Expenses	28,754
Revenues	0
Stockholders Equity	15,508
Net Income	-28,601
Comprehensive Net Income	-28,601
Economic Capital Ratio	-14%



The relative strengths and weaknesses of Arcus Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcus Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Arcus Biosciences Inc. is the variable Intangible Assets, reducing the Economic Capital Ratio by 4.6% points.

The company's Economic Capital Ratio, given in the ranking table, is 223%, being 179% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	1,067,000
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	193,000
Liabilities, Non-Current	0
Other Assets	243,000
Other Compr. Net Income	-6,000
Other Expenses	1,000
Other Liabilities	0
Other Net Income	14,000
Other Revenues	112,000
Property and Equipment	35,000
Research and Development	288,000
Selling, General and Administrative Expense	104,000

Output Variable	Value in 1000 USD
Assets	1,345,000
Liabilities	193,000
Expenses	393,000
Revenues	112,000
Stockholders Equity	1,152,000
Net Income	-267,000
Comprehensive Net Income	-270,000
Economic Capital Ratio	223%



PHARMACEUTICAL 2023

OCULAR THERAPEUTIX INC
Rank 307 of 446





RealRate

PHARMACEUTICAL 2023

OCULAR THERAPEUTIX INC Rank 307 of 446



The relative strengths and weaknesses of OCULAR THERAPEUTIX INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OCULAR THERAPEUTIX INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 23% points. The greatest weakness of OCULAR THERAPEUTIX INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is -7.7%, being 51% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	129,627
Cost of Goods Sold	4,540
Intangible Assets	0
Liabilities, Current	31,395
Liabilities, Non-Current	22,158
Other Assets	9,806
Other Compr. Net Income	0
Other Expenses	39,922
Other Liabilities	60,357
Other Net Income	7,616
Other Revenues	51,494
Property and Equipment	9,856
Research and Development	53,462
Selling, General and Administrative Expense	32,224

Output Variable	Value in 1000 USD
Assets	149,289
Liabilities	113,910
Expenses	130,148
Revenues	51,494
Stockholders Equity	35,379
Net Income	-71,038
Comprehensive Net Income	-71,038
Economic Capital Ratio	-7.7%



PHARMACEUTICAL 2023

InMed Pharmaceuticals Inc.
Rank 334 of 446





PHARMACEUTICAL 2023

InMed Pharmaceuticals Inc.
Rank 334 of 446


The relative strengths and weaknesses of InMed Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of InMed Pharmaceuticals Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 27% points. The greatest weakness of InMed Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is -36%, being 79% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	9,598
Cost of Goods Sold	546
Intangible Assets	2,109
Liabilities, Current	3,320
Liabilities, Non-Current	389
Other Assets	1,081
Other Compr. Net Income	0
Other Expenses	4,973
Other Liabilities	0
Other Net Income	-21
Other Revenues	1,089
Property and Equipment	0
Research and Development	7,283
Selling, General and Administrative Expense	6,867

Output Variable	Value in 1000 USD
Assets	12,788
Liabilities	3,709
Expenses	19,668
Revenues	1,089
Stockholders Equity	9,079
Net Income	-18,600
Comprehensive Net Income	-18,600
Economic Capital Ratio	-36%





PHARMACEUTICAL 2023

ONCOSEC MEDICAL Inc
Rank 371 of 446




The relative strengths and weaknesses of ONCOSEC MEDICAL Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ONCOSEC MEDICAL Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 30% points. The greatest weakness of ONCOSEC MEDICAL Inc is the variable Net Income, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is -125%, being 168% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	15,232
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,633
Liabilities, Non-Current	4,127
Other Assets	5,667
Other Compr. Net Income	326
Other Expenses	-3,313
Other Liabilities	5,000
Other Net Income	-481
Other Revenues	0
Property and Equipment	979
Research and Development	25,822
Selling, General and Administrative Expense	11,191

Output Variable	Value in 1000 USD
Assets	21,878
Liabilities	15,760
Expenses	33,699
Revenues	0
Stockholders Equity	6,118
Net Income	-34,180
Comprehensive Net Income	-34,016
Economic Capital Ratio	-125%




The relative strengths and weaknesses of Lyell Immunopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lyell Immunopharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Lyell Immunopharma Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 7.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 239%, being 196% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	651,295
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	37,028
Liabilities, Non-Current	67,281
Other Assets	163,243
Other Compr. Net Income	-5,976
Other Expenses	-4,754
Other Liabilities	0
Other Net Income	3,940
Other Revenues	84,683
Property and Equipment	123,023
Research and Development	159,188
Selling, General and Administrative Expense	117,307

Output Variable	Value in 1000 USD
Assets	937,561
Liabilities	104,309
Expenses	271,741
Revenues	84,683
Stockholders Equity	833,252
Net Income	-183,118
Comprehensive Net Income	-186,106
Economic Capital Ratio	239%




The relative strengths and weaknesses of Keros Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keros Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Keros Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 222%, being 178% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	285,767
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,547
Liabilities, Non-Current	12,811
Other Assets	18,993
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	10,111
Other Revenues	0
Property and Equipment	2,021
Research and Development	87,265
Selling, General and Administrative Expense	27,525

Output Variable	Value in 1000 USD
Assets	306,781
Liabilities	29,358
Expenses	114,790
Revenues	0
Stockholders Equity	277,423
Net Income	-104,679
Comprehensive Net Income	-104,679
Economic Capital Ratio	222%




The relative strengths and weaknesses of Larimar Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Larimar Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Larimar Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 219%, being 176% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	120,739
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,705
Liabilities, Non-Current	4,797
Other Assets	4,835
Other Compr. Net Income	-31
Other Expenses	0
Other Liabilities	0
Other Net Income	1,171
Other Revenues	0
Property and Equipment	831
Research and Development	24,250
Selling, General and Administrative Expense	12,276

Output Variable	Value in 1000 USD
Assets	126,405
Liabilities	15,502
Expenses	36,526
Revenues	0
Stockholders Equity	110,903
Net Income	-35,355
Comprehensive Net Income	-35,370
Economic Capital Ratio	219%





PHARMACEUTICAL 2023

Lexaria Bioscience Corp.
Rank 162 of 446



The relative strengths and weaknesses of Lexaria Bioscience Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lexaria Bioscience Corp. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Lexaria Bioscience Corp. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is 143%, being 100% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	6,978
Cost of Goods Sold	72
Intangible Assets	0
Liabilities, Current	194
Liabilities, Non-Current	7.4
Other Assets	541
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	255
Property and Equipment	316
Research and Development	1,843
Selling, General and Administrative Expense	5,725


Output Variable	Value in 1000 USD
Assets	7,834
Liabilities	201
Expenses	7,639
Revenues	255
Stockholders Equity	7,632
Net Income	-7,384
Comprehensive Net Income	-7,384
Economic Capital Ratio	143%



PHARMACEUTICAL 2023

Revance Therapeutics Inc.
Rank 344 of 446

REVANCE®





PHARMACEUTICAL 2023

Revance Therapeutics Inc.
Rank 344 of 446

REVANCE®

The relative strengths and weaknesses of Revance Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Revance Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Revance Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 103% points.

The company's Economic Capital Ratio, given in the ranking table, is -58%, being 101% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	374,727
Cost of Goods Sold	0
Intangible Assets	104,179
Liabilities, Current	75,682
Liabilities, Non-Current	114,244
Other Assets	80,855
Other Compr. Net Income	-356
Other Expenses	166,477
Other Liabilities	379,374
Other Net Income	2,710
Other Revenues	132,565
Property and Equipment	22,139
Research and Development	101,286
Selling, General and Administrative Expense	223,934

Output Variable	Value in 1000 USD
Assets	581,900
Liabilities	569,300
Expenses	491,697
Revenues	132,565
Stockholders Equity	12,600
Net Income	-356,422
Comprehensive Net Income	-356,600
Economic Capital Ratio	-58%



PHARMACEUTICAL 2023

Corvus Pharmaceuticals Inc.
Rank 171 of 446





PHARMACEUTICAL 2023

Corvus Pharmaceuticals Inc.
Rank 171 of 446

The relative strengths and weaknesses of Corvus Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corvus Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Corvus Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 134%, being 91% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	43,664
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,752
Liabilities, Non-Current	1,373
Other Assets	24,223
Other Compr. Net Income	-2,432
Other Expenses	0
Other Liabilities	0
Other Net Income	-8,742
Other Revenues	0
Property and Equipment	353
Research and Development	24,468
Selling, General and Administrative Expense	8,097

Output Variable	Value in 1000 USD
Assets	68,240
Liabilities	12,125
Expenses	32,565
Revenues	0
Stockholders Equity	56,115
Net Income	-41,307
Comprehensive Net Income	-42,523
Economic Capital Ratio	134%



PHARMACEUTICAL 2023

MARAVAI LIFESCIENCES HOLDINGS INC.
Rank 204 of 446





PHARMACEUTICAL 2023

MARAVAI LIFESCIENCES HOLDINGS INC. Rank 204 of 446




The relative strengths and weaknesses of MARAVAI LIFESCIENCES HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MARAVAI LIFESCIENCES HOLDINGS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 91% points. The greatest weakness of MARAVAI LIFESCIENCES HOLDINGS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is 105%, being 61% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	847,902
Cost of Goods Sold	168,957
Intangible Assets	500,331
Liabilities, Current	110,144
Liabilities, Non-Current	590,972
Other Assets	881,388
Other Compr. Net Income	-270,458
Other Expenses	77,525
Other Liabilities	675,956
Other Net Income	1,772
Other Revenues	883,001
Property and Equipment	52,694
Research and Development	18,369
Selling, General and Administrative Expense	129,259

Output Variable	Value in 1000 USD
Assets	2,282,315
Liabilities	1,377,072
Expenses	394,110
Revenues	883,001
Stockholders Equity	905,243
Net Income	490,663
Comprehensive Net Income	355,434
Economic Capital Ratio	105%





PHARMACEUTICAL 2023

MANNKIND CORP
Rank 369 of 446

mannkind


The relative strengths and weaknesses of MANNKIND CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MANNKIND CORP compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 39% points. The greatest weakness of MANNKIND CORP is the variable Other Liabilities, reducing the Economic Capital Ratio by 189% points.

The company's Economic Capital Ratio, given in the ranking table, is -123%, being 166% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	234,896
Cost of Goods Sold	16,003
Intangible Assets	3,581
Liabilities, Current	67,296
Liabilities, Non-Current	43,027
Other Assets	11,679
Other Compr. Net Income	0
Other Expenses	90,436
Other Liabilities	435,497
Other Net Income	-23,290
Other Revenues	99,770
Property and Equipment	45,126
Research and Development	19,721
Selling, General and Administrative Expense	37,720

Output Variable	Value in 1000 USD
Assets	295,282
Liabilities	545,820
Expenses	163,880
Revenues	99,770
Stockholders Equity	-250,538
Net Income	-87,400
Comprehensive Net Income	-87,400
Economic Capital Ratio	-123%





PHARMACEUTICAL 2023

Cartesian Therapeutics Inc.
Rank 137 of 446




The relative strengths and weaknesses of Cartesian Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cartesian Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 111% points. The greatest weakness of Cartesian Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is 165%, being 122% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	148,138
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	25,077
Liabilities, Non-Current	10,055
Other Assets	14,954
Other Compr. Net Income	8.0
Other Expenses	-18,460
Other Liabilities	36,926
Other Net Income	2,381
Other Revenues	110,777
Property and Equipment	2,794
Research and Development	72,377
Selling, General and Administrative Expense	23,862

Output Variable	Value in 1000 USD
Assets	165,886
Liabilities	72,058
Expenses	77,779
Revenues	110,777
Stockholders Equity	93,828
Net Income	35,379
Comprehensive Net Income	35,383
Economic Capital Ratio	165%





PHARMACEUTICAL 2023

Annovis Bio Inc.
Rank 201 of 446




The relative strengths and weaknesses of Annovis Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Annovis Bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Annovis Bio Inc. is the variable Net Income, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 107%, being 64% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	36,022
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,699
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	183
Other Revenues	0
Property and Equipment	0
Research and Development	16,516
Selling, General and Administrative Expense	8,996

Output Variable	Value in 1000 USD
Assets	36,022
Liabilities	7,699
Expenses	25,511
Revenues	0
Stockholders Equity	28,324
Net Income	-25,329
Comprehensive Net Income	-25,329
Economic Capital Ratio	107%





PHARMACEUTICAL 2023



VERTEX PHARMACEUTICALS INC MA Rank 48 of 446




The relative strengths and weaknesses of VERTEX PHARMACEUTICALS INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VERTEX PHARMACEUTICALS INC MA compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 104% points. The greatest weakness of VERTEX PHARMACEUTICALS INC MA is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 4.6% points.

The company's Economic Capital Ratio, given in the ranking table, is 243%, being 200% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	13,234,800
Cost of Goods Sold	1,080,300
Intangible Assets	1,691,600
Liabilities, Current	2,742,100
Liabilities, Non-Current	1,065,300
Other Assets	3,224,500
Other Compr. Net Income	-15,100
Other Expenses	968,400
Other Liabilities	430,800
Other Net Income	-75,000
Other Revenues	8,930,700
Property and Equipment	0
Research and Development	2,540,300
Selling, General and Administrative Expense	944,700

Output Variable	Value in 1000 USD
Assets	18,150,900
Liabilities	4,238,200
Expenses	5,533,700
Revenues	8,930,700
Stockholders Equity	13,912,700
Net Income	3,322,000
Comprehensive Net Income	3,314,450
Economic Capital Ratio	243%





RealRate

PHARMACEUTICAL 2023

Salarius Pharmaceuticals Inc. Rank 377 of 446



The relative strengths and weaknesses of Salarius Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Salarius Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Salarius Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 213% points.

The company's Economic Capital Ratio, given in the ranking table, is -145%, being 188% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	14,520
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,858
Liabilities, Non-Current	0
Other Assets	131
Other Compr. Net Income	0
Other Expenses	8,851
Other Liabilities	1,408
Other Net Income	219
Other Revenues	0
Property and Equipment	0
Research and Development	15,837
Selling, General and Administrative Expense	7,138

Output Variable	Value in 1000 USD
Assets	14,651
Liabilities	4,266
Expenses	31,827
Revenues	0
Stockholders Equity	10,385
Net Income	-31,608
Comprehensive Net Income	-31,608
Economic Capital Ratio	-145%



PHARMACEUTICAL 2023

LEXICON PHARMACEUTICALS INC.
Rank 234 of 446





PHARMACEUTICAL 2023

LEXICON PHARMACEUTICALS INC.
Rank 234 of 446




The relative strengths and weaknesses of LEXICON PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LEXICON PHARMACEUTICALS INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 38% points. The greatest weakness of LEXICON PHARMACEUTICALS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 57% points.

The company's Economic Capital Ratio, given in the ranking table, is 73%, being 30% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	140,866
Cost of Goods Sold	0
Intangible Assets	44,543
Liabilities, Current	23,172
Liabilities, Non-Current	5,424
Other Assets	6,819
Other Compr. Net Income	-418
Other Expenses	2,780
Other Liabilities	48,579
Other Net Income	1,596
Other Revenues	139
Property and Equipment	2,071
Research and Development	52,816
Selling, General and Administrative Expense	48,083

Output Variable	Value in 1000 USD
Assets	194,299
Liabilities	77,175
Expenses	103,679
Revenues	139
Stockholders Equity	117,124
Net Income	-101,944
Comprehensive Net Income	-102,153
Economic Capital Ratio	73%





RealRate

PHARMACEUTICAL 2023

Kaya Holdings Inc.
Rank 418 of 446



The relative strengths and weaknesses of Kaya Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kaya Holdings Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 48% points. The greatest weakness of Kaya Holdings Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 205% points.

The company's Economic Capital Ratio, given in the ranking table, is -353%, being 396% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	58
Cost of Goods Sold	225
Intangible Assets	0
Liabilities, Current	10,418
Liabilities, Non-Current	8,029
Other Assets	785
Other Compr. Net Income	0
Other Expenses	1,740
Other Liabilities	0.0010
Other Net Income	-1,926
Other Revenues	685
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	526

Output Variable	Value in 1000 USD
Assets	843
Liabilities	18,447
Expenses	2,491
Revenues	685
Stockholders Equity	-17,604
Net Income	-3,732
Comprehensive Net Income	-3,732
Economic Capital Ratio	-353%



PHARMACEUTICAL 2023

Scopus BioPharma Inc.
Rank 446 of 446





PHARMACEUTICAL 2023

Scopus BioPharma Inc.
Rank 446 of 446


The relative strengths and weaknesses of Scopus BioPharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Scopus BioPharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 627% points. The greatest weakness of Scopus BioPharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 635% points.

The company's Economic Capital Ratio, given in the ranking table, is -836%, being 879% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	390
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,454
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	187
Other Expenses	9,033
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property and Equipment	2.3
Research and Development	2,682
Selling, General and Administrative Expense	9,033

Output Variable	Value in 1000 USD
Assets	392
Liabilities	7,454
Expenses	20,748
Revenues	0
Stockholders Equity	-7,062
Net Income	-20,748
Comprehensive Net Income	-20,655
Economic Capital Ratio	-836%





PHARMACEUTICAL 2023

Shattuck Labs Inc.
Rank 128 of 446




The relative strengths and weaknesses of Shattuck Labs Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Shattuck Labs Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Shattuck Labs Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 128% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	184,584
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,965
Liabilities, Non-Current	4,202
Other Assets	3,069
Other Compr. Net Income	-317
Other Expenses	0
Other Liabilities	0
Other Net Income	1,384
Other Revenues	652
Property and Equipment	17,671
Research and Development	82,899
Selling, General and Administrative Expense	21,082

Output Variable	Value in 1000 USD
Assets	205,324
Liabilities	29,167
Expenses	103,981
Revenues	652
Stockholders Equity	176,157
Net Income	-101,945
Comprehensive Net Income	-102,104
Economic Capital Ratio	171%





RealRate

PHARMACEUTICAL 2023

Actinium Pharmaceuticals Inc. Rank 212 of 446




The relative strengths and weaknesses of Actinium Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Actinium Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Actinium Pharmaceuticals Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is 100%, being 57% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	110,942
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,628
Liabilities, Non-Current	0
Other Assets	2,646
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	37,083
Other Net Income	1,087
Other Revenues	1,030
Property and Equipment	604
Research and Development	23,135
Selling, General and Administrative Expense	11,999

Output Variable	Value in 1000 USD
Assets	114,192
Liabilities	47,711
Expenses	35,134
Revenues	1,030
Stockholders Equity	66,481
Net Income	-33,017
Comprehensive Net Income	-33,017
Economic Capital Ratio	100%





PHARMACEUTICAL 2023

Phathom Pharmaceuticals Inc.
Rank 382 of 446




The relative strengths and weaknesses of Phathom Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Phathom Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 16% points. The greatest weakness of Phathom Pharmaceuticals Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is -161%, being 205% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	160,512
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,237
Liabilities, Non-Current	103,862
Other Assets	3,091
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	109,525
Other Net Income	-25,283
Other Revenues	0
Property and Equipment	1,207
Research and Development	71,441
Selling, General and Administrative Expense	100,999

Output Variable	Value in 1000 USD
Assets	164,810
Liabilities	239,624
Expenses	172,440
Revenues	0
Stockholders Equity	-74,814
Net Income	-197,723
Comprehensive Net Income	-197,723
Economic Capital Ratio	-161%





RealRate

PHARMACEUTICAL 2023

Tango Therapeutics Inc. Rank 210 of 446



The relative strengths and weaknesses of Tango Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tango Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Tango Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is 102%, being 59% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	375,272
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	55,545
Liabilities, Non-Current	131,449
Other Assets	50,314
Other Compr. Net Income	-2,940
Other Expenses	54
Other Liabilities	0
Other Net Income	2,949
Other Revenues	24,860
Property and Equipment	10,884
Research and Development	105,906
Selling, General and Administrative Expense	30,025


Output Variable	Value in 1000 USD
Assets	436,470
Liabilities	186,994
Expenses	135,985
Revenues	24,860
Stockholders Equity	249,476
Net Income	-108,176
Comprehensive Net Income	-109,646
Economic Capital Ratio	102%



RealRate

PHARMACEUTICAL 2023

Spero Therapeutics Inc.
Rank 215 of 446





PHARMACEUTICAL 2023

Spero Therapeutics Inc.
Rank 215 of 446



The relative strengths and weaknesses of Spero Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spero Therapeutics Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Spero Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 97%, being 54% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	113,570
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,649
Liabilities, Non-Current	4,957
Other Assets	10,864
Other Compr. Net Income	2.0
Other Expenses	11,630
Other Liabilities	22,262
Other Net Income	-4,218
Other Revenues	53,509
Property and Equipment	368
Research and Development	47,593
Selling, General and Administrative Expense	36,483

Output Variable	Value in 1000 USD
Assets	124,802
Liabilities	48,868
Expenses	95,706
Revenues	53,509
Stockholders Equity	75,934
Net Income	-46,415
Comprehensive Net Income	-46,414
Economic Capital Ratio	97%



PHARMACEUTICAL 2023

iBio Inc.
Rank 225 of 446





PHARMACEUTICAL 2023

iBio Inc.
Rank 225 of 446



The relative strengths and weaknesses of iBio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of iBio Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 84% points. The greatest weakness of iBio Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 87%, being 44% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	45,070
Cost of Goods Sold	216
Intangible Assets	4,851
Liabilities, Current	30,436
Liabilities, Non-Current	5,455
Other Assets	12,824
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	30
Other Net Income	-614
Other Revenues	2,383
Property and Equipment	36,661
Research and Development	17,729
Selling, General and Administrative Expense	34,128

Output Variable	Value in 1000 USD
Assets	99,406
Liabilities	35,921
Expenses	52,073
Revenues	2,383
Stockholders Equity	63,485
Net Income	-50,304
Comprehensive Net Income	-50,304
Economic Capital Ratio	87%



PHARMACEUTICAL 2023

Applied Molecular Transport Inc.
Rank 327 of 446





PHARMACEUTICAL 2023

Applied Molecular Transport Inc.
Rank 327 of 446

The relative strengths and weaknesses of Applied Molecular Transport Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Applied Molecular Transport Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Applied Molecular Transport Inc. is the variable Net Income, reducing the Economic Capital Ratio by 82% points.

The company's Economic Capital Ratio, given in the ranking table, is -28%, being 71% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	64,019
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,087
Liabilities, Non-Current	31,472
Other Assets	35,244
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	49
Other Net Income	894
Other Revenues	0
Property and Equipment	8,183
Research and Development	89,826
Selling, General and Administrative Expense	37,393


Output Variable	Value in 1000 USD
Assets	107,446
Liabilities	46,608
Expenses	127,219
Revenues	0
Stockholders Equity	60,838
Net Income	-126,325
Comprehensive Net Income	-126,325
Economic Capital Ratio	-28%



RealRate

PHARMACEUTICAL 2023

Immunome Inc.
Rank 340 of 446





PHARMACEUTICAL 2023

Immunome Inc.
Rank 340 of 446


The relative strengths and weaknesses of Immunome Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immunome Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 25% points. The greatest weakness of Immunome Inc. is the variable Net Income, reducing the Economic Capital Ratio by 137% points.

The company's Economic Capital Ratio, given in the ranking table, is -53%, being 96% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	22,649
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,331
Liabilities, Non-Current	62
Other Assets	716
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	5.0
Other Revenues	0
Property and Equipment	681
Research and Development	23,272
Selling, General and Administrative Expense	13,629

Output Variable	Value in 1000 USD
Assets	24,046
Liabilities	7,393
Expenses	36,901
Revenues	0
Stockholders Equity	16,653
Net Income	-36,896
Comprehensive Net Income	-36,896
Economic Capital Ratio	-53%



The relative strengths and weaknesses of Sensei Biotherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sensei Biotherapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 82% points. The greatest weakness of Sensei Biotherapeutics Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 193%, being 150% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	108,589
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,066
Liabilities, Non-Current	4,323
Other Assets	7,737
Other Compr. Net Income	-671
Other Expenses	30,602
Other Liabilities	1,579
Other Net Income	1,819
Other Revenues	0
Property and Equipment	2,049
Research and Development	0
Selling, General and Administrative Expense	19,805

Output Variable	Value in 1000 USD
Assets	118,375
Liabilities	14,968
Expenses	50,407
Revenues	0
Stockholders Equity	103,407
Net Income	-48,588
Comprehensive Net Income	-48,924
Economic Capital Ratio	193%



PHARMACEUTICAL 2023

Acurx Pharmaceuticals Inc.
Rank 290 of 446





PHARMACEUTICAL 2023

Acurx Pharmaceuticals Inc.
Rank 290 of 446

The relative strengths and weaknesses of Acurx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acurx Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 871% points. The greatest weakness of Acurx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 136% points.

The company's Economic Capital Ratio, given in the ranking table, is 8.6%, being 35% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,062
Liabilities, Non-Current	0
Other Assets	9,377
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property and Equipment	0
Research and Development	4,754
Selling, General and Administrative Expense	7,339

Output Variable	Value in 1000 USD
Assets	9,377
Liabilities	2,062
Expenses	12,093
Revenues	0
Stockholders Equity	7,315
Net Income	-12,093
Comprehensive Net Income	-12,093
Economic Capital Ratio	8.6%



PHARMACEUTICAL 2023

COLLEGIUM PHARMACEUTICAL INC
Rank 273 of 446





RealRate

PHARMACEUTICAL 2023

COLLEGIUM PHARMACEUTICAL INC Rank 273 of 446



The relative strengths and weaknesses of COLLEGIUM PHARMACEUTICAL INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of COLLEGIUM PHARMACEUTICAL INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 124% points. The greatest weakness of COLLEGIUM PHARMACEUTICAL INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is 29%, being 14% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	419,989
Cost of Goods Sold	254,445
Intangible Assets	701,163
Liabilities, Current	433,726
Liabilities, Non-Current	7,112
Other Assets	33,458
Other Compr. Net Income	0
Other Expenses	59,368
Other Liabilities	538,451
Other Net Income	1,047
Other Revenues	463,933
Property and Equipment	19,521
Research and Development	3,983
Selling, General and Administrative Expense	172,186

Output Variable	Value in 1000 USD
Assets	1,174,131
Liabilities	979,289
Expenses	489,982
Revenues	463,933
Stockholders Equity	194,842
Net Income	-25,002
Comprehensive Net Income	-25,002
Economic Capital Ratio	29%



PHARMACEUTICAL 2023

Xilio Therapeutics Inc.
Rank 198 of 446





PHARMACEUTICAL 2023

Xilio Therapeutics Inc.
Rank 198 of 446




The relative strengths and weaknesses of Xilio Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xilio Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Xilio Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 108%, being 65% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	124,496
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,119
Liabilities, Non-Current	9,234
Other Assets	7,414
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3,165
Other Net Income	927
Other Revenues	0
Property and Equipment	7,255
Research and Development	59,201
Selling, General and Administrative Expense	29,948

Output Variable	Value in 1000 USD
Assets	139,165
Liabilities	33,518
Expenses	89,149
Revenues	0
Stockholders Equity	105,647
Net Income	-88,222
Comprehensive Net Income	-88,222
Economic Capital Ratio	108%






The relative strengths and weaknesses of China Health Industries Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of China Health Industries Holdings Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of China Health Industries Holdings Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 247%, being 204% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	45,597
Cost of Goods Sold	1.7
Intangible Assets	1,413
Liabilities, Current	7,945
Liabilities, Non-Current	0
Other Assets	579
Other Compr. Net Income	-1,618
Other Expenses	714
Other Liabilities	0
Other Net Income	1,297
Other Revenues	0.27
Property and Equipment	3,158
Research and Development	0
Selling, General and Administrative Expense	935

Output Variable	Value in 1000 USD
Assets	50,748
Liabilities	7,945
Expenses	1,651
Revenues	0.27
Stockholders Equity	42,803
Net Income	-354
Comprehensive Net Income	-1,163
Economic Capital Ratio	247%





PHARMACEUTICAL 2023

Evofem Biosciences Inc.
Rank 411 of 446


The relative strengths and weaknesses of Evofem Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evofem Biosciences Inc. compared to the market average is the variable Other Compr. Net Income, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Evofem Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 259% points.

The company's Economic Capital Ratio, given in the ranking table, is -291%, being 335% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	12,699
Cost of Goods Sold	4,415
Intangible Assets	0
Liabilities, Current	93,830
Liabilities, Non-Current	3,133
Other Assets	8,524
Other Compr. Net Income	44,438
Other Expenses	43,995
Other Liabilities	0
Other Net Income	7,470
Other Revenues	16,837
Property and Equipment	3,940
Research and Development	25,032
Selling, General and Administrative Expense	27,563

Output Variable	Value in 1000 USD
Assets	25,163
Liabilities	96,963
Expenses	101,005
Revenues	16,837
Stockholders Equity	-71,800
Net Income	-76,698
Comprehensive Net Income	-54,479
Economic Capital Ratio	-291%





RealRate

PHARMACEUTICAL 2023

AgeX Therapeutics Inc.
Rank 416 of 446




The relative strengths and weaknesses of AgeX Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AgeX Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 31% points. The greatest weakness of AgeX Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 186% points.

The company's Economic Capital Ratio, given in the ranking table, is -339%, being 382% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,453
Cost of Goods Sold	13
Intangible Assets	738
Liabilities, Current	10,078
Liabilities, Non-Current	0
Other Assets	50
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	10,478
Other Net Income	-3,547
Other Revenues	34
Property and Equipment	0
Research and Development	1,025
Selling, General and Administrative Expense	5,971

Output Variable	Value in 1000 USD
Assets	3,241
Liabilities	20,556
Expenses	7,009
Revenues	34
Stockholders Equity	-17,315
Net Income	-10,522
Comprehensive Net Income	-10,522
Economic Capital Ratio	-339%



The relative strengths and weaknesses of NANOVIRICIDES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NANOVIRICIDES INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 68% points. The greatest weakness of NANOVIRICIDES INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 264%, being 221% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	14,416
Cost of Goods Sold	0
Intangible Assets	342
Liabilities, Current	413
Liabilities, Non-Current	0
Other Assets	42
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	6.7
Other Revenues	0
Property and Equipment	8,694
Research and Development	5,785
Selling, General and Administrative Expense	2,329


Output Variable	Value in 1000 USD
Assets	23,495
Liabilities	413
Expenses	8,114
Revenues	0
Stockholders Equity	23,082
Net Income	-8,107
Comprehensive Net Income	-8,107
Economic Capital Ratio	264%



RealRate

PHARMACEUTICAL 2023

ANI PHARMACEUTICALS INC Rank 221 of 446





RealRate

PHARMACEUTICAL 2023

ANI PHARMACEUTICALS INC Rank 221 of 446




The relative strengths and weaknesses of ANI PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANI PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 63% points. The greatest weakness of ANI PHARMACEUTICALS INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is 92%, being 49% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	344,261
Cost of Goods Sold	0
Intangible Assets	279,856
Liabilities, Current	99,439
Liabilities, Non-Current	287,050
Other Assets	92,724
Other Compr. Net Income	15,223
Other Expenses	190,537
Other Liabilities	35,058
Other Net Income	-27,382
Other Revenues	316,385
Property and Equipment	43,246
Research and Development	22,318
Selling, General and Administrative Expense	124,044

Output Variable	Value in 1000 USD
Assets	760,087
Liabilities	421,547
Expenses	336,899
Revenues	316,385
Stockholders Equity	338,540
Net Income	-47,896
Comprehensive Net Income	-40,284
Economic Capital Ratio	92%



The relative strengths and weaknesses of NextCure Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NextCure Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of NextCure Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 212%, being 169% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	163,983
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,127
Liabilities, Non-Current	7,504
Other Assets	8,281
Other Compr. Net Income	-831
Other Expenses	0
Other Liabilities	0
Other Net Income	1,176
Other Revenues	0
Property and Equipment	11,897
Research and Development	54,199
Selling, General and Administrative Expense	21,710


Output Variable	Value in 1000 USD
Assets	184,161
Liabilities	16,631
Expenses	75,909
Revenues	0
Stockholders Equity	167,530
Net Income	-74,733
Comprehensive Net Income	-75,148
Economic Capital Ratio	212%



PHARMACEUTICAL 2023

BELLICUM PHARMACEUTICALS INC

Rank 240 of 446





PHARMACEUTICAL 2023

BELLICUM PHARMACEUTICALS INC Rank 240 of 446




The relative strengths and weaknesses of BELLICUM PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BELLICUM PHARMACEUTICALS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 47% points. The greatest weakness of BELLICUM PHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is 69%, being 26% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	23,801
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,772
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-16
Other Expenses	2.0
Other Liabilities	0
Other Net Income	2,010
Other Revenues	1,500
Property and Equipment	22
Research and Development	22,764
Selling, General and Administrative Expense	5,717

Output Variable	Value in 1000 USD
Assets	23,823
Liabilities	3,772
Expenses	28,483
Revenues	1,500
Stockholders Equity	20,051
Net Income	-24,973
Comprehensive Net Income	-24,981
Economic Capital Ratio	69%





PHARMACEUTICAL 2023

Edesa Biotech Inc.
Rank 315 of 446




The relative strengths and weaknesses of Edesa Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Edesa Biotech Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 133% points. The greatest weakness of Edesa Biotech Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 257% points.

The company's Economic Capital Ratio, given in the ranking table, is -20%, being 63% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	9,092
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,141
Liabilities, Non-Current	0
Other Assets	2,471
Other Compr. Net Income	-8.3
Other Expenses	0.80
Other Liabilities	44
Other Net Income	-17,548
Other Revenues	0
Property and Equipment	13
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	11,576
Liabilities	2,184
Expenses	0.80
Revenues	0
Stockholders Equity	9,391
Net Income	-17,549
Comprehensive Net Income	-17,553
Economic Capital Ratio	-20%





**TherapeuticsMD Inc.
Rank 60 of 446**


The relative strengths and weaknesses of TherapeuticsMD Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of TherapeuticsMD Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 275% points. The greatest weakness of TherapeuticsMD Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 237%, being 193% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	55,351
Cost of Goods Sold	1,397
Intangible Assets	6,943
Liabilities, Current	46,839
Liabilities, Non-Current	8,476
Other Assets	28,086
Other Compr. Net Income	0
Other Expenses	9,472
Other Liabilities	0
Other Net Income	110,806
Other Revenues	69,963
Property and Equipment	78
Research and Development	0
Selling, General and Administrative Expense	57,903

Output Variable	Value in 1000 USD
Assets	90,458
Liabilities	55,315
Expenses	68,772
Revenues	69,963
Stockholders Equity	35,143
Net Income	111,997
Comprehensive Net Income	111,997
Economic Capital Ratio	237%





RealRate

PHARMACEUTICAL 2023

Athenex Inc.
Rank 349 of 446



The relative strengths and weaknesses of Athenex Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Athenex Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Athenex Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is -67%, being 110% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	124,929
Cost of Goods Sold	76,118
Intangible Assets	72,112
Liabilities, Current	114,879
Liabilities, Non-Current	5,782
Other Assets	5,190
Other Compr. Net Income	2,370
Other Expenses	26,269
Other Liabilities	107,575
Other Net Income	-8,219
Other Revenues	102,821
Property and Equipment	1,824
Research and Development	51,758
Selling, General and Administrative Expense	44,880

Output Variable	Value in 1000 USD
Assets	204,055
Liabilities	228,236
Expenses	199,025
Revenues	102,821
Stockholders Equity	-24,181
Net Income	-104,423
Comprehensive Net Income	-103,238
Economic Capital Ratio	-67%



PHARMACEUTICAL 2023

Catalent Inc.
Rank 200 of 446





PHARMACEUTICAL 2023

Catalent Inc.
Rank 200 of 446




The relative strengths and weaknesses of Catalent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Catalent Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Catalent Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is 108%, being 64% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,916,000
Cost of Goods Sold	3,188,000
Intangible Assets	4,066,000
Liabilities, Current	1,072,000
Liabilities, Non-Current	164,000
Other Assets	398,000
Other Compr. Net Income	-77,000
Other Expenses	127,000
Other Liabilities	4,476,000
Other Net Income	-150,000
Other Revenues	4,828,000
Property and Equipment	3,127,000
Research and Development	0
Selling, General and Administrative Expense	844,000

Output Variable	Value in 1000 USD
Assets	10,507,000
Liabilities	5,712,000
Expenses	4,159,000
Revenues	4,828,000
Stockholders Equity	4,795,000
Net Income	519,000
Comprehensive Net Income	480,500
Economic Capital Ratio	108%



The relative strengths and weaknesses of PLIANT THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PLIANT THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 93% points. The greatest weakness of PLIANT THERAPEUTICS INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 214%, being 171% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	340,311
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	23,913
Liabilities, Non-Current	3,429
Other Assets	5,816
Other Compr. Net Income	-1,757
Other Expenses	0
Other Liabilities	9,929
Other Net Income	3,879
Other Revenues	9,685
Property and Equipment	4,486
Research and Development	96,936
Selling, General and Administrative Expense	39,949

Output Variable	Value in 1000 USD
Assets	350,613
Liabilities	37,271
Expenses	136,885
Revenues	9,685
Stockholders Equity	313,342
Net Income	-123,321
Comprehensive Net Income	-124,200
Economic Capital Ratio	214%



PHARMACEUTICAL 2023

Summit Therapeutics Inc.
Rank 277 of 446





PHARMACEUTICAL 2023

Summit Therapeutics Inc.
Rank 277 of 446



The relative strengths and weaknesses of Summit Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Summit Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Summit Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 211% points.

The company's Economic Capital Ratio, given in the ranking table, is 23%, being 20% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	656,712
Cost of Goods Sold	0
Intangible Assets	1,798
Liabilities, Current	38,782
Liabilities, Non-Current	4,192
Other Assets	4,752
Other Compr. Net Income	304
Other Expenses	8,468
Other Liabilities	494,540
Other Net Income	-6,693
Other Revenues	15,121
Property and Equipment	906
Research and Development	51,999
Selling, General and Administrative Expense	26,743


Output Variable	Value in 1000 USD
Assets	664,168
Liabilities	537,514
Expenses	87,210
Revenues	15,121
Stockholders Equity	126,654
Net Income	-78,782
Comprehensive Net Income	-78,630
Economic Capital Ratio	23%



RealRate

PHARMACEUTICAL 2023

BioXcel Therapeutics Inc. Rank 314 of 446





RealRate

PHARMACEUTICAL 2023

BioXcel Therapeutics Inc. Rank 314 of 446




The relative strengths and weaknesses of BioXcel Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BioXcel Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 43% points. The greatest weakness of BioXcel Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 92% points.

The company's Economic Capital Ratio, given in the ranking table, is -20%, being 63% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	202,868
Cost of Goods Sold	20
Intangible Assets	0
Liabilities, Current	32,898
Liabilities, Non-Current	93,837
Other Assets	1,901
Other Compr. Net Income	0
Other Expenses	8,213
Other Liabilities	2,343
Other Net Income	2,101
Other Revenues	375
Property and Equipment	1,084
Research and Development	91,239
Selling, General and Administrative Expense	68,761

Output Variable	Value in 1000 USD
Assets	205,853
Liabilities	129,078
Expenses	168,233
Revenues	375
Stockholders Equity	76,775
Net Income	-165,757
Comprehensive Net Income	-165,757
Economic Capital Ratio	-20%





RealRate

PHARMACEUTICAL 2023

Qualigen Therapeutics Inc. Rank 331 of 446



The relative strengths and weaknesses of Qualigen Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Qualigen Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Qualigen Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is -32%, being 75% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	10,821
Cost of Goods Sold	0
Intangible Assets	6,471
Liabilities, Current	8,608
Liabilities, Non-Current	1,302
Other Assets	1,447
Other Compr. Net Income	2,445
Other Expenses	9,227
Other Liabilities	407
Other Net Income	882
Other Revenues	4,984
Property and Equipment	345
Research and Development	6,837
Selling, General and Administrative Expense	10,836


Output Variable	Value in 1000 USD
Assets	19,083
Liabilities	10,317
Expenses	26,900
Revenues	4,984
Stockholders Equity	8,767
Net Income	-21,035
Comprehensive Net Income	-19,812
Economic Capital Ratio	-32%



PHARMACEUTICAL 2023

Thorne Healthtech Inc.
Rank 131 of 446

THORNE®





PHARMACEUTICAL 2023

Thorne Healthtech Inc.
Rank 131 of 446

THORNE®

The relative strengths and weaknesses of Thorne Healthtech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Thorne Healthtech Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 119% points. The greatest weakness of Thorne Healthtech Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 128% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	116,621
Cost of Goods Sold	113,797
Intangible Assets	31,871
Liabilities, Current	39,561
Liabilities, Non-Current	28,430
Other Assets	32,135
Other Compr. Net Income	712
Other Expenses	19,133
Other Liabilities	15,160
Other Net Income	2,142
Other Revenues	228,731
Property and Equipment	49,177
Research and Development	7,424
Selling, General and Administrative Expense	75,586

Output Variable	Value in 1000 USD
Assets	229,804
Liabilities	83,152
Expenses	215,940
Revenues	228,731
Stockholders Equity	146,652
Net Income	14,933
Comprehensive Net Income	15,289
Economic Capital Ratio	171%



PHARMACEUTICAL 2023

Schrodinger Inc.
Rank 172 of 446





RealRate

PHARMACEUTICAL 2023

Schrodinger Inc.
Rank 172 of 446



The relative strengths and weaknesses of Schrodinger Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Schrodinger Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Schrodinger Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 134%, being 90% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	533,989
Cost of Goods Sold	79,933
Intangible Assets	5,378
Liabilities, Current	108,799
Liabilities, Non-Current	131,883
Other Assets	134,976
Other Compr. Net Income	-1,728
Other Expenses	30,705
Other Liabilities	0
Other Net Income	-2,309
Other Revenues	180,955
Property and Equipment	14,244
Research and Development	126,372
Selling, General and Administrative Expense	90,825


Output Variable	Value in 1000 USD
Assets	688,587
Liabilities	240,682
Expenses	327,835
Revenues	180,955
Stockholders Equity	447,905
Net Income	-149,189
Comprehensive Net Income	-150,053
Economic Capital Ratio	134%



PHARMACEUTICAL 2023

SANGUI BIOTECH INTERNATIONAL INC

Rank 410 of 446





PHARMACEUTICAL 2023

SANGUI BIOTECH INTERNATIONAL INC Rank 410 of 446


The relative strengths and weaknesses of SANGUI BIOTECH INTERNATIONAL INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SANGUI BIOTECH INTERNATIONAL INC compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 36% points. The greatest weakness of SANGUI BIOTECH INTERNATIONAL INC is the variable Assets, Current, reducing the Economic Capital Ratio by 165% points.

The company's Economic Capital Ratio, given in the ranking table, is -290%, being 333% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	68
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	936
Liabilities, Non-Current	90
Other Assets	63
Other Compr. Net Income	0
Other Expenses	147
Other Liabilities	0
Other Net Income	0
Other Revenues	69
Property and Equipment	0.36
Research and Development	8.6
Selling, General and Administrative Expense	53

Output Variable	Value in 1000 USD
Assets	131
Liabilities	1,026
Expenses	209
Revenues	69
Stockholders Equity	-895
Net Income	-139
Comprehensive Net Income	-139
Economic Capital Ratio	-290%




The relative strengths and weaknesses of BIOMARIN PHARMACEUTICAL INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOMARIN PHARMACEUTICAL INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 71% points. The greatest weakness of BIOMARIN PHARMACEUTICAL INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 198%, being 154% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,751,457
Cost of Goods Sold	483,669
Intangible Assets	534,768
Liabilities, Current	588,884
Liabilities, Non-Current	100,015
Other Assets	2,015,483
Other Compr. Net Income	-18,299
Other Expenses	-16,822
Other Liabilities	1,083,019
Other Net Income	15,984
Other Revenues	2,096,039
Property and Equipment	1,073,366
Research and Development	649,606
Selling, General and Administrative Expense	854,009

Output Variable	Value in 1000 USD
Assets	6,375,074
Liabilities	1,771,918
Expenses	1,970,462
Revenues	2,096,039
Stockholders Equity	4,603,156
Net Income	141,561
Comprehensive Net Income	132,412
Economic Capital Ratio	198%





RealRate

PHARMACEUTICAL 2023

ALPINE IMMUNE SCIENCES INC. Rank 179 of 446




The relative strengths and weaknesses of ALPINE IMMUNE SCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALPINE IMMUNE SCIENCES INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 46% points. The greatest weakness of ALPINE IMMUNE SCIENCES INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 127%, being 84% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	240,993
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	57,996
Liabilities, Non-Current	49,270
Other Assets	44,109
Other Compr. Net Income	-848
Other Expenses	2,806
Other Liabilities	0
Other Net Income	3,191
Other Revenues	30,064
Property and Equipment	1,584
Research and Development	70,243
Selling, General and Administrative Expense	17,968

Output Variable	Value in 1000 USD
Assets	286,686
Liabilities	107,266
Expenses	91,017
Revenues	30,064
Stockholders Equity	179,420
Net Income	-57,762
Comprehensive Net Income	-58,186
Economic Capital Ratio	127%





PHARMACEUTICAL 2023

Celularity Inc
Rank 189 of 446




The relative strengths and weaknesses of Celularity Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Celularity Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 130% points. The greatest weakness of Celularity Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is 118%, being 75% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	33,502
Cost of Goods Sold	0
Intangible Assets	240,688
Liabilities, Current	62,088
Liabilities, Non-Current	30,525
Other Assets	51,221
Other Compr. Net Income	9.0
Other Expenses	-100,796
Other Liabilities	109,552
Other Net Income	39,805
Other Revenues	17,975
Property and Equipment	75,655
Research and Development	78,363
Selling, General and Administrative Expense	66,021

Output Variable	Value in 1000 USD
Assets	401,066
Liabilities	202,165
Expenses	43,588
Revenues	17,975
Stockholders Equity	198,901
Net Income	14,192
Comprehensive Net Income	14,196
Economic Capital Ratio	118%





PHARMACEUTICAL 2023

KIORA PHARMACEUTICALS INC Rank 257 of 446




The relative strengths and weaknesses of KIORA PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KIORA PHARMACEUTICALS INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 174% points. The greatest weakness of KIORA PHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 46%, being 3.0% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	7,681
Cost of Goods Sold	0
Intangible Assets	10,743
Liabilities, Current	3,272
Liabilities, Non-Current	3,998
Other Assets	199
Other Compr. Net Income	-96
Other Expenses	470
Other Liabilities	0
Other Net Income	-1,387
Other Revenues	0
Property and Equipment	55
Research and Development	3,449
Selling, General and Administrative Expense	8,278

Output Variable	Value in 1000 USD
Assets	18,678
Liabilities	7,271
Expenses	12,197
Revenues	0
Stockholders Equity	11,408
Net Income	-13,584
Comprehensive Net Income	-13,632
Economic Capital Ratio	46%



The relative strengths and weaknesses of Edgewise Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Edgewise Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Edgewise Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 273%, being 230% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	356,999
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,585
Liabilities, Non-Current	3,800
Other Assets	1,569
Other Compr. Net Income	-841
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	4,018
Property and Equipment	8,533
Research and Development	54,032
Selling, General and Administrative Expense	17,626

Output Variable	Value in 1000 USD
Assets	367,101
Liabilities	20,385
Expenses	71,658
Revenues	4,018
Stockholders Equity	346,716
Net Income	-67,640
Comprehensive Net Income	-68,060
Economic Capital Ratio	273%



PHARMACEUTICAL 2023

CONTRAFECT Corp
Rank 413 of 446





PHARMACEUTICAL 2023

CONTRAFECT Corp Rank 413 of 446


The relative strengths and weaknesses of CONTRAFECT Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CONTRAFECT Corp compared to the market average is the variable Cost of Goods Sold, increasing the Economic Capital Ratio by 6.8% points. The greatest weakness of CONTRAFECT Corp is the variable Assets, Current, reducing the Economic Capital Ratio by 192% points.

The company's Economic Capital Ratio, given in the ranking table, is -321%, being 365% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	17,706
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,840
Liabilities, Non-Current	2,392
Other Assets	2,346
Other Compr. Net Income	52
Other Expenses	7,719
Other Liabilities	9,299
Other Net Income	-545
Other Revenues	0
Property and Equipment	627
Research and Development	44,738
Selling, General and Administrative Expense	12,151

Output Variable	Value in 1000 USD
Assets	20,679
Liabilities	32,531
Expenses	64,608
Revenues	0
Stockholders Equity	-11,852
Net Income	-65,153
Comprehensive Net Income	-65,127
Economic Capital Ratio	-321%





PHARMACEUTICAL 2023

Protagonist Therapeutics Inc Rank 125 of 446




The relative strengths and weaknesses of Protagonist Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Protagonist Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Protagonist Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is 174%, being 131% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	243,077
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,179
Liabilities, Non-Current	1,141
Other Assets	3,286
Other Compr. Net Income	-60
Other Expenses	0
Other Liabilities	0
Other Net Income	3,980
Other Revenues	26,581
Property and Equipment	1,565
Research and Development	126,215
Selling, General and Administrative Expense	31,739

Output Variable	Value in 1000 USD
Assets	247,928
Liabilities	32,320
Expenses	157,954
Revenues	26,581
Stockholders Equity	215,608
Net Income	-127,393
Comprehensive Net Income	-127,423
Economic Capital Ratio	174%




The relative strengths and weaknesses of ARS Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARS Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of ARS Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 300%, being 257% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	277,700
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,444
Liabilities, Non-Current	3,105
Other Assets	3,406
Other Compr. Net Income	407
Other Expenses	0
Other Liabilities	0
Other Net Income	834
Other Revenues	1,316
Property and Equipment	329
Research and Development	18,376
Selling, General and Administrative Expense	18,456

Output Variable	Value in 1000 USD
Assets	281,435
Liabilities	8,549
Expenses	36,832
Revenues	1,316
Stockholders Equity	272,886
Net Income	-34,682
Comprehensive Net Income	-34,478
Economic Capital Ratio	300%




The relative strengths and weaknesses of Amphastar Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amphastar Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 107% points. The greatest weakness of Amphastar Pharmaceuticals Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 209%, being 166% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	378,319
Cost of Goods Sold	250,127
Intangible Assets	0
Liabilities, Current	94,862
Liabilities, Non-Current	38,259
Other Assets	125,402
Other Compr. Net Income	-1,859
Other Expenses	45,008
Other Liabilities	80,208
Other Net Income	7,366
Other Revenues	498,987
Property and Equipment	238,266
Research and Development	74,771
Selling, General and Administrative Expense	45,061

Output Variable	Value in 1000 USD
Assets	741,987
Liabilities	213,329
Expenses	414,967
Revenues	498,987
Stockholders Equity	528,658
Net Income	91,386
Comprehensive Net Income	90,456
Economic Capital Ratio	209%





ACELRX PHARMACEUTICALS INC
Rank 65 of 446


The relative strengths and weaknesses of ACELRX PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ACELRX PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 252% points. The greatest weakness of ACELRX PHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 233%, being 190% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	24,566
Cost of Goods Sold	2,591
Intangible Assets	8,819
Liabilities, Current	13,770
Liabilities, Non-Current	4,805
Other Assets	3,841
Other Compr. Net Income	0
Other Expenses	4,961
Other Liabilities	7,098
Other Net Income	84,401
Other Revenues	1,771
Property and Equipment	10,261
Research and Development	5,193
Selling, General and Administrative Expense	25,672

Output Variable	Value in 1000 USD
Assets	47,487
Liabilities	25,673
Expenses	38,417
Revenues	1,771
Stockholders Equity	21,814
Net Income	47,755
Comprehensive Net Income	47,755
Economic Capital Ratio	233%





PHARMACEUTICAL 2023

NEXIEN BIOPHARMA INC. Rank 438 of 446


The relative strengths and weaknesses of NEXIEN BIOPHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEXIEN BIOPHARMA INC. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 75% points. The greatest weakness of NEXIEN BIOPHARMA INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 285% points.

The company's Economic Capital Ratio, given in the ranking table, is -452%, being 495% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	125
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	242
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	33
Other Liabilities	0
Other Net Income	-62
Other Revenues	0
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	531

Output Variable	Value in 1000 USD
Assets	125
Liabilities	242
Expenses	564
Revenues	0
Stockholders Equity	-118
Net Income	-626
Comprehensive Net Income	-626
Economic Capital Ratio	-452%





The relative strengths and weaknesses of Aerovate Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aerovate Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Aerovate Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 231%, being 188% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	131,496
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,782
Liabilities, Non-Current	705
Other Assets	3,563
Other Compr. Net Income	-407
Other Expenses	25
Other Liabilities	71
Other Net Income	1,751
Other Revenues	0
Property and Equipment	242
Research and Development	38,622
Selling, General and Administrative Expense	14,615

Output Variable	Value in 1000 USD
Assets	135,301
Liabilities	8,558
Expenses	53,262
Revenues	0
Stockholders Equity	126,743
Net Income	-51,511
Comprehensive Net Income	-51,714
Economic Capital Ratio	231%



PHARMACEUTICAL 2023

Immix Biopharma Inc.
Rank 127 of 446





PHARMACEUTICAL 2023

Immix Biopharma Inc.
Rank 127 of 446


The relative strengths and weaknesses of Immix Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immix Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 114% points. The greatest weakness of Immix Biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 173%, being 130% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	14,898
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,273
Liabilities, Non-Current	0
Other Assets	6.7
Other Compr. Net Income	-38
Other Expenses	10
Other Liabilities	475
Other Net Income	-0.50
Other Revenues	0
Property and Equipment	3.6
Research and Development	4,196
Selling, General and Administrative Expense	4,023

Output Variable	Value in 1000 USD
Assets	14,908
Liabilities	1,748
Expenses	8,229
Revenues	0
Stockholders Equity	13,160
Net Income	-8,230
Comprehensive Net Income	-8,249
Economic Capital Ratio	173%



INTEGRATED BIOPHARMA INC
Rank 74 of 446


The relative strengths and weaknesses of INTEGRATED BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTEGRATED BIOPHARMA INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 297% points. The greatest weakness of INTEGRATED BIOPHARMA INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 298% points.

The company's Economic Capital Ratio, given in the ranking table, is 224%, being 181% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	16,626
Cost of Goods Sold	49,694
Intangible Assets	0
Liabilities, Current	5,263
Liabilities, Non-Current	1,412
Other Assets	6,714
Other Compr. Net Income	0
Other Expenses	-1,241
Other Liabilities	0
Other Net Income	-148
Other Revenues	56,246
Property and Equipment	1,910
Research and Development	0
Selling, General and Administrative Expense	3,807

Output Variable	Value in 1000 USD
Assets	25,250
Liabilities	6,675
Expenses	52,260
Revenues	56,246
Stockholders Equity	18,575
Net Income	3,838
Comprehensive Net Income	3,838
Economic Capital Ratio	224%





Repare Therapeutics Inc.
Rank 97 of 446


The relative strengths and weaknesses of Repare Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Repare Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Repare Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 201%, being 158% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	353,979
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	78,619
Liabilities, Non-Current	5,939
Other Assets	5,868
Other Compr. Net Income	-428
Other Expenses	15,147
Other Liabilities	0
Other Net Income	137,726
Other Revenues	0
Property and Equipment	4,228
Research and Development	119,066
Selling, General and Administrative Expense	32,560

Output Variable	Value in 1000 USD
Assets	364,075
Liabilities	84,558
Expenses	166,773
Revenues	0
Stockholders Equity	279,517
Net Income	-29,047
Comprehensive Net Income	-29,261
Economic Capital Ratio	201%





RealRate

PHARMACEUTICAL 2023

Phio Pharmaceuticals Corp. Rank 216 of 446




The relative strengths and weaknesses of Phio Pharmaceuticals Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Phio Pharmaceuticals Corp. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Phio Pharmaceuticals Corp. is the variable Net Income, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 97%, being 54% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	12,446
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,939
Liabilities, Non-Current	35
Other Assets	185
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-18
Other Revenues	0
Property and Equipment	183
Research and Development	7,012
Selling, General and Administrative Expense	4,450

Output Variable	Value in 1000 USD
Assets	12,814
Liabilities	1,974
Expenses	11,462
Revenues	0
Stockholders Equity	10,840
Net Income	-11,480
Comprehensive Net Income	-11,480
Economic Capital Ratio	97%





Lipocine Inc.
Rank 38 of 446

The relative strengths and weaknesses of Lipocine Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lipocine Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Lipocine Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 256%, being 213% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	34,135
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,678
Liabilities, Non-Current	0
Other Assets	3,276
Other Compr. Net Income	-2.3
Other Expenses	0.68
Other Liabilities	230
Other Net Income	1,361
Other Revenues	500
Property and Equipment	132
Research and Development	8,557
Selling, General and Administrative Expense	4,062

Output Variable	Value in 1000 USD
Assets	37,543
Liabilities	1,908
Expenses	12,620
Revenues	500
Stockholders Equity	35,635
Net Income	-10,759
Comprehensive Net Income	-10,760
Economic Capital Ratio	256%



PHARMACEUTICAL 2023

Greater Cannabis Company Inc.
Rank 400 of 446





PHARMACEUTICAL 2023

Greater Cannabis Company Inc.
Rank 400 of 446

The relative strengths and weaknesses of Greater Cannabis Company Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Greater Cannabis Company Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Greater Cannabis Company Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 228% points.

The company's Economic Capital Ratio, given in the ranking table, is -235%, being 278% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	270
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16
Liabilities, Non-Current	0
Other Assets	10
Other Compr. Net Income	0
Other Expenses	177
Other Liabilities	809
Other Net Income	-183
Other Revenues	0
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	280
Liabilities	825
Expenses	177
Revenues	0
Stockholders Equity	-545
Net Income	-360
Comprehensive Net Income	-360
Economic Capital Ratio	-235%



PHARMACEUTICAL 2023

Y-mAbs Therapeutics Inc.
Rank 203 of 446





RealRate

PHARMACEUTICAL 2023

Y-mAbs Therapeutics Inc. Rank 203 of 446



The relative strengths and weaknesses of Y-mAbs Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Y-mAbs Therapeutics Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Y-mAbs Therapeutics Inc. is the variable Expenses, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 106%, being 63% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	130,447
Cost of Goods Sold	7,467
Intangible Assets	2,986
Liabilities, Current	28,284
Liabilities, Non-Current	1,701
Other Assets	7,419
Other Compr. Net Income	-40
Other Expenses	100
Other Liabilities	2,250
Other Net Income	-757
Other Revenues	65,267
Property and Equipment	604
Research and Development	91,572
Selling, General and Administrative Expense	60,939


Output Variable	Value in 1000 USD
Assets	141,456
Liabilities	32,235
Expenses	160,078
Revenues	65,267
Stockholders Equity	109,221
Net Income	-95,568
Comprehensive Net Income	-95,588
Economic Capital Ratio	106%



RealRate

PHARMACEUTICAL 2023

Virpax Pharmaceuticals Inc.
Rank 245 of 446





RealRate

PHARMACEUTICAL 2023

Virpax Pharmaceuticals Inc. Rank 245 of 446



The relative strengths and weaknesses of Virpax Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Virpax Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Virpax Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is 60%, being 17% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	19,674
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,095
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	194
Other Revenues	0
Property and Equipment	0
Research and Development	10,763
Selling, General and Administrative Expense	11,082


Output Variable	Value in 1000 USD
Assets	19,674
Liabilities	3,095
Expenses	21,845
Revenues	0
Stockholders Equity	16,579
Net Income	-21,651
Comprehensive Net Income	-21,651
Economic Capital Ratio	60%



RealRate

PHARMACEUTICAL 2023

Korro Bio Inc.
Rank 258 of 446





RealRate

PHARMACEUTICAL 2023

Korro Bio Inc.
Rank 258 of 446




The relative strengths and weaknesses of Korro Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Korro Bio Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Korro Bio Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 43%, being 0.013% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	87,493
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,026
Liabilities, Non-Current	26,850
Other Assets	31,006
Other Compr. Net Income	-136
Other Expenses	959
Other Liabilities	4,167
Other Net Income	2,381
Other Revenues	0
Property and Equipment	2,739
Research and Development	49,418
Selling, General and Administrative Expense	33,584

Output Variable	Value in 1000 USD
Assets	121,238
Liabilities	52,043
Expenses	83,961
Revenues	0
Stockholders Equity	69,195
Net Income	-81,580
Comprehensive Net Income	-81,648
Economic Capital Ratio	43%





RealRate

PHARMACEUTICAL 2023

Matinas BioPharma Holdings Inc. Rank 146 of 446

MATINAS
BIOPHARMA

The relative strengths and weaknesses of Matinas BioPharma Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas BioPharma Holdings Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Matinas BioPharma Holdings Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 157%, being 114% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	34,532
Cost of Goods Sold	0
Intangible Assets	4,353
Liabilities, Current	4,286
Liabilities, Non-Current	3,896
Other Assets	3,843
Other Compr. Net Income	-679
Other Expenses	0
Other Liabilities	0
Other Net Income	3,593
Other Revenues	3,188
Property and Equipment	2,091
Research and Development	16,678
Selling, General and Administrative Expense	11,100

Output Variable	Value in 1000 USD
Assets	44,819
Liabilities	8,182
Expenses	27,778
Revenues	3,188
Stockholders Equity	36,637
Net Income	-20,997
Comprehensive Net Income	-21,336
Economic Capital Ratio	157%



PHARMACEUTICAL 2023

CV Sciences Inc.
Rank 352 of 446





PHARMACEUTICAL 2023

CV Sciences Inc.
Rank 352 of 446




The relative strengths and weaknesses of CV Sciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CV Sciences Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 91% points. The greatest weakness of CV Sciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 123% points.

The company's Economic Capital Ratio, given in the ranking table, is -73%, being 116% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	11,130
Cost of Goods Sold	10,655
Intangible Assets	251
Liabilities, Current	13,314
Liabilities, Non-Current	188
Other Assets	780
Other Compr. Net Income	0
Other Expenses	-47
Other Liabilities	11
Other Net Income	-1,414
Other Revenues	16,205
Property and Equipment	575
Research and Development	307
Selling, General and Administrative Expense	12,090

Output Variable	Value in 1000 USD
Assets	12,736
Liabilities	13,513
Expenses	23,005
Revenues	16,205
Stockholders Equity	-777
Net Income	-8,214
Comprehensive Net Income	-8,214
Economic Capital Ratio	-73%



The relative strengths and weaknesses of Tonix Pharmaceuticals Holding Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tonix Pharmaceuticals Holding Corp. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Tonix Pharmaceuticals Holding Corp. is the variable Research and Development, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 202%, being 158% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	130,777
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,180
Liabilities, Non-Current	328
Other Assets	1,099
Other Compr. Net Income	-75
Other Expenses	0
Other Liabilities	0
Other Net Income	1,873
Other Revenues	0
Property and Equipment	93,814
Research and Development	81,876
Selling, General and Administrative Expense	30,215

Output Variable	Value in 1000 USD
Assets	225,690
Liabilities	18,508
Expenses	112,091
Revenues	0
Stockholders Equity	207,182
Net Income	-110,218
Comprehensive Net Income	-110,256
Economic Capital Ratio	202%



PHARMACEUTICAL 2023

Earth Science Tech Inc.
Rank 294 of 446





PHARMACEUTICAL 2023

Earth Science Tech Inc.
Rank 294 of 446

The relative strengths and weaknesses of Earth Science Tech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Earth Science Tech Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 453% points. The greatest weakness of Earth Science Tech Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 670% points.

The company's Economic Capital Ratio, given in the ranking table, is 6.9%, being 36% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	27
Cost of Goods Sold	23
Intangible Assets	0
Liabilities, Current	1,882
Liabilities, Non-Current	0
Other Assets	50
Other Compr. Net Income	0
Other Expenses	102
Other Liabilities	0
Other Net Income	3,400
Other Revenues	14
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	116

Output Variable	Value in 1000 USD
Assets	77
Liabilities	1,882
Expenses	241
Revenues	14
Stockholders Equity	-1,805
Net Income	3,173
Comprehensive Net Income	3,173
Economic Capital Ratio	6.9%



PHARMACEUTICAL 2023

Aclaris Therapeutics Inc.
Rank 140 of 446





PHARMACEUTICAL 2023

Aclaris Therapeutics Inc.
Rank 140 of 446




The relative strengths and weaknesses of Aclaris Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aclaris Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 60% points. The greatest weakness of Aclaris Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 162%, being 119% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	231,550
Cost of Goods Sold	4,023
Intangible Assets	6,973
Liabilities, Current	21,938
Liabilities, Non-Current	1,570
Other Assets	14,974
Other Compr. Net Income	-673
Other Expenses	12,637
Other Liabilities	33,467
Other Net Income	2,946
Other Revenues	29,752
Property and Equipment	1,099
Research and Development	77,813
Selling, General and Administrative Expense	25,133

Output Variable	Value in 1000 USD
Assets	254,596
Liabilities	56,975
Expenses	119,606
Revenues	29,752
Stockholders Equity	197,621
Net Income	-86,908
Comprehensive Net Income	-87,244
Economic Capital Ratio	162%





PHARMACEUTICAL 2023



Vanda Pharmaceuticals Inc. Rank 46 of 446




The relative strengths and weaknesses of Vanda Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vanda Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Vanda Pharmaceuticals Inc. is the variable Intangible Assets, reducing the Economic Capital Ratio by 2.4% points.

The company's Economic Capital Ratio, given in the ranking table, is 246%, being 203% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	519,292
Cost of Goods Sold	0
Intangible Assets	18,565
Liabilities, Current	91,436
Liabilities, Non-Current	15,613
Other Assets	93,817
Other Compr. Net Income	-1,018
Other Expenses	30,823
Other Liabilities	0
Other Net Income	0
Other Revenues	259,353
Property and Equipment	2,573
Research and Development	85,770
Selling, General and Administrative Expense	136,485

Output Variable	Value in 1000 USD
Assets	634,247
Liabilities	107,049
Expenses	253,078
Revenues	259,353
Stockholders Equity	527,198
Net Income	6,275
Comprehensive Net Income	5,766
Economic Capital Ratio	246%





PHARMACEUTICAL 2023

Fortress Biotech Inc.
Rank 337 of 446




The relative strengths and weaknesses of Fortress Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Fortress Biotech Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 10% points. The greatest weakness of Fortress Biotech Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is -47%, being 91% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	230,432
Cost of Goods Sold	30,775
Intangible Assets	27,197
Liabilities, Current	127,715
Liabilities, Non-Current	23,419
Other Assets	23,652
Other Compr. Net Income	0
Other Expenses	449
Other Liabilities	93,142
Other Net Income	-9,900
Other Revenues	75,743
Property and Equipment	13,020
Research and Development	134,876
Selling, General and Administrative Expense	113,656

Output Variable	Value in 1000 USD
Assets	294,301
Liabilities	244,276
Expenses	279,756
Revenues	75,743
Stockholders Equity	50,025
Net Income	-213,913
Comprehensive Net Income	-213,913
Economic Capital Ratio	-47%





RealRate

PHARMACEUTICAL 2023

Bolt Biotherapeutics Inc. Rank 159 of 446




The relative strengths and weaknesses of Bolt Biotherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bolt Biotherapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Bolt Biotherapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 145%, being 102% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	172,746
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	23,118
Liabilities, Non-Current	20,262
Other Assets	48,608
Other Compr. Net Income	-598
Other Expenses	0
Other Liabilities	12,921
Other Net Income	2,223
Other Revenues	5,729
Property and Equipment	6,453
Research and Development	73,123
Selling, General and Administrative Expense	22,927

Output Variable	Value in 1000 USD
Assets	227,807
Liabilities	56,301
Expenses	96,050
Revenues	5,729
Stockholders Equity	171,506
Net Income	-88,098
Comprehensive Net Income	-88,397
Economic Capital Ratio	145%





PHARMACEUTICAL 2023

Nurix Therapeutics Inc.
Rank 178 of 446




The relative strengths and weaknesses of Nurix Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nurix Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 28% points. The greatest weakness of Nurix Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 128%, being 85% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	318,449
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	70,655
Liabilities, Non-Current	42,408
Other Assets	81,147
Other Compr. Net Income	-3,711
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	42,134
Property and Equipment	17,163
Research and Development	184,497
Selling, General and Administrative Expense	37,997

Output Variable	Value in 1000 USD
Assets	416,759
Liabilities	113,063
Expenses	222,494
Revenues	42,134
Stockholders Equity	303,696
Net Income	-180,360
Comprehensive Net Income	-182,216
Economic Capital Ratio	128%



The relative strengths and weaknesses of Ventyx Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ventyx Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Ventyx Biosciences Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 257%, being 214% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	330,688
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,359
Liabilities, Non-Current	1,146
Other Assets	40,305
Other Compr. Net Income	-1,065
Other Expenses	0
Other Liabilities	0
Other Net Income	4,710
Other Revenues	0
Property and Equipment	407
Research and Development	87,738
Selling, General and Administrative Expense	25,398


Output Variable	Value in 1000 USD
Assets	371,400
Liabilities	17,505
Expenses	113,136
Revenues	0
Stockholders Equity	353,895
Net Income	-108,426
Comprehensive Net Income	-108,958
Economic Capital Ratio	257%



RealRate

PHARMACEUTICAL 2023

IntelGenx Technologies Corp. Rank 381 of 446





RealRate

PHARMACEUTICAL 2023

IntelGenx Technologies Corp. Rank 381 of 446




The relative strengths and weaknesses of IntelGenx Technologies Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IntelGenx Technologies Corp. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 107% points. The greatest weakness of IntelGenx Technologies Corp. is the variable Assets, Current, reducing the Economic Capital Ratio by 133% points.

The company's Economic Capital Ratio, given in the ranking table, is -156%, being 199% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	3,788
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,374
Liabilities, Non-Current	425
Other Assets	977
Other Compr. Net Income	-863
Other Expenses	2,635
Other Liabilities	9,814
Other Net Income	-1,277
Other Revenues	950
Property and Equipment	4,425
Research and Development	3,031
Selling, General and Administrative Expense	4,697

Output Variable	Value in 1000 USD
Assets	9,190
Liabilities	12,613
Expenses	10,363
Revenues	950
Stockholders Equity	-3,423
Net Income	-10,690
Comprehensive Net Income	-11,122
Economic Capital Ratio	-156%





RealRate

PHARMACEUTICAL 2023

ALNYLAM PHARMACEUTICALS INC. Rank 335 of 446

Alnylam@20


The relative strengths and weaknesses of ALNYLAM PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALNYLAM PHARMACEUTICALS INC. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 34% points. The greatest weakness of ALNYLAM PHARMACEUTICALS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 103% points.

The company's Economic Capital Ratio, given in the ranking table, is -39%, being 82% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,692,247
Cost of Goods Sold	140,174
Intangible Assets	0
Liabilities, Current	767,915
Liabilities, Non-Current	667,710
Other Assets	330,618
Other Compr. Net Income	-11,395
Other Expenses	32,806
Other Liabilities	2,268,957
Other Net Income	-341,921
Other Revenues	1,037,418
Property and Equipment	523,494
Research and Development	883,015
Selling, General and Administrative Expense	770,658

Output Variable	Value in 1000 USD
Assets	3,546,359
Liabilities	3,704,582
Expenses	1,826,653
Revenues	1,037,418
Stockholders Equity	-158,223
Net Income	-1,131,156
Comprehensive Net Income	-1,136,854
Economic Capital Ratio	-39%





PHARMACEUTICAL 2023

Gain Therapeutics Inc.
Rank 211 of 446




The relative strengths and weaknesses of Gain Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Gain Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 53% points. The greatest weakness of Gain Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 102%, being 58% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	21,091
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,125
Liabilities, Non-Current	1,095
Other Assets	2,864
Other Compr. Net Income	0
Other Expenses	93
Other Liabilities	0
Other Net Income	279
Other Revenues	140
Property and Equipment	144
Research and Development	8,377
Selling, General and Administrative Expense	9,540

Output Variable	Value in 1000 USD
Assets	24,099
Liabilities	5,220
Expenses	18,010
Revenues	140
Stockholders Equity	18,880
Net Income	-17,591
Comprehensive Net Income	-17,591
Economic Capital Ratio	102%




The relative strengths and weaknesses of EQRx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of EQRx Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 63% points. The greatest weakness of EQRx Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 292%, being 249% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,428,086
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	51,916
Liabilities, Non-Current	1,461
Other Assets	24,303
Other Compr. Net Income	-149
Other Expenses	0
Other Liabilities	12,777
Other Net Income	186,788
Other Revenues	0
Property and Equipment	2,627
Research and Development	228,495
Selling, General and Administrative Expense	127,382

Output Variable	Value in 1000 USD
Assets	1,455,016
Liabilities	66,154
Expenses	355,877
Revenues	0
Stockholders Equity	1,388,862
Net Income	-169,089
Comprehensive Net Income	-169,164
Economic Capital Ratio	292%





PHARMACEUTICAL 2023

Dianthus Therapeutics Inc. DE Rank 192 of 446




The relative strengths and weaknesses of Dianthus Therapeutics Inc. DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dianthus Therapeutics Inc. DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Dianthus Therapeutics Inc. DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 113%, being 70% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	115,602
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,549
Liabilities, Non-Current	26,138
Other Assets	24,948
Other Compr. Net Income	-151
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	4,440
Property and Equipment	6,095
Research and Development	55,141
Selling, General and Administrative Expense	25,761

Output Variable	Value in 1000 USD
Assets	146,645
Liabilities	40,687
Expenses	80,902
Revenues	4,440
Stockholders Equity	105,958
Net Income	-76,462
Comprehensive Net Income	-76,538
Economic Capital Ratio	113%




The relative strengths and weaknesses of Homology Medicines Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Homology Medicines Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Homology Medicines Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 216%, being 173% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	181,015
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,576
Liabilities, Non-Current	27,916
Other Assets	46,377
Other Compr. Net Income	-397
Other Expenses	715
Other Liabilities	0
Other Net Income	128,991
Other Revenues	3,208
Property and Equipment	1,078
Research and Development	98,351
Selling, General and Administrative Expense	38,138

Output Variable	Value in 1000 USD
Assets	228,470
Liabilities	50,492
Expenses	137,204
Revenues	3,208
Stockholders Equity	177,978
Net Income	-5,005
Comprehensive Net Income	-5,204
Economic Capital Ratio	216%





RealRate

PHARMACEUTICAL 2023

ATAI Life Sciences N.V.
Rank 129 of 446



The relative strengths and weaknesses of ATAI Life Sciences N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ATAI Life Sciences N.V. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 89% points. The greatest weakness of ATAI Life Sciences N.V. is the variable Net Income, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 128% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	287,145
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,897
Liabilities, Non-Current	3,708
Other Assets	17,368
Other Compr. Net Income	-8,384
Other Expenses	6,586
Other Liabilities	16,070
Other Net Income	-6,401
Other Revenues	233
Property and Equipment	928
Research and Development	74,313
Selling, General and Administrative Expense	70,350

Output Variable	Value in 1000 USD
Assets	305,441
Liabilities	39,675
Expenses	151,249
Revenues	233
Stockholders Equity	265,766
Net Income	-157,417
Comprehensive Net Income	-161,609
Economic Capital Ratio	171%



PHARMACEUTICAL 2023

Equillum Inc.
Rank 308 of 446





PHARMACEUTICAL 2023

Equillium Inc.
Rank 308 of 446


The relative strengths and weaknesses of Equillium Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Equillium Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 19% points. The greatest weakness of Equillium Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is -12%, being 55% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	76,735
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	32,038
Liabilities, Non-Current	824
Other Assets	1,295
Other Compr. Net Income	214
Other Expenses	23,049
Other Liabilities	13,617
Other Net Income	-352
Other Revenues	15,759
Property and Equipment	391
Research and Development	37,547
Selling, General and Administrative Expense	17,239

Output Variable	Value in 1000 USD
Assets	78,421
Liabilities	46,479
Expenses	77,835
Revenues	15,759
Stockholders Equity	31,942
Net Income	-62,428
Comprehensive Net Income	-62,321
Economic Capital Ratio	-12%



**Theravance Biopharma Inc.
Rank 1 of 446**

The relative strengths and weaknesses of Theravance Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theravance Biopharma Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 402% points. The greatest weakness of Theravance Biopharma Inc. is the variable Other Assets, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 587%, being 544% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	353,464
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,715
Liabilities, Non-Current	0
Other Assets	242,061
Other Compr. Net Income	-15
Other Expenses	19,216
Other Liabilities	0
Other Net Income	970,467
Other Revenues	51,346
Property and Equipment	11,875
Research and Development	63,392
Selling, General and Administrative Expense	67,073

Output Variable	Value in 1000 USD
Assets	607,400
Liabilities	28,715
Expenses	149,681
Revenues	51,346
Stockholders Equity	578,685
Net Income	872,132
Comprehensive Net Income	872,124
Economic Capital Ratio	587%



PHARMACEUTICAL 2023

Imunon Inc.
Rank 253 of 446





PHARMACEUTICAL 2023

Imunon Inc.
Rank 253 of 446




The relative strengths and weaknesses of Imunon Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Imunon Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Imunon Inc. is the variable Net Income, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 50%, being 6.5% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	37,155
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,037
Liabilities, Non-Current	0
Other Assets	6,273
Other Compr. Net Income	26
Other Expenses	-1,567
Other Liabilities	4,611
Other Net Income	-12,544
Other Revenues	500
Property and Equipment	548
Research and Development	11,734
Selling, General and Administrative Expense	13,688

Output Variable	Value in 1000 USD
Assets	43,976
Liabilities	14,648
Expenses	23,855
Revenues	500
Stockholders Equity	29,328
Net Income	-35,898
Comprehensive Net Income	-35,885
Economic Capital Ratio	50%





PHARMACEUTICAL 2023

Aquestive Therapeutics Inc.
Rank 396 of 446




The relative strengths and weaknesses of Aquestive Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aquestive Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Aquestive Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 154% points.

The company's Economic Capital Ratio, given in the ranking table, is -222%, being 265% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	39,888
Cost of Goods Sold	0
Intangible Assets	1,435
Liabilities, Current	39,528
Liabilities, Non-Current	38,536
Other Assets	11,662
Other Compr. Net Income	0
Other Expenses	31,829
Other Liabilities	97,560
Other Net Income	0
Other Revenues	47,779
Property and Equipment	4,085
Research and Development	17,481
Selling, General and Administrative Expense	52,879

Output Variable	Value in 1000 USD
Assets	57,070
Liabilities	175,624
Expenses	102,189
Revenues	47,779
Stockholders Equity	-118,554
Net Income	-54,410
Comprehensive Net Income	-54,410
Economic Capital Ratio	-222%





PHARMACEUTICAL 2023

ROYALTY PHARMA

Royalty Pharma plc
Rank 167 of 446

The relative strengths and weaknesses of Royalty Pharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Royalty Pharma plc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 238% points. The greatest weakness of Royalty Pharma plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is 137%, being 94% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	2,554,908
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,166,783
Liabilities, Non-Current	6,121,310
Other Assets	14,258,558
Other Compr. Net Income	-204,850
Other Expenses	1,525,741
Other Liabilities	0
Other Net Income	-77,001
Other Revenues	2,237,215
Property and Equipment	0
Research and Development	177,106
Selling, General and Administrative Expense	227,303

Output Variable	Value in 1000 USD
Assets	16,813,466
Liabilities	7,288,093
Expenses	1,930,150
Revenues	2,237,215
Stockholders Equity	9,525,373
Net Income	230,064
Comprehensive Net Income	127,639
Economic Capital Ratio	137%



PHARMACEUTICAL 2023

Aprea Therapeutics Inc.
Rank 429 of 446





PHARMACEUTICAL 2023

Aprea Therapeutics Inc.
Rank 429 of 446


The relative strengths and weaknesses of Aprea Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aprea Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Aprea Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 477% points.

The company's Economic Capital Ratio, given in the ranking table, is -398%, being 441% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	30,154
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,201
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-264
Other Expenses	76,020
Other Liabilities	0
Other Net Income	730
Other Revenues	0
Property and Equipment	2.3
Research and Development	16,402
Selling, General and Administrative Expense	20,970

Output Variable	Value in 1000 USD
Assets	30,156
Liabilities	3,201
Expenses	113,392
Revenues	0
Stockholders Equity	26,955
Net Income	-112,662
Comprehensive Net Income	-112,794
Economic Capital Ratio	-398%



The relative strengths and weaknesses of Xenetic Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenetic Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 60% points. The greatest weakness of Xenetic Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 214%, being 171% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	13,653
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,073
Liabilities, Non-Current	0
Other Assets	1,067
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	166
Other Revenues	1,707
Property and Equipment	0
Research and Development	4,771
Selling, General and Administrative Expense	3,654

Output Variable	Value in 1000 USD
Assets	14,720
Liabilities	1,073
Expenses	8,425
Revenues	1,707
Stockholders Equity	13,647
Net Income	-6,552
Comprehensive Net Income	-6,552
Economic Capital Ratio	214%



PHARMACEUTICAL 2023

REGENERX BIOPHARMACEUTICALS INC Rank 421 of 446





PHARMACEUTICAL 2023

REGENERX BIOPHARMACEUTICALS INC Rank 421 of 446

The relative strengths and weaknesses of REGENERX BIOPHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENERX BIOPHARMACEUTICALS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 40% points. The greatest weakness of REGENERX BIOPHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 204% points.

The company's Economic Capital Ratio, given in the ranking table, is -364%, being 407% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	307
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	554
Liabilities, Non-Current	1,901
Other Assets	75
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	1,373
Other Net Income	-325
Other Revenues	77
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	1,479

Output Variable	Value in 1000 USD
Assets	382
Liabilities	3,828
Expenses	1,479
Revenues	77
Stockholders Equity	-3,445
Net Income	-1,727
Comprehensive Net Income	-1,727
Economic Capital Ratio	-364%



PHARMACEUTICAL 2023

NeuBase Therapeutics Inc.
Rank 271 of 446





PHARMACEUTICAL 2023

NeuBase Therapeutics Inc.
Rank 271 of 446

The relative strengths and weaknesses of NeuBase Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NeuBase Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 32% points. The greatest weakness of NeuBase Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 29%, being 14% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	24,649
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,166
Liabilities, Non-Current	5,335
Other Assets	5,888
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-458
Other Revenues	0
Property and Equipment	2,157
Research and Development	21,449
Selling, General and Administrative Expense	11,870


Output Variable	Value in 1000 USD
Assets	32,693
Liabilities	9,502
Expenses	33,318
Revenues	0
Stockholders Equity	23,192
Net Income	-33,776
Comprehensive Net Income	-33,776
Economic Capital Ratio	29%



RealRate

PHARMACEUTICAL 2023

ROCKWELL MEDICAL INC. Rank 285 of 446





RealRate

PHARMACEUTICAL 2023

ROCKWELL MEDICAL INC. Rank 285 of 446



The relative strengths and weaknesses of ROCKWELL MEDICAL INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ROCKWELL MEDICAL INC. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 145% points. The greatest weakness of ROCKWELL MEDICAL INC. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 164% points.

The company's Economic Capital Ratio, given in the ranking table, is 14%, being 29% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	35,310
Cost of Goods Sold	68,733
Intangible Assets	921
Liabilities, Current	17,691
Liabilities, Non-Current	10,169
Other Assets	8,210
Other Compr. Net Income	111
Other Expenses	2,094
Other Liabilities	4,669
Other Net Income	-1,899
Other Revenues	72,810
Property and Equipment	2,194
Research and Development	3,119
Selling, General and Administrative Expense	15,644

Output Variable	Value in 1000 USD
Assets	46,635
Liabilities	32,529
Expenses	89,590
Revenues	72,810
Stockholders Equity	14,106
Net Income	-18,679
Comprehensive Net Income	-18,624
Economic Capital Ratio	14%



PHARMACEUTICAL 2023

Organogenesis Holdings Inc.
Rank 156 of 446





RealRate

PHARMACEUTICAL 2023

Organogenesis Holdings Inc. Rank 156 of 446




The relative strengths and weaknesses of Organogenesis Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Organogenesis Holdings Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 113% points. The greatest weakness of Organogenesis Holdings Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 149%, being 106% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	222,609
Cost of Goods Sold	105,019
Intangible Assets	49,561
Liabilities, Current	75,023
Liabilities, Non-Current	42,436
Other Assets	74,726
Other Compr. Net Income	0
Other Expenses	4,750
Other Liabilities	66,231
Other Net Income	-2,022
Other Revenues	450,893
Property and Equipment	102,463
Research and Development	39,762
Selling, General and Administrative Expense	283,808

Output Variable	Value in 1000 USD
Assets	449,359
Liabilities	183,690
Expenses	433,339
Revenues	450,893
Stockholders Equity	265,669
Net Income	15,532
Comprehensive Net Income	15,532
Economic Capital Ratio	149%





PHARMACEUTICAL 2023

BODY & MIND INC.
Rank 336 of 446




The relative strengths and weaknesses of BODY & MIND INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BODY & MIND INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 98% points. The greatest weakness of BODY & MIND INC. is the variable Other Expenses, reducing the Economic Capital Ratio by 213% points.

The company's Economic Capital Ratio, given in the ranking table, is -42%, being 85% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	7,998
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,617
Liabilities, Non-Current	5,515
Other Assets	17,388
Other Compr. Net Income	96
Other Expenses	59,866
Other Liabilities	8,788
Other Net Income	0
Other Revenues	31,638
Property and Equipment	5,641
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	31,026
Liabilities	20,920
Expenses	59,866
Revenues	31,638
Stockholders Equity	10,105
Net Income	-28,228
Comprehensive Net Income	-28,180
Economic Capital Ratio	-42%





RealRate

PHARMACEUTICAL 2023

Corbus Pharmaceuticals Holdings Inc. Rank 272 of 446



The relative strengths and weaknesses of Corbus Pharmaceuticals Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corbus Pharmaceuticals Holdings Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 48% points. The greatest weakness of Corbus Pharmaceuticals Holdings Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 67% points.

The company's Economic Capital Ratio, given in the ranking table, is 29%, being 14% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	60,181
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,640
Liabilities, Non-Current	20,682
Other Assets	4,517
Other Compr. Net Income	-64
Other Expenses	5,000
Other Liabilities	0
Other Net Income	-2,511
Other Revenues	0
Property and Equipment	1,614
Research and Development	16,137
Selling, General and Administrative Expense	18,699

Output Variable	Value in 1000 USD
Assets	66,312
Liabilities	33,322
Expenses	39,835
Revenues	0
Stockholders Equity	32,990
Net Income	-42,347
Comprehensive Net Income	-42,379
Economic Capital Ratio	29%



PHARMACEUTICAL 2023

TEVA PHARMACEUTICAL
INDUSTRIES LTD
Rank 268 of 446





PHARMACEUTICAL 2023

TEVA PHARMACEUTICAL INDUSTRIES LTD Rank 268 of 446




The relative strengths and weaknesses of TEVA PHARMACEUTICAL INDUSTRIES LTD are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of TEVA PHARMACEUTICAL INDUSTRIES LTD compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 110% points. The greatest weakness of TEVA PHARMACEUTICAL INDUSTRIES LTD is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 123% points.

The company's Economic Capital Ratio, given in the ranking table, is 31%, being 12% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	12,051,000
Cost of Goods Sold	7,952,000
Intangible Assets	23,903,000
Liabilities, Current	11,469,000
Liabilities, Non-Current	23,846,000
Other Assets	2,313,000
Other Compr. Net Income	-101,000
Other Expenses	6,523,000
Other Liabilities	0
Other Net Income	-838,000
Other Revenues	14,925,000
Property and Equipment	5,739,000
Research and Development	838,000
Selling, General and Administrative Expense	1,180,000

Output Variable	Value in 1000 USD
Assets	44,006,000
Liabilities	35,315,000
Expenses	16,493,000
Revenues	14,925,000
Stockholders Equity	8,691,000
Net Income	-2,406,000
Comprehensive Net Income	-2,456,500
Economic Capital Ratio	31%




The relative strengths and weaknesses of Sage Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sage Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Sage Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 222%, being 178% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,336,980
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	99,259
Liabilities, Non-Current	4,591
Other Assets	16,571
Other Compr. Net Income	-7,546
Other Expenses	813
Other Liabilities	0
Other Net Income	14,205
Other Revenues	7,686
Property and Equipment	2,898
Research and Development	326,163
Selling, General and Administrative Expense	227,699

Output Variable	Value in 1000 USD
Assets	1,356,449
Liabilities	103,850
Expenses	554,675
Revenues	7,686
Stockholders Equity	1,252,599
Net Income	-532,784
Comprehensive Net Income	-536,557
Economic Capital Ratio	222%





PHARMACEUTICAL 2023

GLYCOMIMETICS INC Rank 224 of 446




The relative strengths and weaknesses of GLYCOMIMETICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GLYCOMIMETICS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 83% points. The greatest weakness of GLYCOMIMETICS INC is the variable Net Income, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is 87%, being 44% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	50,715
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,881
Liabilities, Non-Current	0
Other Assets	853
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	75
Property and Equipment	242
Research and Development	28,391
Selling, General and Administrative Expense	19,087

Output Variable	Value in 1000 USD
Assets	51,811
Liabilities	8,881
Expenses	47,478
Revenues	75
Stockholders Equity	42,930
Net Income	-47,403
Comprehensive Net Income	-47,403
Economic Capital Ratio	87%





PHARMACEUTICAL 2023

VBI Vaccines Inc BC
Rank 293 of 446




The relative strengths and weaknesses of VBI Vaccines Inc BC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VBI Vaccines Inc BC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 84% points. The greatest weakness of VBI Vaccines Inc BC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is 7.0%, being 36% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	77,690
Cost of Goods Sold	0
Intangible Assets	60,472
Liabilities, Current	36,942
Liabilities, Non-Current	53,981
Other Assets	4,671
Other Compr. Net Income	23,005
Other Expenses	15,283
Other Liabilities	0
Other Net Income	-27,476
Other Revenues	1,082
Property and Equipment	12,253
Research and Development	15,506
Selling, General and Administrative Expense	56,120

Output Variable	Value in 1000 USD
Assets	155,086
Liabilities	90,923
Expenses	86,909
Revenues	1,082
Stockholders Equity	64,163
Net Income	-113,303
Comprehensive Net Income	-101,800
Economic Capital Ratio	7.0%





PHARMACEUTICAL 2023

Checkpoint Therapeutics Inc.
Rank 433 of 446




The relative strengths and weaknesses of Checkpoint Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Checkpoint Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Checkpoint Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 252% points.

The company's Economic Capital Ratio, given in the ranking table, is -417%, being 461% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	13,290
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	32,773
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-4,291
Other Revenues	192
Property and Equipment	0
Research and Development	49,825
Selling, General and Administrative Expense	8,700

Output Variable	Value in 1000 USD
Assets	13,290
Liabilities	32,773
Expenses	58,525
Revenues	192
Stockholders Equity	-19,483
Net Income	-62,624
Comprehensive Net Income	-62,624
Economic Capital Ratio	-417%





RealRate

PHARMACEUTICAL 2023

Benitec Biopharma Inc. Rank 409 of 446




The relative strengths and weaknesses of Benitec Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Benitec Biopharma Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 19% points. The greatest weakness of Benitec Biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 265% points.

The company's Economic Capital Ratio, given in the ranking table, is -290%, being 333% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	4,820
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,532
Liabilities, Non-Current	559
Other Assets	931
Other Compr. Net Income	210
Other Expenses	9.0
Other Liabilities	0
Other Net Income	-354
Other Revenues	73
Property and Equipment	222
Research and Development	11,272
Selling, General and Administrative Expense	6,646

Output Variable	Value in 1000 USD
Assets	5,973
Liabilities	3,091
Expenses	17,927
Revenues	73
Stockholders Equity	2,882
Net Income	-18,208
Comprehensive Net Income	-18,103
Economic Capital Ratio	-290%





RealRate

PHARMACEUTICAL 2023

SOLIGENIX INC. Rank 367 of 446




The relative strengths and weaknesses of SOLIGENIX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SOLIGENIX INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 17% points. The greatest weakness of SOLIGENIX INC. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 135% points.

The company's Economic Capital Ratio, given in the ranking table, is -116%, being 160% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	13,853
Cost of Goods Sold	551
Intangible Assets	0
Liabilities, Current	16,517
Liabilities, Non-Current	234
Other Assets	408
Other Compr. Net Income	-17
Other Expenses	-1,155
Other Liabilities	0
Other Net Income	-714
Other Revenues	949
Property and Equipment	18
Research and Development	7,944
Selling, General and Administrative Expense	6,693

Output Variable	Value in 1000 USD
Assets	14,280
Liabilities	16,750
Expenses	14,033
Revenues	949
Stockholders Equity	-2,471
Net Income	-13,798
Comprehensive Net Income	-13,807
Economic Capital Ratio	-116%





RealRate

PHARMACEUTICAL 2023

HCW Biologics Inc.
Rank 123 of 446




The relative strengths and weaknesses of HCW Biologics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HCW Biologics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 51% points. The greatest weakness of HCW Biologics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 176%, being 133% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	34,071
Cost of Goods Sold	4,136
Intangible Assets	0
Liabilities, Current	2,956
Liabilities, Non-Current	0
Other Assets	1,934
Other Compr. Net Income	0
Other Expenses	127
Other Liabilities	6,424
Other Net Income	0
Other Revenues	7,027
Property and Equipment	10,805
Research and Development	9,338
Selling, General and Administrative Expense	8,327

Output Variable	Value in 1000 USD
Assets	46,809
Liabilities	9,381
Expenses	21,928
Revenues	7,027
Stockholders Equity	37,429
Net Income	-14,901
Comprehensive Net Income	-14,901
Economic Capital Ratio	176%





PHARMACEUTICAL 2023

ORAGENICS INC Rank 214 of 446




The relative strengths and weaknesses of ORAGENICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ORAGENICS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 77% points. The greatest weakness of ORAGENICS INC is the variable Net Income, reducing the Economic Capital Ratio by 88% points.

The company's Economic Capital Ratio, given in the ranking table, is 98%, being 55% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	14,290
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,596
Liabilities, Non-Current	152
Other Assets	347
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	127
Other Revenues	132
Property and Equipment	121
Research and Development	10,073
Selling, General and Administrative Expense	4,474

Output Variable	Value in 1000 USD
Assets	14,758
Liabilities	1,749
Expenses	14,547
Revenues	132
Stockholders Equity	13,009
Net Income	-14,288
Comprehensive Net Income	-14,288
Economic Capital Ratio	98%





RealRate

PHARMACEUTICAL 2023

Merus N.V.
Rank 195 of 446

Merus

The relative strengths and weaknesses of Merus N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merus N.V. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Merus N.V. is the variable Research and Development, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 112%, being 69% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	306,443
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	78,926
Liabilities, Non-Current	11,790
Other Assets	57,877
Other Compr. Net Income	-21,227
Other Expenses	959
Other Liabilities	38,771
Other Net Income	29,803
Other Revenues	41,586
Property and Equipment	12,222
Research and Development	149,424
Selling, General and Administrative Expense	52,200

Output Variable	Value in 1000 USD
Assets	376,542
Liabilities	129,487
Expenses	202,583
Revenues	41,586
Stockholders Equity	247,055
Net Income	-131,194
Comprehensive Net Income	-141,808
Economic Capital Ratio	112%



PHARMACEUTICAL 2023

Prelude Therapeutics Inc
Rank 120 of 446





PHARMACEUTICAL 2023

Prelude Therapeutics Inc
Rank 120 of 446




The relative strengths and weaknesses of Prelude Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Prelude Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Prelude Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 179%, being 136% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	204,380
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,702
Liabilities, Non-Current	3,361
Other Assets	11,212
Other Compr. Net Income	-981
Other Expenses	0
Other Liabilities	0
Other Net Income	8,102
Other Revenues	0
Property and Equipment	4,908
Research and Development	92,889
Selling, General and Administrative Expense	30,651

Output Variable	Value in 1000 USD
Assets	220,500
Liabilities	25,063
Expenses	123,540
Revenues	0
Stockholders Equity	195,437
Net Income	-115,438
Comprehensive Net Income	-115,928
Economic Capital Ratio	179%





RealRate

PHARMACEUTICAL 2023

ASSEMBLY BIOSCIENCES INC. Rank 228 of 446




The relative strengths and weaknesses of ASSEMBLY BIOSCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ASSEMBLY BIOSCIENCES INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of ASSEMBLY BIOSCIENCES INC. is the variable Net Income, reducing the Economic Capital Ratio by 74% points.

The company's Economic Capital Ratio, given in the ranking table, is 81%, being 38% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	96,967
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,296
Liabilities, Non-Current	2,834
Other Assets	4,084
Other Compr. Net Income	-384
Other Expenses	0
Other Liabilities	0
Other Net Income	1,022
Other Revenues	0
Property and Equipment	743
Research and Development	69,980
Selling, General and Administrative Expense	24,134

Output Variable	Value in 1000 USD
Assets	101,794
Liabilities	19,130
Expenses	94,114
Revenues	0
Stockholders Equity	82,664
Net Income	-93,092
Comprehensive Net Income	-93,284
Economic Capital Ratio	81%





**Acasti Pharma Inc.
Rank 59 of 446**


The relative strengths and weaknesses of Acasti Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acasti Pharma Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 117% points. The greatest weakness of Acasti Pharma Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 237%, being 194% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	45,531
Cost of Goods Sold	0
Intangible Assets	82,774
Liabilities, Current	3,260
Liabilities, Non-Current	191
Other Assets	315
Other Compr. Net Income	0
Other Expenses	119
Other Liabilities	16,899
Other Net Income	5,122
Other Revenues	0
Property and Equipment	0
Research and Development	5,559
Selling, General and Administrative Expense	9,263

Output Variable	Value in 1000 USD
Assets	128,620
Liabilities	20,350
Expenses	14,941
Revenues	0
Stockholders Equity	108,270
Net Income	-9,819
Comprehensive Net Income	-9,819
Economic Capital Ratio	237%





PHARMACEUTICAL 2023

NexImmune Inc.
Rank 323 of 446




The relative strengths and weaknesses of NexImmune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NexImmune Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 27% points. The greatest weakness of NexImmune Inc. is the variable Net Income, reducing the Economic Capital Ratio by 134% points.

The company's Economic Capital Ratio, given in the ranking table, is -26%, being 69% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	37,369
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,334
Liabilities, Non-Current	426
Other Assets	1,232
Other Compr. Net Income	-3.0
Other Expenses	0
Other Liabilities	0
Other Net Income	577
Other Revenues	0
Property and Equipment	4,459
Research and Development	47,148
Selling, General and Administrative Expense	15,934

Output Variable	Value in 1000 USD
Assets	43,060
Liabilities	10,759
Expenses	63,083
Revenues	0
Stockholders Equity	32,300
Net Income	-62,506
Comprehensive Net Income	-62,508
Economic Capital Ratio	-26%



The relative strengths and weaknesses of Merck & Co. Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merck & Co. Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 102% points. The greatest weakness of Merck & Co. Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 241%, being 197% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	35,722,000
Cost of Goods Sold	17,411,000
Intangible Assets	41,473,000
Liabilities, Current	24,239,000
Liabilities, Non-Current	0
Other Assets	10,543,000
Other Compr. Net Income	-339,000
Other Expenses	3,763,000
Other Liabilities	0
Other Net Income	0
Other Revenues	59,283,000
Property and Equipment	21,422,000
Research and Development	13,548,000
Selling, General and Administrative Expense	10,042,000

Output Variable	Value in 1000 USD
Assets	109,160,000
Liabilities	24,239,000
Expenses	44,764,000
Revenues	59,283,000
Stockholders Equity	84,921,000
Net Income	14,519,000
Comprehensive Net Income	14,349,500
Economic Capital Ratio	241%



PHARMACEUTICAL 2023

Chemomab Therapeutics Ltd.
Rank 165 of 446





PHARMACEUTICAL 2023

Chemomab Therapeutics Ltd.
Rank 165 of 446

The relative strengths and weaknesses of Chemomab Therapeutics Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chemomab Therapeutics Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Chemomab Therapeutics Ltd. is the variable Net Income, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 139%, being 96% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	41,736
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,749
Liabilities, Non-Current	91
Other Assets	960
Other Compr. Net Income	0
Other Expenses	-534
Other Liabilities	0
Other Net Income	353
Other Revenues	0
Property and Equipment	367
Research and Development	16,977
Selling, General and Administrative Expense	11,556

Output Variable	Value in 1000 USD
Assets	43,063
Liabilities	6,840
Expenses	27,999
Revenues	0
Stockholders Equity	36,223
Net Income	-27,646
Comprehensive Net Income	-27,646
Economic Capital Ratio	139%



PHARMACEUTICAL 2023

Bioquest Corp
Rank 445 of 446





PHARMACEUTICAL 2023

Bioquest Corp
Rank 445 of 446

The relative strengths and weaknesses of Bioquest Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bioquest Corp compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 460% points. The greatest weakness of Bioquest Corp is the variable Assets, Current, reducing the Economic Capital Ratio by 462% points.

The company's Economic Capital Ratio, given in the ranking table, is -626%, being 669% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	34
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	467
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	840
Other Liabilities	0
Other Net Income	76
Other Revenues	0
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	56

Output Variable	Value in 1000 USD
Assets	34
Liabilities	467
Expenses	897
Revenues	0
Stockholders Equity	-433
Net Income	-821
Comprehensive Net Income	-821
Economic Capital Ratio	-626%



PHARMACEUTICAL 2023

Calithera Biosciences Inc.
Rank 321 of 446





RealRate

PHARMACEUTICAL 2023

Calithera Biosciences Inc. Rank 321 of 446



The relative strengths and weaknesses of Calithera Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Calithera Biosciences Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Calithera Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is -25%, being 68% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	26,624
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,390
Liabilities, Non-Current	136
Other Assets	1,618
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	758
Other Net Income	2,424
Other Revenues	0
Property and Equipment	434
Research and Development	28,533
Selling, General and Administrative Expense	13,541


Output Variable	Value in 1000 USD
Assets	28,676
Liabilities	8,284
Expenses	42,074
Revenues	0
Stockholders Equity	20,392
Net Income	-39,650
Comprehensive Net Income	-39,650
Economic Capital Ratio	-25%



RealRate

PHARMACEUTICAL 2023

Evoked Pharma Inc
Rank 309 of 446





RealRate

PHARMACEUTICAL 2023

Evoke Pharma Inc
Rank 309 of 446




The relative strengths and weaknesses of Evoke Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evoke Pharma Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 43% points. The greatest weakness of Evoke Pharma Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is -12%, being 55% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	11,722
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,655
Liabilities, Non-Current	6,112
Other Assets	129
Other Compr. Net Income	0
Other Expenses	370
Other Liabilities	0
Other Net Income	-438
Other Revenues	2,509
Property and Equipment	0
Research and Development	301
Selling, General and Administrative Expense	9,624

Output Variable	Value in 1000 USD
Assets	11,851
Liabilities	7,767
Expenses	10,295
Revenues	2,509
Stockholders Equity	4,085
Net Income	-8,224
Comprehensive Net Income	-8,224
Economic Capital Ratio	-12%



The relative strengths and weaknesses of PMV Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PMV Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of PMV Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 237%, being 194% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	247,006
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,832
Liabilities, Non-Current	13,448
Other Assets	12,347
Other Compr. Net Income	-367
Other Expenses	-9.0
Other Liabilities	0
Other Net Income	3,714
Other Revenues	0
Property and Equipment	10,955
Research and Development	51,988
Selling, General and Administrative Expense	25,052

Output Variable	Value in 1000 USD
Assets	270,308
Liabilities	24,280
Expenses	77,031
Revenues	0
Stockholders Equity	246,028
Net Income	-73,317
Comprehensive Net Income	-73,500
Economic Capital Ratio	237%



PHARMACEUTICAL 2023

Savara Inc
Rank 130 of 446





PHARMACEUTICAL 2023

Savara Inc
Rank 130 of 446




The relative strengths and weaknesses of Savara Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Savara Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 90% points. The greatest weakness of Savara Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 128% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	128,954
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,867
Liabilities, Non-Current	26,132
Other Assets	10,772
Other Compr. Net Income	-610
Other Expenses	31
Other Liabilities	0
Other Net Income	689
Other Revenues	0
Property and Equipment	51
Research and Development	27,879
Selling, General and Administrative Expense	10,929

Output Variable	Value in 1000 USD
Assets	139,777
Liabilities	31,999
Expenses	38,839
Revenues	0
Stockholders Equity	107,778
Net Income	-38,150
Comprehensive Net Income	-38,455
Economic Capital Ratio	171%





RealRate

PHARMACEUTICAL 2023

Amneal Pharmaceuticals Inc.
Rank 297 of 446



The relative strengths and weaknesses of Amneal Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amneal Pharmaceuticals Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Amneal Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 164% points.

The company's Economic Capital Ratio, given in the ranking table, is 5.0%, being 38% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	1,411,818
Cost of Goods Sold	1,416,485
Intangible Assets	1,694,946
Liabilities, Current	752,800
Liabilities, Non-Current	2,837,613
Other Assets	222,762
Other Compr. Net Income	159,679
Other Expenses	35,320
Other Liabilities	0
Other Net Income	-419,900
Other Revenues	2,212,304
Property and Equipment	469,815
Research and Development	195,688
Selling, General and Administrative Expense	399,700

Output Variable	Value in 1000 USD
Assets	3,799,341
Liabilities	3,590,413
Expenses	2,047,193
Revenues	2,212,304
Stockholders Equity	208,928
Net Income	-254,789
Comprehensive Net Income	-174,950
Economic Capital Ratio	5.0%



PHARMACEUTICAL 2023

GeoVax Labs Inc.
Rank 124 of 446





PHARMACEUTICAL 2023

GeoVax Labs Inc.
Rank 124 of 446



The relative strengths and weaknesses of GeoVax Labs Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GeoVax Labs Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 87% points. The greatest weakness of GeoVax Labs Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 176%, being 133% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	28,939
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,748
Liabilities, Non-Current	0
Other Assets	2,174
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	7.4
Other Revenues	82
Property and Equipment	235
Research and Development	9,123
Selling, General and Administrative Expense	4,987

Output Variable	Value in 1000 USD
Assets	31,348
Liabilities	4,748
Expenses	14,110
Revenues	82
Stockholders Equity	26,600
Net Income	-14,021
Comprehensive Net Income	-14,021
Economic Capital Ratio	176%



PHARMACEUTICAL 2023

HST Global Inc.
Rank 431 of 446





PHARMACEUTICAL 2023

HST Global Inc.
Rank 431 of 446


The relative strengths and weaknesses of HST Global Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HST Global Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 393% points. The greatest weakness of HST Global Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 229% points.

The company's Economic Capital Ratio, given in the ranking table, is -409%, being 452% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	0.19
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	446
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	120
Other Liabilities	0
Other Net Income	-4.0
Other Revenues	0
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	21

Output Variable	Value in 1000 USD
Assets	0.19
Liabilities	446
Expenses	141
Revenues	0
Stockholders Equity	-446
Net Income	-145
Comprehensive Net Income	-145
Economic Capital Ratio	-409%





PHARMACEUTICAL 2023

Nascent Biotech Inc.
Rank 423 of 446



The relative strengths and weaknesses of Nascent Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nascent Biotech Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 179% points. The greatest weakness of Nascent Biotech Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 379% points.

The company's Economic Capital Ratio, given in the ranking table, is -368%, being 412% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	105
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	777
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,457
Other Liabilities	0
Other Net Income	-13
Other Revenues	1,000
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	105
Liabilities	777
Expenses	1,457
Revenues	1,000
Stockholders Equity	-671
Net Income	-470
Comprehensive Net Income	-470
Economic Capital Ratio	-368%



PHARMACEUTICAL 2023

Eton Pharmaceuticals Inc.
Rank 235 of 446





RealRate

PHARMACEUTICAL 2023

Eton Pharmaceuticals Inc. Rank 235 of 446




The relative strengths and weaknesses of Eton Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eton Pharmaceuticals Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 85% points. The greatest weakness of Eton Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 73%, being 30% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	20,004
Cost of Goods Sold	6,933
Intangible Assets	4,754
Liabilities, Current	6,461
Liabilities, Non-Current	107
Other Assets	200
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	5,384
Other Net Income	-761
Other Revenues	21,251
Property and Equipment	72
Research and Development	3,996
Selling, General and Administrative Expense	18,582

Output Variable	Value in 1000 USD
Assets	25,030
Liabilities	11,952
Expenses	29,511
Revenues	21,251
Stockholders Equity	13,078
Net Income	-9,021
Comprehensive Net Income	-9,021
Economic Capital Ratio	73%





PHARMACEUTICAL 2023

IMMUNIC INC.
Rank 199 of 446


The relative strengths and weaknesses of IMMUNIC INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMMUNIC INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 86% points. The greatest weakness of IMMUNIC INC. is the variable Net Income, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is 108%, being 65% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	125,864
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,077
Liabilities, Non-Current	992
Other Assets	1,595
Other Compr. Net Income	3,287
Other Expenses	32,970
Other Liabilities	0
Other Net Income	-919
Other Revenues	0
Property and Equipment	294
Research and Development	71,255
Selling, General and Administrative Expense	15,263

Output Variable	Value in 1000 USD
Assets	127,753
Liabilities	14,069
Expenses	119,488
Revenues	0
Stockholders Equity	113,684
Net Income	-120,407
Comprehensive Net Income	-118,764
Economic Capital Ratio	108%





RealRate

PHARMACEUTICAL 2023

Mirati Therapeutics Inc.
Rank 166 of 446



The relative strengths and weaknesses of Mirati Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirati Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Mirati Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 137%, being 94% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	1,108,961
Cost of Goods Sold	0
Intangible Assets	14,914
Liabilities, Current	159,448
Liabilities, Non-Current	46,683
Other Assets	61,232
Other Compr. Net Income	-12,787
Other Expenses	1,108
Other Liabilities	0
Other Net Income	19,230
Other Revenues	12,436
Property and Equipment	17,540
Research and Development	531,627
Selling, General and Administrative Expense	239,798

Output Variable	Value in 1000 USD
Assets	1,202,647
Liabilities	206,131
Expenses	772,533
Revenues	12,436
Stockholders Equity	996,516
Net Income	-740,867
Comprehensive Net Income	-747,260
Economic Capital Ratio	137%



PHARMACEUTICAL 2023

SEELOS THERAPEUTICS INC.
Rank 414 of 446





PHARMACEUTICAL 2023

SEELOS THERAPEUTICS INC.
Rank 414 of 446




The relative strengths and weaknesses of SEELOS THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SEELOS THERAPEUTICS INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 15% points. The greatest weakness of SEELOS THERAPEUTICS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 178% points.

The company's Economic Capital Ratio, given in the ranking table, is -327%, being 370% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	22,674
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	25,158
Liabilities, Non-Current	15
Other Assets	72
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	8,184
Other Net Income	-2,618
Other Revenues	0
Property and Equipment	0
Research and Development	58,620
Selling, General and Administrative Expense	12,296

Output Variable	Value in 1000 USD
Assets	22,746
Liabilities	33,357
Expenses	70,916
Revenues	0
Stockholders Equity	-10,611
Net Income	-73,534
Comprehensive Net Income	-73,534
Economic Capital Ratio	-327%




The relative strengths and weaknesses of Theseus Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theseus Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 610% points. The greatest weakness of Theseus Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 258%, being 215% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,130
Liabilities, Non-Current	3,236
Other Assets	222,031
Other Compr. Net Income	-386
Other Expenses	0
Other Liabilities	466
Other Net Income	3,478
Other Revenues	0
Property and Equipment	416
Research and Development	35,698
Selling, General and Administrative Expense	18,388

Output Variable	Value in 1000 USD
Assets	222,447
Liabilities	14,832
Expenses	54,086
Revenues	0
Stockholders Equity	207,615
Net Income	-50,608
Comprehensive Net Income	-50,801
Economic Capital Ratio	258%





RealRate

PHARMACEUTICAL 2023

eFFECTOR Therapeutics Inc. Rank 345 of 446



The relative strengths and weaknesses of eFFECTOR Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of eFFECTOR Therapeutics Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 34% points. The greatest weakness of eFFECTOR Therapeutics Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is -59%, being 102% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	28,014
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	25,075
Liabilities, Non-Current	60
Other Assets	822
Other Compr. Net Income	-18
Other Expenses	0
Other Liabilities	46
Other Net Income	9,738
Other Revenues	3,553
Property and Equipment	241
Research and Development	23,313
Selling, General and Administrative Expense	12,643

Output Variable	Value in 1000 USD
Assets	29,077
Liabilities	25,181
Expenses	35,956
Revenues	3,553
Stockholders Equity	3,896
Net Income	-22,665
Comprehensive Net Income	-22,674
Economic Capital Ratio	-59%



PHARMACEUTICAL 2023

GYRE THERAPEUTICS INC.
Rank 255 of 446





RealRate

PHARMACEUTICAL 2023

GYRE THERAPEUTICS INC. Rank 255 of 446




The relative strengths and weaknesses of GYRE THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GYRE THERAPEUTICS INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 99% points. The greatest weakness of GYRE THERAPEUTICS INC. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is 48%, being 5.2% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	28,206
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,824
Liabilities, Non-Current	0
Other Assets	234
Other Compr. Net Income	0
Other Expenses	-20,650
Other Liabilities	0
Other Net Income	717
Other Revenues	0
Property and Equipment	4.0
Research and Development	13,037
Selling, General and Administrative Expense	17,366

Output Variable	Value in 1000 USD
Assets	28,444
Liabilities	16,824
Expenses	9,753
Revenues	0
Stockholders Equity	11,620
Net Income	-9,036
Comprehensive Net Income	-9,036
Economic Capital Ratio	48%





PHARMACEUTICAL 2023

ARVINAS INC.
Rank 238 of 446




The relative strengths and weaknesses of ARVINAS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARVINAS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of ARVINAS INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 77% points.

The company's Economic Capital Ratio, given in the ranking table, is 69%, being 26% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,240,200
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	295,100
Liabilities, Non-Current	408,800
Other Assets	15,200
Other Compr. Net Income	-14,500
Other Expenses	20,900
Other Liabilities	0
Other Net Income	1,600
Other Revenues	131,400
Property and Equipment	13,400
Research and Development	315,000
Selling, General and Administrative Expense	79,600

Output Variable	Value in 1000 USD
Assets	1,268,800
Liabilities	703,900
Expenses	415,500
Revenues	131,400
Stockholders Equity	564,900
Net Income	-282,500
Comprehensive Net Income	-289,750
Economic Capital Ratio	69%




The relative strengths and weaknesses of Design Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Design Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Design Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 281%, being 238% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	335,119
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,776
Liabilities, Non-Current	3,051
Other Assets	4,071
Other Compr. Net Income	-3,112
Other Expenses	0
Other Liabilities	0
Other Net Income	4,285
Other Revenues	0
Property and Equipment	1,947
Research and Development	48,613
Selling, General and Administrative Expense	18,980

Output Variable	Value in 1000 USD
Assets	341,137
Liabilities	13,827
Expenses	67,593
Revenues	0
Stockholders Equity	327,310
Net Income	-63,308
Comprehensive Net Income	-64,864
Economic Capital Ratio	281%





PHARMACEUTICAL 2023

RVL Pharmaceuticals plc
Rank 265 of 446

R V L

The relative strengths and weaknesses of RVL Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RVL Pharmaceuticals plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 124% points. The greatest weakness of RVL Pharmaceuticals plc is the variable Other Liabilities, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is 34%, being 8.8% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	56,975
Cost of Goods Sold	9,456
Intangible Assets	69,747
Liabilities, Current	19,723
Liabilities, Non-Current	94
Other Assets	1,788
Other Compr. Net Income	-1,700
Other Expenses	13,290
Other Liabilities	57,600
Other Net Income	7,278
Other Revenues	49,721
Property and Equipment	0
Research and Development	3,966
Selling, General and Administrative Expense	81,979

Output Variable	Value in 1000 USD
Assets	128,510
Liabilities	77,417
Expenses	108,691
Revenues	49,721
Stockholders Equity	51,093
Net Income	-51,692
Comprehensive Net Income	-52,542
Economic Capital Ratio	34%



PHARMACEUTICAL 2023

REVELATION BIOSCIENCES INC. Rank 387 of 446





RealRate

PHARMACEUTICAL 2023

REVELATION BIOSCIENCES INC. Rank 387 of 446

The relative strengths and weaknesses of REVELATION BIOSCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REVELATION BIOSCIENCES INC. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 13% points. The greatest weakness of REVELATION BIOSCIENCES INC. is the variable Net Income, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is -181%, being 224% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	5,413
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,451
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	35
Other Revenues	0
Property and Equipment	90
Research and Development	5,377
Selling, General and Administrative Expense	5,487

Output Variable	Value in 1000 USD
Assets	5,503
Liabilities	4,451
Expenses	10,865
Revenues	0
Stockholders Equity	1,052
Net Income	-10,830
Comprehensive Net Income	-10,830
Economic Capital Ratio	-181%



PHARMACEUTICAL 2023

Sarepta Therapeutics Inc.
Rank 302 of 446





RealRate

PHARMACEUTICAL 2023

Sarepta Therapeutics Inc.
Rank 302 of 446



The relative strengths and weaknesses of Sarepta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sarepta Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 41% points. The greatest weakness of Sarepta Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is -1.4%, being 45% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	2,557,861
Cost of Goods Sold	0
Intangible Assets	7,578
Liabilities, Current	619,604
Liabilities, Non-Current	542,620
Other Assets	382,890
Other Compr. Net Income	-1,644
Other Expenses	154,228
Other Liabilities	1,581,192
Other Net Income	-153,762
Other Revenues	933,013
Property and Equipment	180,037
Research and Development	877,090
Selling, General and Administrative Expense	451,421

Output Variable	Value in 1000 USD
Assets	3,128,366
Liabilities	2,743,416
Expenses	1,482,739
Revenues	933,013
Stockholders Equity	384,950
Net Income	-703,488
Comprehensive Net Income	-704,310
Economic Capital Ratio	-1.4%



PHARMACEUTICAL 2023

Inozyme Pharma Inc.
Rank 132 of 446





PHARMACEUTICAL 2023

Inozyme Pharma Inc.
Rank 132 of 446


The relative strengths and weaknesses of Inozyme Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Inozyme Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Inozyme Pharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 127% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	131,393
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,715
Liabilities, Non-Current	1,947
Other Assets	5,784
Other Compr. Net Income	-223
Other Expenses	0
Other Liabilities	4,139
Other Net Income	1,614
Other Revenues	0
Property and Equipment	2,018
Research and Development	47,849
Selling, General and Administrative Expense	20,826

Output Variable	Value in 1000 USD
Assets	139,195
Liabilities	20,801
Expenses	68,675
Revenues	0
Stockholders Equity	118,394
Net Income	-67,061
Comprehensive Net Income	-67,172
Economic Capital Ratio	171%





RealRate

PHARMACEUTICAL 2023

Landos Biopharma Inc. Rank 202 of 446




The relative strengths and weaknesses of Landos Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Landos Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 92% points. The greatest weakness of Landos Biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is 107%, being 64% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	45,253
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,122
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	1,453
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property and Equipment	0
Research and Development	25,680
Selling, General and Administrative Expense	14,881

Output Variable	Value in 1000 USD
Assets	45,253
Liabilities	6,122
Expenses	40,561
Revenues	0
Stockholders Equity	39,131
Net Income	-40,561
Comprehensive Net Income	-39,834
Economic Capital Ratio	107%




The relative strengths and weaknesses of AbCellera Biologics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AbCellera Biologics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 83% points. The greatest weakness of AbCellera Biologics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 247%, being 203% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,025,491
Cost of Goods Sold	0
Intangible Assets	179,308
Liabilities, Current	118,320
Liabilities, Non-Current	189,310
Other Assets	118,853
Other Compr. Net Income	-1,671
Other Expenses	186,129
Other Liabilities	0
Other Net Income	22,588
Other Revenues	485,424
Property and Equipment	217,255
Research and Development	107,879
Selling, General and Administrative Expense	55,485

Output Variable	Value in 1000 USD
Assets	1,540,907
Liabilities	307,630
Expenses	349,493
Revenues	485,424
Stockholders Equity	1,233,277
Net Income	158,519
Comprehensive Net Income	157,684
Economic Capital Ratio	247%





RealRate

PHARMACEUTICAL 2023

Dare Bioscience Inc.
Rank 329 of 446



The relative strengths and weaknesses of Dare Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dare Bioscience Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 21% points. The greatest weakness of Dare Bioscience Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is -31%, being 74% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	43,039
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,624
Liabilities, Non-Current	1,090
Other Assets	723
Other Compr. Net Income	-196
Other Expenses	100
Other Liabilities	0
Other Net Income	438
Other Revenues	10,000
Property and Equipment	65
Research and Development	30,042
Selling, General and Administrative Expense	11,243

Output Variable	Value in 1000 USD
Assets	43,826
Liabilities	32,714
Expenses	41,385
Revenues	10,000
Stockholders Equity	11,112
Net Income	-30,948
Comprehensive Net Income	-31,046
Economic Capital Ratio	-31%



PHARMACEUTICAL 2023

Sio Gene Therapies Inc.
Rank 237 of 446





PHARMACEUTICAL 2023

Sio Gene Therapies Inc.
Rank 237 of 446



The relative strengths and weaknesses of Sio Gene Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sio Gene Therapies Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Sio Gene Therapies Inc. is the variable Net Income, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 71%, being 28% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	71,736
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,002
Liabilities, Non-Current	1,730
Other Assets	2,444
Other Compr. Net Income	2.0
Other Expenses	286
Other Liabilities	0
Other Net Income	-39
Other Revenues	0
Property and Equipment	900
Research and Development	53,399
Selling, General and Administrative Expense	18,163

Output Variable	Value in 1000 USD
Assets	75,080
Liabilities	14,732
Expenses	71,848
Revenues	0
Stockholders Equity	60,348
Net Income	-71,887
Comprehensive Net Income	-71,886
Economic Capital Ratio	71%



PHARMACEUTICAL 2023

REVIVA PHARMACEUTICALS HOLDINGS INC. Rank 320 of 446





PHARMACEUTICAL 2023

REVIVA PHARMACEUTICALS HOLDINGS INC. Rank 320 of 446


The relative strengths and weaknesses of REVIVA PHARMACEUTICALS HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REVIVA PHARMACEUTICALS HOLDINGS INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 680% points. The greatest weakness of REVIVA PHARMACEUTICALS HOLDINGS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 145% points.

The company's Economic Capital Ratio, given in the ranking table, is -25%, being 68% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,040
Liabilities, Non-Current	0
Other Assets	18,924
Other Compr. Net Income	0
Other Expenses	21
Other Liabilities	567
Other Net Income	-12
Other Revenues	0
Property and Equipment	0
Research and Development	18,948
Selling, General and Administrative Expense	5,359

Output Variable	Value in 1000 USD
Assets	18,924
Liabilities	6,607
Expenses	24,327
Revenues	0
Stockholders Equity	12,316
Net Income	-24,339
Comprehensive Net Income	-24,339
Economic Capital Ratio	-25%




The relative strengths and weaknesses of Ocuphire Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ocuphire Pharma Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 168% points. The greatest weakness of Ocuphire Pharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 9.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 377%, being 333% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	48,986
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,753
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	324
Other Liabilities	0
Other Net Income	-14
Other Revenues	39,850
Property and Equipment	6.0
Research and Development	14,355
Selling, General and Administrative Expense	7,269

Output Variable	Value in 1000 USD
Assets	48,992
Liabilities	2,753
Expenses	21,948
Revenues	39,850
Stockholders Equity	46,239
Net Income	17,888
Comprehensive Net Income	17,888
Economic Capital Ratio	377%





PHARMACEUTICAL 2023

AVADEL PHARMACEUTICALS PLC Rank 368 of 446



The relative strengths and weaknesses of AVADEL PHARMACEUTICALS PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AVADEL PHARMACEUTICALS PLC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 27% points. The greatest weakness of AVADEL PHARMACEUTICALS PLC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 88% points.

The company's Economic Capital Ratio, given in the ranking table, is -122%, being 165% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	100,843
Cost of Goods Sold	0
Intangible Assets	16,836
Liabilities, Current	55,793
Liabilities, Non-Current	98,137
Other Assets	14,267
Other Compr. Net Income	-2,401
Other Expenses	41,712
Other Liabilities	0
Other Net Income	-536
Other Revenues	0
Property and Equipment	839
Research and Development	20,700
Selling, General and Administrative Expense	74,516

Output Variable	Value in 1000 USD
Assets	132,785
Liabilities	153,930
Expenses	136,928
Revenues	0
Stockholders Equity	-21,145
Net Income	-137,464
Comprehensive Net Income	-138,664
Economic Capital Ratio	-122%



PHARMACEUTICAL 2023

AXIM BIOTECHNOLOGIES INC.
Rank 384 of 446





PHARMACEUTICAL 2023

AXIM BIOTECHNOLOGIES INC. Rank 384 of 446


The relative strengths and weaknesses of AXIM BIOTECHNOLOGIES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AXIM BIOTECHNOLOGIES INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 157% points. The greatest weakness of AXIM BIOTECHNOLOGIES INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 167% points.

The company's Economic Capital Ratio, given in the ranking table, is -172%, being 215% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	104
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,392
Liabilities, Non-Current	5,645
Other Assets	4,014
Other Compr. Net Income	0
Other Expenses	426
Other Liabilities	0
Other Net Income	1,590
Other Revenues	8.9
Property and Equipment	94
Research and Development	154
Selling, General and Administrative Expense	4,082

Output Variable	Value in 1000 USD
Assets	4,212
Liabilities	9,037
Expenses	4,662
Revenues	8.9
Stockholders Equity	-4,825
Net Income	-3,063
Comprehensive Net Income	-3,063
Economic Capital Ratio	-172%




The relative strengths and weaknesses of Eliem Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eliem Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 100% points. The greatest weakness of Eliem Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 249%, being 206% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	134,393
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,097
Liabilities, Non-Current	180
Other Assets	599
Other Compr. Net Income	-235
Other Expenses	0
Other Liabilities	0
Other Net Income	-109
Other Revenues	0
Property and Equipment	0
Research and Development	26,214
Selling, General and Administrative Expense	18,921

Output Variable	Value in 1000 USD
Assets	134,992
Liabilities	6,277
Expenses	45,135
Revenues	0
Stockholders Equity	128,715
Net Income	-45,244
Comprehensive Net Income	-45,362
Economic Capital Ratio	249%





PHARMACEUTICAL 2023

PERRIGO Co plc
Rank 219 of 446




The relative strengths and weaknesses of PERRIGO Co plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PERRIGO Co plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 67% points. The greatest weakness of PERRIGO Co plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 135% points.

The company's Economic Capital Ratio, given in the ranking table, is 95%, being 52% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,719,900
Cost of Goods Sold	2,996,200
Intangible Assets	3,230,200
Liabilities, Current	1,113,600
Liabilities, Non-Current	5,061,600
Other Assets	4,140,900
Other Compr. Net Income	-62,500
Other Expenses	732,900
Other Liabilities	0
Other Net Income	-227,700
Other Revenues	4,451,600
Property and Equipment	926,300
Research and Development	123,100
Selling, General and Administrative Expense	512,300

Output Variable	Value in 1000 USD
Assets	11,017,300
Liabilities	6,175,200
Expenses	4,364,500
Revenues	4,451,600
Stockholders Equity	4,842,100
Net Income	-140,600
Comprehensive Net Income	-171,850
Economic Capital Ratio	95%




The relative strengths and weaknesses of IO Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IO Biotech Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 98% points. The greatest weakness of IO Biotech Inc. is the variable Net Income, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 198%, being 155% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	148,219
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,676
Liabilities, Non-Current	2,275
Other Assets	2,845
Other Compr. Net Income	-8,652
Other Expenses	1,273
Other Liabilities	0
Other Net Income	1,239
Other Revenues	0
Property and Equipment	741
Research and Development	46,986
Selling, General and Administrative Expense	24,438

Output Variable	Value in 1000 USD
Assets	151,805
Liabilities	12,951
Expenses	72,697
Revenues	0
Stockholders Equity	138,854
Net Income	-71,458
Comprehensive Net Income	-75,784
Economic Capital Ratio	198%





PHARMACEUTICAL 2023

MACROGENICS INC Rank 247 of 446




The relative strengths and weaknesses of MACROGENICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MACROGENICS INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 47% points. The greatest weakness of MACROGENICS INC is the variable Research and Development, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 59%, being 16% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	222,180
Cost of Goods Sold	3,351
Intangible Assets	0
Liabilities, Current	48,611
Liabilities, Non-Current	30,364
Other Assets	28,713
Other Compr. Net Income	56
Other Expenses	4,033
Other Liabilities	59,480
Other Net Income	1,660
Other Revenues	151,941
Property and Equipment	29,575
Research and Development	207,026
Selling, General and Administrative Expense	58,949

Output Variable	Value in 1000 USD
Assets	280,468
Liabilities	138,455
Expenses	273,359
Revenues	151,941
Stockholders Equity	142,013
Net Income	-119,758
Comprehensive Net Income	-119,730
Economic Capital Ratio	59%





PHARMACEUTICAL 2023

GELESIS HOLDINGS INC. Rank 351 of 446


The relative strengths and weaknesses of GELESIS HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GELESIS HOLDINGS INC. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 129% points. The greatest weakness of GELESIS HOLDINGS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is -71%, being 114% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	23,496
Cost of Goods Sold	27,558
Intangible Assets	13,413
Liabilities, Current	78,346
Liabilities, Non-Current	1,865
Other Assets	7,080
Other Compr. Net Income	-115
Other Expenses	-3,346
Other Liabilities	35,579
Other Net Income	60,413
Other Revenues	25,767
Property and Equipment	59,335
Research and Development	18,613
Selling, General and Administrative Expense	99,135

Output Variable	Value in 1000 USD
Assets	103,324
Liabilities	115,790
Expenses	141,960
Revenues	25,767
Stockholders Equity	-12,466
Net Income	-55,780
Comprehensive Net Income	-55,838
Economic Capital Ratio	-71%





PHARMACEUTICAL 2023

LANNETT CO INC
Rank 365 of 446




The relative strengths and weaknesses of LANNETT CO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LANNETT CO INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 45% points. The greatest weakness of LANNETT CO INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 192% points.

The company's Economic Capital Ratio, given in the ranking table, is -109%, being 152% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	290,116
Cost of Goods Sold	0
Intangible Assets	32,179
Liabilities, Current	104,940
Liabilities, Non-Current	630,558
Other Assets	28,962
Other Compr. Net Income	137
Other Expenses	411,163
Other Liabilities	0
Other Net Income	-57,651
Other Revenues	340,579
Property and Equipment	133,178
Research and Development	22,362
Selling, General and Administrative Expense	81,023

Output Variable	Value in 1000 USD
Assets	484,435
Liabilities	735,498
Expenses	514,548
Revenues	340,579
Stockholders Equity	-251,063
Net Income	-231,620
Comprehensive Net Income	-231,552
Economic Capital Ratio	-109%




The relative strengths and weaknesses of Immuneering Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immuneering Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Immuneering Corp is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 205%, being 162% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	108,747
Cost of Goods Sold	158
Intangible Assets	7,099
Liabilities, Current	8,054
Liabilities, Non-Current	4,463
Other Assets	5,151
Other Compr. Net Income	19
Other Expenses	30
Other Liabilities	0
Other Net Income	1,231
Other Revenues	317
Property and Equipment	1,370
Research and Development	36,267
Selling, General and Administrative Expense	15,607

Output Variable	Value in 1000 USD
Assets	122,367
Liabilities	12,517
Expenses	52,062
Revenues	317
Stockholders Equity	109,850
Net Income	-50,514
Comprehensive Net Income	-50,504
Economic Capital Ratio	205%




The relative strengths and weaknesses of POINT Biopharma Global Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of POINT Biopharma Global Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 99% points. The greatest weakness of POINT Biopharma Global Inc. is the variable Other Assets, reducing the Economic Capital Ratio by 3.0% points.

The company's Economic Capital Ratio, given in the ranking table, is 279%, being 236% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	530,823
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	79,738
Liabilities, Non-Current	10,178
Other Assets	16,119
Other Compr. Net Income	-457
Other Expenses	31,293
Other Liabilities	1,452
Other Net Income	4,064
Other Revenues	226,580
Property and Equipment	31,381
Research and Development	82,050
Selling, General and Administrative Expense	19,007

Output Variable	Value in 1000 USD
Assets	578,323
Liabilities	91,369
Expenses	132,350
Revenues	226,580
Stockholders Equity	486,954
Net Income	98,293
Comprehensive Net Income	98,065
Economic Capital Ratio	279%



The relative strengths and weaknesses of Adicet Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Adicet Bio Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 48% points. The greatest weakness of Adicet Bio Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 1.8% points.

The company's Economic Capital Ratio, given in the ranking table, is 235%, being 192% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	261,038
Cost of Goods Sold	0
Intangible Assets	19,462
Liabilities, Current	19,707
Liabilities, Non-Current	18,645
Other Assets	21,480
Other Compr. Net Income	0
Other Expenses	80
Other Liabilities	0
Other Net Income	-919
Other Revenues	28,750
Property and Equipment	28,710
Research and Development	71,246
Selling, General and Administrative Expense	26,295

Output Variable	Value in 1000 USD
Assets	330,690
Liabilities	38,352
Expenses	97,621
Revenues	28,750
Stockholders Equity	292,338
Net Income	-69,790
Comprehensive Net Income	-69,790
Economic Capital Ratio	235%



PHARMACEUTICAL 2023

Erasca Inc.
Rank 153 of 446





PHARMACEUTICAL 2023

Erasca Inc.
Rank 153 of 446


The relative strengths and weaknesses of Erasca Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Erasca Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Erasca Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 151%, being 107% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	444,496
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	48,690
Liabilities, Non-Current	54,366
Other Assets	45,598
Other Compr. Net Income	-879
Other Expenses	102,000
Other Liabilities	0
Other Net Income	4,645
Other Revenues	0
Property and Equipment	24,815
Research and Development	112,457
Selling, General and Administrative Expense	32,993

Output Variable	Value in 1000 USD
Assets	514,909
Liabilities	103,056
Expenses	247,450
Revenues	0
Stockholders Equity	411,853
Net Income	-242,805
Comprehensive Net Income	-243,244
Economic Capital Ratio	151%



The relative strengths and weaknesses of Syndax Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syndax Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 96% points. The greatest weakness of Syndax Pharmaceuticals Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 248%, being 205% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	489,786
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	29,065
Liabilities, Non-Current	722
Other Assets	7,430
Other Compr. Net Income	-851
Other Expenses	0
Other Liabilities	0
Other Net Income	2,419
Other Revenues	0
Property and Equipment	20
Research and Development	118,499
Selling, General and Administrative Expense	33,258

Output Variable	Value in 1000 USD
Assets	497,236
Liabilities	29,787
Expenses	151,757
Revenues	0
Stockholders Equity	467,449
Net Income	-149,338
Comprehensive Net Income	-149,764
Economic Capital Ratio	248%



PHARMACEUTICAL 2023

CytomX Therapeutics Inc.
Rank 354 of 446





PHARMACEUTICAL 2023

CytomX Therapeutics Inc.
Rank 354 of 446




The relative strengths and weaknesses of CytomX Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytomX Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 28% points. The greatest weakness of CytomX Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is -81%, being 124% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	237,102
Cost of Goods Sold	0
Intangible Assets	949
Liabilities, Current	152,608
Liabilities, Non-Current	194,034
Other Assets	17,768
Other Compr. Net Income	252
Other Expenses	0
Other Liabilities	0
Other Net Income	2,018
Other Revenues	53,163
Property and Equipment	5,072
Research and Development	111,649
Selling, General and Administrative Expense	42,849

Output Variable	Value in 1000 USD
Assets	260,891
Liabilities	346,642
Expenses	154,498
Revenues	53,163
Stockholders Equity	-85,751
Net Income	-99,317
Comprehensive Net Income	-99,191
Economic Capital Ratio	-81%



The relative strengths and weaknesses of Terns Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Terns Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Terns Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 280%, being 237% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	285,185
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,468
Liabilities, Non-Current	544
Other Assets	1,084
Other Compr. Net Income	-484
Other Expenses	358
Other Liabilities	1,071
Other Net Income	2,042
Other Revenues	0
Property and Equipment	757
Research and Development	39,617
Selling, General and Administrative Expense	22,412

Output Variable	Value in 1000 USD
Assets	287,026
Liabilities	10,083
Expenses	62,387
Revenues	0
Stockholders Equity	276,943
Net Income	-60,345
Comprehensive Net Income	-60,587
Economic Capital Ratio	280%



PHARMACEUTICAL 2023

OptiNose Inc.
Rank 357 of 446





RealRate

PHARMACEUTICAL 2023

OptiNose Inc.
Rank 357 of 446




The relative strengths and weaknesses of OptiNose Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OptiNose Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 37% points. The greatest weakness of OptiNose Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 127% points.

The company's Economic Capital Ratio, given in the ranking table, is -100%, being 143% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	140,484
Cost of Goods Sold	9,263
Intangible Assets	0
Liabilities, Current	178,730
Liabilities, Non-Current	626
Other Assets	2,943
Other Compr. Net Income	-3.0
Other Expenses	16,843
Other Liabilities	21,490
Other Net Income	-698
Other Revenues	74,880
Property and Equipment	795
Research and Development	15,260
Selling, General and Administrative Expense	107,649

Output Variable	Value in 1000 USD
Assets	144,222
Liabilities	200,846
Expenses	149,015
Revenues	74,880
Stockholders Equity	-56,624
Net Income	-74,833
Comprehensive Net Income	-74,834
Economic Capital Ratio	-100%



The relative strengths and weaknesses of Rezolute Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rezolute Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Rezolute Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 278%, being 235% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	152,104
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,462
Liabilities, Non-Current	80
Other Assets	300
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	407
Other Net Income	783
Other Revenues	0
Property and Equipment	16
Research and Development	32,486
Selling, General and Administrative Expense	9,357

Output Variable	Value in 1000 USD
Assets	152,420
Liabilities	2,949
Expenses	41,843
Revenues	0
Stockholders Equity	149,471
Net Income	-41,060
Comprehensive Net Income	-41,060
Economic Capital Ratio	278%



PHARMACEUTICAL 2023

DURECT CORP
Rank 279 of 446





PHARMACEUTICAL 2023

DURECT CORP
Rank 279 of 446




The relative strengths and weaknesses of DURECT CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DURECT CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 26% points. The greatest weakness of DURECT CORP is the variable Liabilities, Current, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 20%, being 23% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	51,394
Cost of Goods Sold	1,588
Intangible Assets	6,169
Liabilities, Current	34,004
Liabilities, Non-Current	0
Other Assets	2,349
Other Compr. Net Income	-3.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-251
Other Revenues	19,283
Property and Equipment	188
Research and Development	36,862
Selling, General and Administrative Expense	15,915

Output Variable	Value in 1000 USD
Assets	60,100
Liabilities	34,004
Expenses	54,365
Revenues	19,283
Stockholders Equity	26,096
Net Income	-35,333
Comprehensive Net Income	-35,334
Economic Capital Ratio	20%





PHARMACEUTICAL 2023

Lifevantage Corp
Rank 208 of 446




The relative strengths and weaknesses of Lifevantage Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lifevantage Corp compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 316% points. The greatest weakness of Lifevantage Corp is the variable Other Expenses, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is 103%, being 60% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	46,957
Cost of Goods Sold	38,097
Intangible Assets	587
Liabilities, Current	25,728
Liabilities, Non-Current	13,462
Other Assets	13,662
Other Compr. Net Income	-1,227
Other Expenses	98,834
Other Liabilities	0
Other Net Income	-2,884
Other Revenues	206,360
Property and Equipment	9,500
Research and Development	0
Selling, General and Administrative Expense	63,425

Output Variable	Value in 1000 USD
Assets	70,706
Liabilities	39,190
Expenses	200,356
Revenues	206,360
Stockholders Equity	31,516
Net Income	3,120
Comprehensive Net Income	2,506
Economic Capital Ratio	103%





RealRate

PHARMACEUTICAL 2023

Arcturus Therapeutics Holdings Inc. Rank 154 of 446




The relative strengths and weaknesses of Arcturus Therapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcturus Therapeutics Holdings Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Arcturus Therapeutics Holdings Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 150%, being 107% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	403,333
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	126,984
Liabilities, Non-Current	33,020
Other Assets	34,639
Other Compr. Net Income	0
Other Expenses	1,295
Other Liabilities	20,071
Other Net Income	-1,533
Other Revenues	205,999
Property and Equipment	12,415
Research and Development	147,751
Selling, General and Administrative Expense	46,071

Output Variable	Value in 1000 USD
Assets	450,387
Liabilities	180,075
Expenses	195,117
Revenues	205,999
Stockholders Equity	270,312
Net Income	9,349
Comprehensive Net Income	9,349
Economic Capital Ratio	150%




The relative strengths and weaknesses of Forte Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Forte Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 104% points. The greatest weakness of Forte Biosciences Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 234%, being 191% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	41,511
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,179
Liabilities, Non-Current	0
Other Assets	486
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	17
Other Revenues	0
Property and Equipment	0
Research and Development	5,594
Selling, General and Administrative Expense	8,302

Output Variable	Value in 1000 USD
Assets	41,997
Liabilities	3,179
Expenses	13,896
Revenues	0
Stockholders Equity	38,818
Net Income	-13,879
Comprehensive Net Income	-13,879
Economic Capital Ratio	234%




The relative strengths and weaknesses of ALX ONCOLOGY HOLDINGS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALX ONCOLOGY HOLDINGS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of ALX ONCOLOGY HOLDINGS INC is the variable Research and Development, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 188%, being 145% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	270,969
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,325
Liabilities, Non-Current	14,700
Other Assets	31,631
Other Compr. Net Income	-845
Other Expenses	64
Other Liabilities	0
Other Net Income	4,018
Other Revenues	0
Property and Equipment	3,889
Research and Development	98,400
Selling, General and Administrative Expense	29,036

Output Variable	Value in 1000 USD
Assets	306,489
Liabilities	43,025
Expenses	127,500
Revenues	0
Stockholders Equity	263,464
Net Income	-123,482
Comprehensive Net Income	-123,904
Economic Capital Ratio	188%






The relative strengths and weaknesses of SCYNEXIS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SCYNEXIS INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 20% points. The greatest weakness of SCYNEXIS INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is -66%, being 110% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	79,061
Cost of Goods Sold	0
Intangible Assets	408
Liabilities, Current	17,618
Liabilities, Non-Current	2,921
Other Assets	8,341
Other Compr. Net Income	0
Other Expenses	-4,072
Other Liabilities	64,038
Other Net Income	18,248
Other Revenues	5,091
Property and Equipment	0
Research and Development	27,259
Selling, General and Administrative Expense	62,961

Output Variable	Value in 1000 USD
Assets	87,810
Liabilities	84,577
Expenses	86,148
Revenues	5,091
Stockholders Equity	3,233
Net Income	-62,809
Comprehensive Net Income	-62,809
Economic Capital Ratio	-66%





PHARMACEUTICAL 2023

Unity Biotechnology Inc.
Rank 244 of 446




The relative strengths and weaknesses of Unity Biotechnology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Unity Biotechnology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Unity Biotechnology Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 60%, being 17% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	96,535
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,620
Liabilities, Non-Current	37,882
Other Assets	19,990
Other Compr. Net Income	-207
Other Expenses	3,558
Other Liabilities	0
Other Net Income	1,203
Other Revenues	236
Property and Equipment	7,825
Research and Development	36,859
Selling, General and Administrative Expense	20,949

Output Variable	Value in 1000 USD
Assets	124,350
Liabilities	57,502
Expenses	61,366
Revenues	236
Stockholders Equity	66,848
Net Income	-59,927
Comprehensive Net Income	-60,030
Economic Capital Ratio	60%





RealRate

PHARMACEUTICAL 2023

Minerva Neurosciences Inc. Rank 360 of 446




The relative strengths and weaknesses of Minerva Neurosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Minerva Neurosciences Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Minerva Neurosciences Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 255% points.

The company's Economic Capital Ratio, given in the ranking table, is -102%, being 145% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	40,159
Cost of Goods Sold	0
Intangible Assets	14,869
Liabilities, Current	1,378
Liabilities, Non-Current	0
Other Assets	43
Other Compr. Net Income	0
Other Expenses	7,407
Other Liabilities	73,734
Other Net Income	529
Other Revenues	0
Property and Equipment	16
Research and Development	14,649
Selling, General and Administrative Expense	10,582

Output Variable	Value in 1000 USD
Assets	55,087
Liabilities	75,111
Expenses	32,638
Revenues	0
Stockholders Equity	-20,024
Net Income	-32,109
Comprehensive Net Income	-32,109
Economic Capital Ratio	-102%





PHARMACEUTICAL 2023

IVERIC bio Inc.
Rank 115 of 446




The relative strengths and weaknesses of IVERIC bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IVERIC bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 115% points. The greatest weakness of IVERIC bio Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 184%, being 141% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	662,826
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	35,587
Liabilities, Non-Current	96,579
Other Assets	3,051
Other Compr. Net Income	-139
Other Expenses	0
Other Liabilities	0
Other Net Income	4,695
Other Revenues	0
Property and Equipment	946
Research and Development	117,012
Selling, General and Administrative Expense	72,894

Output Variable	Value in 1000 USD
Assets	666,823
Liabilities	132,166
Expenses	189,906
Revenues	0
Stockholders Equity	534,657
Net Income	-185,211
Comprehensive Net Income	-185,280
Economic Capital Ratio	184%





RealRate

PHARMACEUTICAL 2023

CymaBay Therapeutics Inc. Rank 333 of 446




The relative strengths and weaknesses of CymaBay Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CymaBay Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 35% points. The greatest weakness of CymaBay Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 135% points.

The company's Economic Capital Ratio, given in the ranking table, is -36%, being 79% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	138,073
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,441
Liabilities, Non-Current	30
Other Assets	3,078
Other Compr. Net Income	-313
Other Expenses	0
Other Liabilities	90,227
Other Net Income	-12,890
Other Revenues	0
Property and Equipment	701
Research and Development	67,995
Selling, General and Administrative Expense	25,116

Output Variable	Value in 1000 USD
Assets	141,852
Liabilities	105,698
Expenses	93,111
Revenues	0
Stockholders Equity	36,154
Net Income	-106,001
Comprehensive Net Income	-106,158
Economic Capital Ratio	-36%




The relative strengths and weaknesses of COMPASS Pathways plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of COMPASS Pathways plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 72% points. The greatest weakness of COMPASS Pathways plc is the variable Other Revenues, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 195%, being 151% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	191,651
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,596
Liabilities, Non-Current	418
Other Assets	5,026
Other Compr. Net Income	-25,707
Other Expenses	408
Other Liabilities	0
Other Net Income	19,306
Other Revenues	0
Property and Equipment	617
Research and Development	65,053
Selling, General and Administrative Expense	45,350

Output Variable	Value in 1000 USD
Assets	197,294
Liabilities	16,014
Expenses	110,811
Revenues	0
Stockholders Equity	181,280
Net Income	-91,505
Comprehensive Net Income	-104,358
Economic Capital Ratio	195%




The relative strengths and weaknesses of Anixa Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anixa Biosciences Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 108% points. The greatest weakness of Anixa Biosciences Inc is the variable Net Income, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 213%, being 170% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	30,200
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,037
Liabilities, Non-Current	175
Other Assets	212
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	104
Other Revenues	0
Property and Equipment	0
Research and Development	6,703
Selling, General and Administrative Expense	7,172

Output Variable	Value in 1000 USD
Assets	30,412
Liabilities	2,212
Expenses	13,875
Revenues	0
Stockholders Equity	28,200
Net Income	-13,771
Comprehensive Net Income	-13,771
Economic Capital Ratio	213%



ENANTA PHARMACEUTICALS INC
Rank 99 of 446


The relative strengths and weaknesses of ENANTA PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENANTA PHARMACEUTICALS INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 54% points. The greatest weakness of ENANTA PHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 200%, being 157% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	311,713
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	29,827
Liabilities, Non-Current	22,826
Other Assets	57,524
Other Compr. Net Income	-3,342
Other Expenses	-433
Other Liabilities	1,423
Other Net Income	1,656
Other Revenues	86,160
Property and Equipment	6,173
Research and Development	164,522
Selling, General and Administrative Expense	45,482

Output Variable	Value in 1000 USD
Assets	375,410
Liabilities	54,076
Expenses	209,571
Revenues	86,160
Stockholders Equity	321,334
Net Income	-121,755
Comprehensive Net Income	-123,426
Economic Capital Ratio	200%




The relative strengths and weaknesses of XOMA Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Corp compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 51% points. The greatest weakness of XOMA Corp is the variable Other Revenues, reducing the Economic Capital Ratio by 7.3% points.

The company's Economic Capital Ratio, given in the ranking table, is 250%, being 207% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	61,253
Cost of Goods Sold	0
Intangible Assets	15,150
Liabilities, Current	6,818
Liabilities, Non-Current	0
Other Assets	63,972
Other Compr. Net Income	0
Other Expenses	82
Other Liabilities	9,550
Other Net Income	295
Other Revenues	6,027
Property and Equipment	7.0
Research and Development	153
Selling, General and Administrative Expense	23,191

Output Variable	Value in 1000 USD
Assets	140,382
Liabilities	16,368
Expenses	23,426
Revenues	6,027
Stockholders Equity	124,014
Net Income	-17,104
Comprehensive Net Income	-17,104
Economic Capital Ratio	250%





PHARMACEUTICAL 2023

AYTU BIOPHARMA INC

Rank 324 of 446




The relative strengths and weaknesses of AYTU BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AYTU BIOPHARMA INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 117% points. The greatest weakness of AYTU BIOPHARMA INC is the variable Assets, Current, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is -27%, being 70% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	59,929
Cost of Goods Sold	44,386
Intangible Assets	70,632
Liabilities, Current	64,442
Liabilities, Non-Current	12,810
Other Assets	7,062
Other Compr. Net Income	0
Other Expenses	118,128
Other Liabilities	14,279
Other Net Income	1,278
Other Revenues	96,669
Property and Equipment	0
Research and Development	14,439
Selling, General and Administrative Expense	31,167

Output Variable	Value in 1000 USD
Assets	137,623
Liabilities	91,531
Expenses	208,120
Revenues	96,669
Stockholders Equity	46,092
Net Income	-110,173
Comprehensive Net Income	-110,173
Economic Capital Ratio	-27%




The relative strengths and weaknesses of Xencor Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xencor Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Xencor Inc is the variable Intangible Assets, reducing the Economic Capital Ratio by 2.3% points.

The company's Economic Capital Ratio, given in the ranking table, is 247%, being 204% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	675,342
Cost of Goods Sold	0
Intangible Assets	18,500
Liabilities, Current	63,844
Liabilities, Non-Current	54,926
Other Assets	93,241
Other Compr. Net Income	-5,442
Other Expenses	673
Other Liabilities	0
Other Net Income	27,965
Other Revenues	164,579
Property and Equipment	59,183
Research and Development	199,563
Selling, General and Administrative Expense	47,489

Output Variable	Value in 1000 USD
Assets	846,266
Liabilities	118,770
Expenses	247,725
Revenues	164,579
Stockholders Equity	727,496
Net Income	-55,181
Comprehensive Net Income	-57,902
Economic Capital Ratio	247%



The relative strengths and weaknesses of CASSAVA SCIENCES INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CASSAVA SCIENCES INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of CASSAVA SCIENCES INC is the variable Other Expenses, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 260%, being 217% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	211,226
Cost of Goods Sold	0
Intangible Assets	622
Liabilities, Current	7,063
Liabilities, Non-Current	232
Other Assets	122
Other Compr. Net Income	0
Other Expenses	68,032
Other Liabilities	0
Other Net Income	997
Other Revenues	2,777
Property and Equipment	22,864
Research and Development	0
Selling, General and Administrative Expense	11,988

Output Variable	Value in 1000 USD
Assets	234,834
Liabilities	7,295
Expenses	80,020
Revenues	2,777
Stockholders Equity	227,539
Net Income	-76,246
Comprehensive Net Income	-76,246
Economic Capital Ratio	260%



PHARMACEUTICAL 2023

ARROWHEAD PHARMACEUTICALS INC.
 Rank 193 of 446





PHARMACEUTICAL 2023

ARROWHEAD PHARMACEUTICALS INC. Rank 193 of 446




The relative strengths and weaknesses of ARROWHEAD PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARROWHEAD PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 40% points. The greatest weakness of ARROWHEAD PHARMACEUTICALS INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 112%, being 69% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	405,299
Cost of Goods Sold	0
Intangible Assets	11,962
Liabilities, Current	138,850
Liabilities, Non-Current	134,750
Other Assets	164,381
Other Compr. Net Income	-67
Other Expenses	3,785
Other Liabilities	0
Other Net Income	5,798
Other Revenues	243,231
Property and Equipment	110,297
Research and Development	297,307
Selling, General and Administrative Expense	124,431

Output Variable	Value in 1000 USD
Assets	691,939
Liabilities	273,600
Expenses	425,523
Revenues	243,231
Stockholders Equity	418,339
Net Income	-176,494
Comprehensive Net Income	-176,528
Economic Capital Ratio	112%





RealRate

PHARMACEUTICAL 2023

SPRUCE BIOSCIENCES INC. Rank 164 of 446




The relative strengths and weaknesses of SPRUCE BIOSCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SPRUCE BIOSCIENCES INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 97% points. The greatest weakness of SPRUCE BIOSCIENCES INC. is the variable Research and Development, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 139%, being 96% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	83,608
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,447
Liabilities, Non-Current	4,715
Other Assets	2,040
Other Compr. Net Income	-374
Other Expenses	420
Other Liabilities	0
Other Net Income	0
Other Revenues	1,523
Property and Equipment	0
Research and Development	35,198
Selling, General and Administrative Expense	12,085

Output Variable	Value in 1000 USD
Assets	85,648
Liabilities	17,162
Expenses	47,703
Revenues	1,523
Stockholders Equity	68,486
Net Income	-46,180
Comprehensive Net Income	-46,367
Economic Capital Ratio	139%





PHARMACEUTICAL 2023

Emergent BioSolutions Inc.
Rank 223 of 446

EMERGENT


The relative strengths and weaknesses of Emergent BioSolutions Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Emergent BioSolutions Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Emergent BioSolutions Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 87%, being 44% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,210,700
Cost of Goods Sold	693,700
Intangible Assets	947,000
Liabilities, Current	1,229,900
Liabilities, Non-Current	481,900
Other Assets	191,300
Other Compr. Net Income	19,200
Other Expenses	68,700
Other Liabilities	71,800
Other Net Income	-49,000
Other Revenues	1,120,900
Property and Equipment	817,600
Research and Development	193,000
Selling, General and Administrative Expense	340,300

Output Variable	Value in 1000 USD
Assets	3,166,600
Liabilities	1,783,600
Expenses	1,295,700
Revenues	1,120,900
Stockholders Equity	1,383,000
Net Income	-223,800
Comprehensive Net Income	-214,200
Economic Capital Ratio	87%



The relative strengths and weaknesses of ESSA Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ESSA Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of ESSA Pharma Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 294%, being 250% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	169,059
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,310
Liabilities, Non-Current	76
Other Assets	446
Other Compr. Net Income	-59
Other Expenses	-98
Other Liabilities	0
Other Net Income	22
Other Revenues	1,737
Property and Equipment	0
Research and Development	24,415
Selling, General and Administrative Expense	12,545


Output Variable	Value in 1000 USD
Assets	169,505
Liabilities	2,387
Expenses	36,862
Revenues	1,737
Stockholders Equity	167,118
Net Income	-35,103
Comprehensive Net Income	-35,133
Economic Capital Ratio	294%



RealRate

PHARMACEUTICAL 2023

One World Products Inc.
Rank 373 of 446





RealRate

PHARMACEUTICAL 2023

One World Products Inc. Rank 373 of 446




The relative strengths and weaknesses of One World Products Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of One World Products Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 126% points. The greatest weakness of One World Products Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 151% points.

The company's Economic Capital Ratio, given in the ranking table, is -132%, being 175% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	123
Cost of Goods Sold	301
Intangible Assets	0
Liabilities, Current	2,977
Liabilities, Non-Current	342
Other Assets	2,056
Other Compr. Net Income	14
Other Expenses	474
Other Liabilities	900
Other Net Income	-823
Other Revenues	126
Property and Equipment	989
Research and Development	0
Selling, General and Administrative Expense	1,587

Output Variable	Value in 1000 USD
Assets	3,168
Liabilities	4,219
Expenses	2,362
Revenues	126
Stockholders Equity	-1,051
Net Income	-3,059
Comprehensive Net Income	-3,053
Economic Capital Ratio	-132%





PHARMACEUTICAL 2023

Eterna Therapeutics Inc.
Rank 317 of 446



The relative strengths and weaknesses of Eterna Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eterna Therapeutics Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Eterna Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 93% points.

The company's Economic Capital Ratio, given in the ranking table, is -23%, being 66% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	13,681
Cost of Goods Sold	0
Intangible Assets	2,044
Liabilities, Current	7,654
Liabilities, Non-Current	981
Other Assets	6,318
Other Compr. Net Income	0
Other Expenses	6,035
Other Liabilities	1,537
Other Net Income	8,683
Other Revenues	0
Property and Equipment	236
Research and Development	10,392
Selling, General and Administrative Expense	16,835

Output Variable	Value in 1000 USD
Assets	22,279
Liabilities	10,172
Expenses	33,262
Revenues	0
Stockholders Equity	12,107
Net Income	-24,579
Comprehensive Net Income	-24,579
Economic Capital Ratio	-23%



PHARMACEUTICAL 2023

Indaptus Therapeutics Inc.
Rank 121 of 446





PHARMACEUTICAL 2023

Indaptus Therapeutics Inc.
Rank 121 of 446

The relative strengths and weaknesses of Indaptus Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Indaptus Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Indaptus Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 178%, being 135% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	27,244
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,433
Liabilities, Non-Current	0
Other Assets	818
Other Compr. Net Income	96
Other Expenses	0
Other Liabilities	0
Other Net Income	588
Other Revenues	0
Property and Equipment	2.0
Research and Development	6,325
Selling, General and Administrative Expense	8,586

Output Variable	Value in 1000 USD
Assets	28,064
Liabilities	3,433
Expenses	14,911
Revenues	0
Stockholders Equity	24,630
Net Income	-14,323
Comprehensive Net Income	-14,275
Economic Capital Ratio	178%



PHARMACEUTICAL 2023

MADRIGAL PHARMACEUTICALS INC. Rank 353 of 446





PHARMACEUTICAL 2023

MADRIGAL PHARMACEUTICALS INC. Rank 353 of 446




The relative strengths and weaknesses of MADRIGAL PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MADRIGAL PHARMACEUTICALS INC. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 25% points. The greatest weakness of MADRIGAL PHARMACEUTICALS INC. is the variable Net Income, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is -76%, being 119% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	361,369
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	115,894
Liabilities, Non-Current	49,289
Other Assets	602
Other Compr. Net Income	48
Other Expenses	249,405
Other Liabilities	0
Other Net Income	2,185
Other Revenues	0
Property and Equipment	601
Research and Development	245,441
Selling, General and Administrative Expense	48,130

Output Variable	Value in 1000 USD
Assets	362,572
Liabilities	165,183
Expenses	542,976
Revenues	0
Stockholders Equity	197,389
Net Income	-540,791
Comprehensive Net Income	-540,767
Economic Capital Ratio	-76%




The relative strengths and weaknesses of Tyra Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tyra Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Tyra Biosciences Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 283%, being 240% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	257,288
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,701
Liabilities, Non-Current	2,651
Other Assets	7,816
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	3,602
Other Revenues	0
Property and Equipment	1,077
Research and Development	43,008
Selling, General and Administrative Expense	15,919

Output Variable	Value in 1000 USD
Assets	266,181
Liabilities	8,352
Expenses	58,927
Revenues	0
Stockholders Equity	257,829
Net Income	-55,325
Comprehensive Net Income	-55,325
Economic Capital Ratio	283%



The relative strengths and weaknesses of CORCEPT THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CORCEPT THERAPEUTICS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 123% points. The greatest weakness of CORCEPT THERAPEUTICS INC is the variable Intangible Assets, reducing the Economic Capital Ratio by 3.1% points.

The company's Economic Capital Ratio, given in the ranking table, is 290%, being 247% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	499,253
Cost of Goods Sold	5,385
Intangible Assets	0
Liabilities, Current	72,491
Liabilities, Non-Current	0
Other Assets	83,544
Other Compr. Net Income	-642
Other Expenses	14,773
Other Liabilities	9,097
Other Net Income	3,557
Other Revenues	401,858
Property and Equipment	633
Research and Development	130,991
Selling, General and Administrative Expense	152,848

Output Variable	Value in 1000 USD
Assets	583,430
Liabilities	81,588
Expenses	303,997
Revenues	401,858
Stockholders Equity	501,842
Net Income	101,418
Comprehensive Net Income	101,097
Economic Capital Ratio	290%



PHARMACEUTICAL 2023

GRI BIO Inc.
Rank 358 of 446





PHARMACEUTICAL 2023

GRI BIO Inc.
Rank 358 of 446


The relative strengths and weaknesses of GRI BIO Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GRI BIO Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 21% points. The greatest weakness of GRI BIO Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 146% points.

The company's Economic Capital Ratio, given in the ranking table, is -100%, being 144% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	4,152
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,810
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	2.0
Other Expenses	122
Other Liabilities	0
Other Net Income	26
Other Revenues	0
Property and Equipment	0
Research and Development	1,170
Selling, General and Administrative Expense	5,758

Output Variable	Value in 1000 USD
Assets	4,152
Liabilities	1,810
Expenses	7,050
Revenues	0
Stockholders Equity	2,342
Net Income	-7,024
Comprehensive Net Income	-7,023
Economic Capital Ratio	-100%




The relative strengths and weaknesses of Synaptogenix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Synaptogenix Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Synaptogenix Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 265%, being 222% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	38,586
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,313
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	1,880
Other Net Income	10,561
Other Revenues	0
Property and Equipment	22
Research and Development	6,325
Selling, General and Administrative Expense	9,810

Output Variable	Value in 1000 USD
Assets	38,608
Liabilities	3,193
Expenses	16,135
Revenues	0
Stockholders Equity	35,415
Net Income	-5,574
Comprehensive Net Income	-5,574
Economic Capital Ratio	265%





PHARMACEUTICAL 2023

GERON CORP
Rank 303 of 446




The relative strengths and weaknesses of GERON CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GERON CORP compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 39% points. The greatest weakness of GERON CORP is the variable Liabilities, Current, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is -2.9%, being 46% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	180,246
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	76,694
Liabilities, Non-Current	33,883
Other Assets	9,536
Other Compr. Net Income	-46
Other Expenses	6,882
Other Liabilities	0
Other Net Income	3,531
Other Revenues	596
Property and Equipment	793
Research and Development	95,518
Selling, General and Administrative Expense	43,628

Output Variable	Value in 1000 USD
Assets	190,575
Liabilities	110,577
Expenses	146,028
Revenues	596
Stockholders Equity	79,998
Net Income	-141,901
Comprehensive Net Income	-141,924
Economic Capital Ratio	-2.9%



The relative strengths and weaknesses of ELITE PHARMACEUTICALS INC NV are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELITE PHARMACEUTICALS INC NV compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 144% points. The greatest weakness of ELITE PHARMACEUTICALS INC NV is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is 232%, being 189% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	18,861
Cost of Goods Sold	17,467
Intangible Assets	6,634
Liabilities, Current	6,694
Liabilities, Non-Current	3,233
Other Assets	3,700
Other Compr. Net Income	0
Other Expenses	-527
Other Liabilities	0
Other Net Income	2,091
Other Revenues	32,262
Property and Equipment	5,953
Research and Development	4,051
Selling, General and Administrative Expense	4,464

Output Variable	Value in 1000 USD
Assets	35,149
Liabilities	9,927
Expenses	25,455
Revenues	32,262
Stockholders Equity	25,222
Net Income	8,898
Comprehensive Net Income	8,898
Economic Capital Ratio	232%



PHARMACEUTICAL 2023

CHINOOK THERAPEUTICS INC. Rank 141 of 446





RealRate

PHARMACEUTICAL 2023

CHINOOK THERAPEUTICS INC. Rank 141 of 446



The relative strengths and weaknesses of CHINOOK THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHINOOK THERAPEUTICS INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 31% points. The greatest weakness of CHINOOK THERAPEUTICS INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 162%, being 118% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	385,592
Cost of Goods Sold	0
Intangible Assets	24,404
Liabilities, Current	50,835
Liabilities, Non-Current	34,494
Other Assets	147,180
Other Compr. Net Income	-3,109
Other Expenses	18,050
Other Liabilities	46,814
Other Net Income	1,559
Other Revenues	6,128
Property and Equipment	16,908
Research and Development	141,211
Selling, General and Administrative Expense	36,291


Output Variable	Value in 1000 USD
Assets	574,084
Liabilities	132,143
Expenses	195,552
Revenues	6,128
Stockholders Equity	441,941
Net Income	-187,865
Comprehensive Net Income	-189,420
Economic Capital Ratio	162%



RealRate

PHARMACEUTICAL 2023

Pulmatrix Inc.
Rank 168 of 446





PHARMACEUTICAL 2023

Pulmatrix Inc.
Rank 168 of 446




The relative strengths and weaknesses of Pulmatrix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pulmatrix Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Pulmatrix Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 137%, being 93% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	38,147
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,022
Liabilities, Non-Current	0
Other Assets	2,571
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	4,822
Other Net Income	111
Other Revenues	6,071
Property and Equipment	235
Research and Development	18,240
Selling, General and Administrative Expense	6,778

Output Variable	Value in 1000 USD
Assets	40,953
Liabilities	9,844
Expenses	25,018
Revenues	6,071
Stockholders Equity	31,109
Net Income	-18,836
Comprehensive Net Income	-18,836
Economic Capital Ratio	137%




The relative strengths and weaknesses of Lantern Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lantern Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 92% points. The greatest weakness of Lantern Pharma Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 266%, being 223% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	58,723
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,798
Liabilities, Non-Current	0
Other Assets	66
Other Compr. Net Income	-279
Other Expenses	0
Other Liabilities	0
Other Net Income	173
Other Revenues	0
Property and Equipment	48
Research and Development	8,603
Selling, General and Administrative Expense	5,830

Output Variable	Value in 1000 USD
Assets	58,836
Liabilities	2,798
Expenses	14,433
Revenues	0
Stockholders Equity	56,038
Net Income	-14,260
Comprehensive Net Income	-14,399
Economic Capital Ratio	266%



The relative strengths and weaknesses of UNITED THERAPEUTICS Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UNITED THERAPEUTICS Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 84% points. The greatest weakness of UNITED THERAPEUTICS Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 246%, being 203% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	3,380,300
Cost of Goods Sold	151,600
Intangible Assets	0
Liabilities, Current	343,200
Liabilities, Non-Current	104,600
Other Assets	1,802,700
Other Compr. Net Income	-32,500
Other Expenses	705,400
Other Liabilities	800,000
Other Net Income	-29,100
Other Revenues	1,936,300
Property and Equipment	861,500
Research and Development	322,900
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	6,044,500
Liabilities	1,247,800
Expenses	1,179,900
Revenues	1,936,300
Stockholders Equity	4,796,700
Net Income	727,300
Comprehensive Net Income	711,050
Economic Capital Ratio	246%



PHARMACEUTICAL 2023

Dyne Therapeutics Inc.
Rank 157 of 446





PHARMACEUTICAL 2023

Dyne Therapeutics Inc.
Rank 157 of 446

The relative strengths and weaknesses of Dyne Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dyne Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Dyne Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 148%, being 104% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	265,594
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,088
Liabilities, Non-Current	25,873
Other Assets	34,786
Other Compr. Net Income	-302
Other Expenses	0
Other Liabilities	0
Other Net Income	2,863
Other Revenues	0
Property and Equipment	5,945
Research and Development	142,760
Selling, General and Administrative Expense	28,202

Output Variable	Value in 1000 USD
Assets	306,325
Liabilities	53,961
Expenses	170,962
Revenues	0
Stockholders Equity	252,364
Net Income	-168,099
Comprehensive Net Income	-168,250
Economic Capital Ratio	148%



PHARMACEUTICAL 2023

Avalo Therapeutics Inc.
Rank 380 of 446





PHARMACEUTICAL 2023

Avalo Therapeutics Inc.
Rank 380 of 446



The relative strengths and weaknesses of Avalo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avalo Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Avalo Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 155% points.

The company's Economic Capital Ratio, given in the ranking table, is -156%, being 199% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	16,416
Cost of Goods Sold	3,434
Intangible Assets	14,409
Liabilities, Current	22,114
Liabilities, Non-Current	1,711
Other Assets	2,542
Other Compr. Net Income	0
Other Expenses	66
Other Liabilities	20,457
Other Net Income	-4,190
Other Revenues	18,051
Property and Equipment	0
Research and Development	31,308
Selling, General and Administrative Expense	20,711


Output Variable	Value in 1000 USD
Assets	33,367
Liabilities	44,282
Expenses	55,519
Revenues	18,051
Stockholders Equity	-10,915
Net Income	-41,658
Comprehensive Net Income	-41,658
Economic Capital Ratio	-156%



RealRate

PHARMACEUTICAL 2023

LEAP THERAPEUTICS INC. Rank 190 of 446





RealRate

PHARMACEUTICAL 2023

LEAP THERAPEUTICS INC. Rank 190 of 446




The relative strengths and weaknesses of LEAP THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LEAP THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 80% points. The greatest weakness of LEAP THERAPEUTICS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is 114%, being 71% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	67,950
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,225
Liabilities, Non-Current	262
Other Assets	2,383
Other Compr. Net Income	395
Other Expenses	201
Other Liabilities	0
Other Net Income	317
Other Revenues	2,051
Property and Equipment	20
Research and Development	44,965
Selling, General and Administrative Expense	11,798

Output Variable	Value in 1000 USD
Assets	70,353
Liabilities	11,487
Expenses	56,964
Revenues	2,051
Stockholders Equity	58,866
Net Income	-54,596
Comprehensive Net Income	-54,398
Economic Capital Ratio	114%





PHARMACEUTICAL 2023

Genprex Inc.
Rank 205 of 446

The relative strengths and weaknesses of Genprex Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Genprex Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Genprex Inc. is the variable Net Income, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is 104%, being 61% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	21,473
Cost of Goods Sold	0
Intangible Assets	702
Liabilities, Current	2,810
Liabilities, Non-Current	0
Other Assets	2,887
Other Compr. Net Income	0
Other Expenses	26
Other Liabilities	0
Other Net Income	90
Other Revenues	0
Property and Equipment	23
Research and Development	11,510
Selling, General and Administrative Expense	12,295

Output Variable	Value in 1000 USD
Assets	25,085
Liabilities	2,810
Expenses	23,831
Revenues	0
Stockholders Equity	22,275
Net Income	-23,741
Comprehensive Net Income	-23,741
Economic Capital Ratio	104%



PHARMACEUTICAL 2023

LIXTE BIOTECHNOLOGY HOLDINGS
INC.
Rank 226 of 446





PHARMACEUTICAL 2023

LIXTE BIOTECHNOLOGY HOLDINGS INC. Rank 226 of 446

The relative strengths and weaknesses of LIXTE BIOTECHNOLOGY HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIXTE BIOTECHNOLOGY HOLDINGS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 86% points. The greatest weakness of LIXTE BIOTECHNOLOGY HOLDINGS INC. is the variable Net Income, reducing the Economic Capital Ratio by 119% points.

The company's Economic Capital Ratio, given in the ranking table, is 86%, being 43% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	5,560
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	395
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	2,423
Other Liabilities	0
Other Net Income	7.8
Other Revenues	0
Property and Equipment	0
Research and Development	1,349
Selling, General and Administrative Expense	2,548

Output Variable	Value in 1000 USD
Assets	5,560
Liabilities	395
Expenses	6,320
Revenues	0
Stockholders Equity	5,165
Net Income	-6,313
Comprehensive Net Income	-6,313
Economic Capital Ratio	86%



PHARMACEUTICAL 2023

Molecular Templates Inc.
Rank 366 of 446





PHARMACEUTICAL 2023

Molecular Templates Inc.
Rank 366 of 446

The relative strengths and weaknesses of Molecular Templates Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Molecular Templates Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Molecular Templates Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 82% points.

The company's Economic Capital Ratio, given in the ranking table, is -113%, being 156% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	68,298
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	57,082
Liabilities, Non-Current	49,694
Other Assets	14,618
Other Compr. Net Income	-18
Other Expenses	4,835
Other Liabilities	5,904
Other Net Income	20,742
Other Revenues	0
Property and Equipment	14,632
Research and Development	82,425
Selling, General and Administrative Expense	26,200

Output Variable	Value in 1000 USD
Assets	97,548
Liabilities	112,680
Expenses	113,460
Revenues	0
Stockholders Equity	-15,132
Net Income	-92,718
Comprehensive Net Income	-92,727
Economic Capital Ratio	-113%



PHARMACEUTICAL 2023

Guardion Health Sciences Inc.
Rank 252 of 446





PHARMACEUTICAL 2023

Guardion Health Sciences Inc.
Rank 252 of 446




The relative strengths and weaknesses of Guardion Health Sciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Guardion Health Sciences Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Guardion Health Sciences Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is 51%, being 8.0% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	21,637
Cost of Goods Sold	6,529
Intangible Assets	0
Liabilities, Current	4,012
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	12,169
Other Liabilities	4,507
Other Net Income	2,498
Other Revenues	11,050
Property and Equipment	49
Research and Development	194
Selling, General and Administrative Expense	9,578

Output Variable	Value in 1000 USD
Assets	21,686
Liabilities	8,518
Expenses	28,470
Revenues	11,050
Stockholders Equity	13,168
Net Income	-14,922
Comprehensive Net Income	-14,922
Economic Capital Ratio	51%





PHARMACEUTICAL 2023

Jaguar Health Inc.
Rank 361 of 446




The relative strengths and weaknesses of Jaguar Health Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jaguar Health Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 100% points. The greatest weakness of Jaguar Health Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 117% points.

The company's Economic Capital Ratio, given in the ranking table, is -106%, being 149% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	22,321
Cost of Goods Sold	2,019
Intangible Assets	22,439
Liabilities, Current	30,339
Liabilities, Non-Current	725
Other Assets	2,135
Other Compr. Net Income	-680
Other Expenses	21,580
Other Liabilities	17,744
Other Net Income	-1,237
Other Revenues	11,956
Property and Equipment	557
Research and Development	17,647
Selling, General and Administrative Expense	17,868

Output Variable	Value in 1000 USD
Assets	47,452
Liabilities	48,808
Expenses	59,114
Revenues	11,956
Stockholders Equity	-1,356
Net Income	-48,395
Comprehensive Net Income	-48,735
Economic Capital Ratio	-106%





PHARMACEUTICAL 2023

CytoDyn Inc.
Rank 442 of 446




The relative strengths and weaknesses of CytoDyn Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytoDyn Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 179% points. The greatest weakness of CytoDyn Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 349% points.

The company's Economic Capital Ratio, given in the ranking table, is -489%, being 532% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	10,515
Cost of Goods Sold	53
Intangible Assets	132
Liabilities, Current	123,161
Liabilities, Non-Current	422
Other Assets	18,465
Other Compr. Net Income	0
Other Expenses	139,687
Other Liabilities	0
Other Net Income	0
Other Revenues	266
Property and Equipment	73
Research and Development	27,043
Selling, General and Administrative Expense	44,303

Output Variable	Value in 1000 USD
Assets	29,185
Liabilities	123,583
Expenses	211,086
Revenues	266
Stockholders Equity	-94,398
Net Income	-210,820
Comprehensive Net Income	-210,820
Economic Capital Ratio	-489%





RealRate

PHARMACEUTICAL 2023

ABEONA THERAPEUTICS INC. Rank 289 of 446



The relative strengths and weaknesses of ABEONA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ABEONA THERAPEUTICS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 26% points. The greatest weakness of ABEONA THERAPEUTICS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is 8.6%, being 35% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	53,099
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,779
Liabilities, Non-Current	5,854
Other Assets	5,374
Other Compr. Net Income	-3,884
Other Expenses	-4,539
Other Liabilities	23,820
Other Net Income	431
Other Revenues	1,555
Property and Equipment	5,741
Research and Development	28,965
Selling, General and Administrative Expense	17,256

Output Variable	Value in 1000 USD
Assets	64,214
Liabilities	37,453
Expenses	41,682
Revenues	1,555
Stockholders Equity	26,761
Net Income	-39,696
Comprehensive Net Income	-41,638
Economic Capital Ratio	8.6%



PHARMACEUTICAL 2023

Theriva Biologics Inc.
Rank 136 of 446





PHARMACEUTICAL 2023

Theriva Biologics Inc.
Rank 136 of 446


The relative strengths and weaknesses of Theriva Biologics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theriva Biologics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Theriva Biologics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 166%, being 122% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	45,520
Cost of Goods Sold	0
Intangible Assets	24,675
Liabilities, Current	7,060
Liabilities, Non-Current	1,187
Other Assets	1,321
Other Compr. Net Income	-679
Other Expenses	-1,425
Other Liabilities	9,050
Other Net Income	471
Other Revenues	0
Property and Equipment	345
Research and Development	11,723
Selling, General and Administrative Expense	9,858

Output Variable	Value in 1000 USD
Assets	71,861
Liabilities	17,297
Expenses	20,156
Revenues	0
Stockholders Equity	54,564
Net Income	-19,685
Comprehensive Net Income	-20,024
Economic Capital Ratio	166%





PHARMACEUTICAL 2023

KINETA INC. DE
Rank 422 of 446




The relative strengths and weaknesses of KINETA INC. DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KINETA INC. DE compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 12% points. The greatest weakness of KINETA INC. DE is the variable Net Income, reducing the Economic Capital Ratio by 274% points.

The company's Economic Capital Ratio, given in the ranking table, is -367%, being 410% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	13,600
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,487
Liabilities, Non-Current	547
Other Assets	3,586
Other Compr. Net Income	0
Other Expenses	18,860
Other Liabilities	831
Other Net Income	-21,922
Other Revenues	1,953
Property and Equipment	249
Research and Development	15,928
Selling, General and Administrative Expense	8,696

Output Variable	Value in 1000 USD
Assets	17,435
Liabilities	12,865
Expenses	43,484
Revenues	1,953
Stockholders Equity	4,570
Net Income	-63,453
Comprehensive Net Income	-63,453
Economic Capital Ratio	-367%



Jazz Pharmaceuticals plc
Rank 19 of 446

The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Jazz Pharmaceuticals plc is the variable Assets, Current, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 279%, being 236% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	2,606,140
Cost of Goods Sold	0
Intangible Assets	7,487,099
Liabilities, Current	933,193
Liabilities, Non-Current	0
Other Assets	742,016
Other Compr. Net Income	-725,149
Other Expenses	1,114,689
Other Liabilities	0
Other Net Income	-317,177
Other Revenues	3,659,374
Property and Equipment	0
Research and Development	1,034,601
Selling, General and Administrative Expense	1,416,967

Output Variable	Value in 1000 USD
Assets	10,835,255
Liabilities	933,193
Expenses	3,566,257
Revenues	3,659,374
Stockholders Equity	9,902,062
Net Income	-224,060
Comprehensive Net Income	-586,634
Economic Capital Ratio	279%



PHARMACEUTICAL 2023

AILERON THERAPEUTICS INC
Rank 261 of 446





PHARMACEUTICAL 2023

AILERON THERAPEUTICS INC Rank 261 of 446


The relative strengths and weaknesses of AILERON THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AILERON THERAPEUTICS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of AILERON THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 121% points.

The company's Economic Capital Ratio, given in the ranking table, is 37%, being 6.2% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	21,873
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,384
Liabilities, Non-Current	0
Other Assets	64
Other Compr. Net Income	-35
Other Expenses	0
Other Liabilities	0
Other Net Income	318
Other Revenues	0
Property and Equipment	70
Research and Development	17,967
Selling, General and Administrative Expense	9,680

Output Variable	Value in 1000 USD
Assets	22,007
Liabilities	3,384
Expenses	27,647
Revenues	0
Stockholders Equity	18,623
Net Income	-27,329
Comprehensive Net Income	-27,346
Economic Capital Ratio	37%





RealRate

PHARMACEUTICAL 2023

LUMOS PHARMA INC. Rank 134 of 446




The relative strengths and weaknesses of LUMOS PHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LUMOS PHARMA INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 106% points. The greatest weakness of LUMOS PHARMA INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 168%, being 125% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	72,009
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,708
Liabilities, Non-Current	6,000
Other Assets	230
Other Compr. Net Income	-9.0
Other Expenses	-13
Other Liabilities	0
Other Net Income	965
Other Revenues	1,523
Property and Equipment	53
Research and Development	17,857
Selling, General and Administrative Expense	15,706

Output Variable	Value in 1000 USD
Assets	72,292
Liabilities	12,708
Expenses	33,550
Revenues	1,523
Stockholders Equity	59,584
Net Income	-31,062
Comprehensive Net Income	-31,066
Economic Capital Ratio	168%




The relative strengths and weaknesses of Nuvation Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nuvation Bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Nuvation Bio Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 296%, being 253% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	667,318
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,161
Liabilities, Non-Current	3,054
Other Assets	3,929
Other Compr. Net Income	-4,341
Other Expenses	0
Other Liabilities	850
Other Net Income	15,535
Other Revenues	0
Property and Equipment	894
Research and Development	87,815
Selling, General and Administrative Expense	31,919

Output Variable	Value in 1000 USD
Assets	672,141
Liabilities	17,065
Expenses	119,734
Revenues	0
Stockholders Equity	655,076
Net Income	-104,199
Comprehensive Net Income	-106,370
Economic Capital Ratio	296%





PHARMACEUTICAL 2023

ACADIA PHARMACEUTICALS INC Rank 183 of 446




The relative strengths and weaknesses of ACADIA PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ACADIA PHARMACEUTICALS INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 100% points. The greatest weakness of ACADIA PHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 122%, being 79% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	507,937
Cost of Goods Sold	10,166
Intangible Assets	0
Liabilities, Current	125,630
Liabilities, Non-Current	61,769
Other Assets	73,854
Other Compr. Net Income	-783
Other Expenses	2,531
Other Liabilities	0
Other Net Income	10,152
Other Revenues	517,235
Property and Equipment	6,021
Research and Development	361,575
Selling, General and Administrative Expense	369,090

Output Variable	Value in 1000 USD
Assets	587,812
Liabilities	187,399
Expenses	743,362
Revenues	517,235
Stockholders Equity	400,413
Net Income	-215,975
Comprehensive Net Income	-216,366
Economic Capital Ratio	122%





PHARMACEUTICAL 2023

BIOXYTRAN INC Rank 432 of 446


The relative strengths and weaknesses of BIOXYTRAN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOXYTRAN INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 187% points. The greatest weakness of BIOXYTRAN INC is the variable Assets, Current, reducing the Economic Capital Ratio by 244% points.

The company's Economic Capital Ratio, given in the ranking table, is -412%, being 456% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	295
Cost of Goods Sold	0
Intangible Assets	76
Liabilities, Current	3,663
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	223
Other Liabilities	0
Other Net Income	-523
Other Revenues	0
Property and Equipment	0
Research and Development	978
Selling, General and Administrative Expense	934

Output Variable	Value in 1000 USD
Assets	371
Liabilities	3,663
Expenses	2,134
Revenues	0
Stockholders Equity	-3,293
Net Income	-2,657
Comprehensive Net Income	-2,657
Economic Capital Ratio	-412%





PHARMACEUTICAL 2023

Ampio Pharmaceuticals Inc.
Rank 251 of 446



The relative strengths and weaknesses of Ampio Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ampio Pharmaceuticals Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Ampio Pharmaceuticals Inc. is the variable Expenses, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is 51%, being 8.1% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	13,329
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,192
Liabilities, Non-Current	274
Other Assets	75
Other Compr. Net Income	0
Other Expenses	1,936
Other Liabilities	333
Other Net Income	5,981
Other Revenues	0
Property and Equipment	184
Research and Development	8,916
Selling, General and Administrative Expense	11,466

Output Variable	Value in 1000 USD
Assets	13,588
Liabilities	1,799
Expenses	22,318
Revenues	0
Stockholders Equity	11,789
Net Income	-16,337
Comprehensive Net Income	-16,337
Economic Capital Ratio	51%



PHARMACEUTICAL 2023

Viatrix Inc
Rank 218 of 446





PHARMACEUTICAL 2023

Viatrix Inc
Rank 218 of 446



The relative strengths and weaknesses of Viatrix Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viatrix Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 149% points. The greatest weakness of Viatrix Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is 96%, being 53% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	10,635,400
Cost of Goods Sold	9,765,700
Intangible Assets	33,032,900
Liabilities, Current	6,746,200
Liabilities, Non-Current	19,771,700
Other Assets	3,329,400
Other Compr. Net Income	-1,016,900
Other Expenses	1,367,800
Other Liabilities	2,432,000
Other Net Income	1,790,700
Other Revenues	16,262,700
Property and Equipment	3,024,500
Research and Development	662,200
Selling, General and Administrative Expense	4,179,100


Output Variable	Value in 1000 USD
Assets	50,022,200
Liabilities	28,949,900
Expenses	15,974,800
Revenues	16,262,700
Stockholders Equity	21,072,300
Net Income	2,078,600
Comprehensive Net Income	1,570,150
Economic Capital Ratio	96%



RealRate

PHARMACEUTICAL 2023

NGM BIOPHARMACEUTICALS INC Rank 143 of 446





RealRate

PHARMACEUTICAL 2023

NGM BIOPHARMACEUTICALS INC Rank 143 of 446




The relative strengths and weaknesses of NGM BIOPHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NGM BIOPHARMACEUTICALS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of NGM BIOPHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 160%, being 117% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	288,859
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	47,842
Liabilities, Non-Current	0
Other Assets	10,047
Other Compr. Net Income	-173
Other Expenses	0
Other Liabilities	0
Other Net Income	3,582
Other Revenues	55,333
Property and Equipment	8,496
Research and Development	181,067
Selling, General and Administrative Expense	40,515

Output Variable	Value in 1000 USD
Assets	307,402
Liabilities	47,842
Expenses	221,582
Revenues	55,333
Stockholders Equity	259,560
Net Income	-162,667
Comprehensive Net Income	-162,754
Economic Capital Ratio	160%





PHARMACEUTICAL 2023

PIERIS PHARMACEUTICALS INC.
Rank 281 of 446




The relative strengths and weaknesses of PIERIS PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PIERIS PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 33% points. The greatest weakness of PIERIS PHARMACEUTICALS INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 17%, being 26% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	73,424
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	36,583
Liabilities, Non-Current	30,978
Other Assets	5,074
Other Compr. Net Income	-1,083
Other Expenses	0
Other Liabilities	0
Other Net Income	10,197
Other Revenues	25,902
Property and Equipment	16,992
Research and Development	52,982
Selling, General and Administrative Expense	16,394

Output Variable	Value in 1000 USD
Assets	95,490
Liabilities	67,561
Expenses	69,376
Revenues	25,902
Stockholders Equity	27,929
Net Income	-33,277
Comprehensive Net Income	-33,818
Economic Capital Ratio	17%





PHARMACEUTICAL 2023

2seventy bio Inc.
Rank 250 of 446



The relative strengths and weaknesses of 2seventy bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of 2seventy bio Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 77% points. The greatest weakness of 2seventy bio Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is 56%, being 12% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	300,882
Cost of Goods Sold	1,726
Intangible Assets	19,358
Liabilities, Current	79,794
Liabilities, Non-Current	266,405
Other Assets	280,690
Other Compr. Net Income	-2,165
Other Expenses	24,725
Other Liabilities	0
Other Net Income	8,987
Other Revenues	91,496
Property and Equipment	55,735
Research and Development	248,735
Selling, General and Administrative Expense	79,450

Output Variable	Value in 1000 USD
Assets	656,665
Liabilities	346,199
Expenses	354,636
Revenues	91,496
Stockholders Equity	310,466
Net Income	-254,153
Comprehensive Net Income	-255,236
Economic Capital Ratio	56%



PHARMACEUTICAL 2023

IGM Biosciences Inc.
Rank 232 of 446





PHARMACEUTICAL 2023

IGM Biosciences Inc.
Rank 232 of 446


The relative strengths and weaknesses of IGM Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IGM Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of IGM Biosciences Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is 74%, being 31% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	438,421
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	44,685
Liabilities, Non-Current	35,356
Other Assets	41,594
Other Compr. Net Income	-635
Other Expenses	0
Other Liabilities	146,195
Other Net Income	7,923
Other Revenues	0
Property and Equipment	33,484
Research and Development	179,289
Selling, General and Administrative Expense	49,736

Output Variable	Value in 1000 USD
Assets	513,499
Liabilities	226,236
Expenses	229,025
Revenues	0
Stockholders Equity	287,263
Net Income	-221,102
Comprehensive Net Income	-221,420
Economic Capital Ratio	74%



The relative strengths and weaknesses of Karuna Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karuna Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Karuna Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 276%, being 233% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	1,154,769
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	33,946
Liabilities, Non-Current	3,150
Other Assets	5,364
Other Compr. Net Income	-2,793
Other Expenses	1,418
Other Liabilities	0
Other Net Income	14,758
Other Revenues	10,637
Property and Equipment	3,201
Research and Development	224,247
Selling, General and Administrative Expense	76,066

Output Variable	Value in 1000 USD
Assets	1,163,334
Liabilities	37,096
Expenses	301,731
Revenues	10,637
Stockholders Equity	1,126,238
Net Income	-276,336
Comprehensive Net Income	-277,732
Economic Capital Ratio	276%



PHARMACEUTICAL 2023

EAGLE PHARMACEUTICALS INC.
Rank 151 of 446





RealRate

PHARMACEUTICAL 2023

EAGLE PHARMACEUTICALS INC. Rank 151 of 446




The relative strengths and weaknesses of EAGLE PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of EAGLE PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 104% points. The greatest weakness of EAGLE PHARMACEUTICALS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 151%, being 108% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	188,754
Cost of Goods Sold	85,458
Intangible Assets	163,360
Liabilities, Current	111,087
Liabilities, Non-Current	61,513
Other Assets	52,878
Other Compr. Net Income	-1,018
Other Expenses	35,269
Other Liabilities	0
Other Net Income	-19,527
Other Revenues	316,610
Property and Equipment	1,168
Research and Development	34,088
Selling, General and Administrative Expense	106,626

Output Variable	Value in 1000 USD
Assets	406,160
Liabilities	172,600
Expenses	261,441
Revenues	316,610
Stockholders Equity	233,560
Net Income	35,642
Comprehensive Net Income	35,133
Economic Capital Ratio	151%



The relative strengths and weaknesses of Aurinia Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aurinia Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Aurinia Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 220%, being 177% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	442,539
Cost of Goods Sold	5,664
Intangible Assets	6,425
Liabilities, Current	46,107
Liabilities, Non-Current	19,318
Other Assets	18,246
Other Compr. Net Income	-209
Other Expenses	305
Other Liabilities	0
Other Net Income	5,118
Other Revenues	134,030
Property and Equipment	3,650
Research and Development	44,988
Selling, General and Administrative Expense	196,371

Output Variable	Value in 1000 USD
Assets	470,860
Liabilities	65,425
Expenses	247,328
Revenues	134,030
Stockholders Equity	405,435
Net Income	-108,180
Comprehensive Net Income	-108,284
Economic Capital Ratio	220%



PHARMACEUTICAL 2023

Regen BioPharma Inc
Rank 402 of 446





PHARMACEUTICAL 2023

Regen BioPharma Inc
Rank 402 of 446

The relative strengths and weaknesses of Regen BioPharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regen BioPharma Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 116% points. The greatest weakness of Regen BioPharma Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 361% points.

The company's Economic Capital Ratio, given in the ranking table, is -249%, being 292% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	336
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,595
Liabilities, Non-Current	0
Other Assets	223
Other Compr. Net Income	0
Other Expenses	389
Other Liabilities	0
Other Net Income	2,893
Other Revenues	126
Property and Equipment	0
Research and Development	158
Selling, General and Administrative Expense	28

Output Variable	Value in 1000 USD
Assets	559
Liabilities	8,595
Expenses	575
Revenues	126
Stockholders Equity	-8,036
Net Income	2,444
Comprehensive Net Income	2,444
Economic Capital Ratio	-249%



PHARMACEUTICAL 2023

NovaBay Pharmaceuticals Inc.
Rank 266 of 446





PHARMACEUTICAL 2023

NovaBay Pharmaceuticals Inc.
Rank 266 of 446




The relative strengths and weaknesses of NovaBay Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NovaBay Pharmaceuticals Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 92% points. The greatest weakness of NovaBay Pharmaceuticals Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 112% points.

The company's Economic Capital Ratio, given in the ranking table, is 34%, being 9.6% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	11,332
Cost of Goods Sold	6,623
Intangible Assets	2,628
Liabilities, Current	4,257
Liabilities, Non-Current	1,588
Other Assets	2,320
Other Compr. Net Income	0
Other Expenses	14,535
Other Liabilities	0
Other Net Income	0
Other Revenues	14,404
Property and Equipment	119
Research and Development	174
Selling, General and Administrative Expense	7,489

Output Variable	Value in 1000 USD
Assets	16,399
Liabilities	5,845
Expenses	28,821
Revenues	14,404
Stockholders Equity	10,554
Net Income	-14,417
Comprehensive Net Income	-14,417
Economic Capital Ratio	34%



The relative strengths and weaknesses of Disc Medicine Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Disc Medicine Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 107% points. The greatest weakness of Disc Medicine Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 230%, being 186% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	198,491
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,578
Liabilities, Non-Current	1,027
Other Assets	1,546
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	648
Other Revenues	0
Property and Equipment	168
Research and Development	33,437
Selling, General and Administrative Expense	14,038

Output Variable	Value in 1000 USD
Assets	200,205
Liabilities	23,605
Expenses	47,475
Revenues	0
Stockholders Equity	176,600
Net Income	-46,827
Comprehensive Net Income	-46,827
Economic Capital Ratio	230%



PHARMACEUTICAL 2023

Traverse Therapeutics Inc.
Rank 330 of 446





RealRate

PHARMACEUTICAL 2023

Traverse Therapeutics Inc. Rank 330 of 446




The relative strengths and weaknesses of Traverse Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Traverse Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Traverse Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 117% points.

The company's Economic Capital Ratio, given in the ranking table, is -32%, being 75% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	486,437
Cost of Goods Sold	7,592
Intangible Assets	145,038
Liabilities, Current	142,163
Liabilities, Non-Current	47,826
Other Assets	32,061
Other Compr. Net Income	-2,345
Other Expenses	15,319
Other Liabilities	439,745
Other Net Income	-11,603
Other Revenues	212,018
Property and Equipment	9,049
Research and Development	235,780
Selling, General and Administrative Expense	220,206

Output Variable	Value in 1000 USD
Assets	672,585
Liabilities	629,734
Expenses	478,897
Revenues	212,018
Stockholders Equity	42,851
Net Income	-278,482
Comprehensive Net Income	-279,654
Economic Capital Ratio	-32%



The relative strengths and weaknesses of CHIMERIX INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHIMERIX INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 213% points. The greatest weakness of CHIMERIX INC is the variable Other Revenues, reducing the Economic Capital Ratio by 5.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 407%, being 364% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	228,138
Cost of Goods Sold	447
Intangible Assets	0
Liabilities, Current	20,415
Liabilities, Non-Current	1,819
Other Assets	50,976
Other Compr. Net Income	-316
Other Expenses	36
Other Liabilities	250
Other Net Income	232,589
Other Revenues	33,824
Property and Equipment	227
Research and Development	71,631
Selling, General and Administrative Expense	22,132

Output Variable	Value in 1000 USD
Assets	279,341
Liabilities	22,484
Expenses	94,246
Revenues	33,824
Stockholders Equity	256,857
Net Income	172,167
Comprehensive Net Income	172,009
Economic Capital Ratio	407%



PHARMACEUTICAL 2023

Sigilon Therapeutics Inc.
Rank 264 of 446





PHARMACEUTICAL 2023

Sigilon Therapeutics Inc.
Rank 264 of 446




The relative strengths and weaknesses of Sigilon Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sigilon Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 23% points. The greatest weakness of Sigilon Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 35%, being 8.4% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	74,411
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	30,994
Liabilities, Non-Current	17,142
Other Assets	10,013
Other Compr. Net Income	-419
Other Expenses	0
Other Liabilities	0
Other Net Income	105
Other Revenues	12,944
Property and Equipment	2,854
Research and Development	37,631
Selling, General and Administrative Expense	18,979

Output Variable	Value in 1000 USD
Assets	87,278
Liabilities	48,136
Expenses	56,610
Revenues	12,944
Stockholders Equity	39,142
Net Income	-43,561
Comprehensive Net Income	-43,770
Economic Capital Ratio	35%





RealRate

PHARMACEUTICAL 2023

Neoleukin Therapeutics Inc. Rank 150 of 446



The relative strengths and weaknesses of Neoleukin Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neoleukin Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Neoleukin Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 152%, being 109% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	99,134
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,062
Liabilities, Non-Current	10,322
Other Assets	16,814
Other Compr. Net Income	-21
Other Expenses	0
Other Liabilities	233
Other Net Income	1,540
Other Revenues	0
Property and Equipment	0
Research and Development	41,129
Selling, General and Administrative Expense	17,968


Output Variable	Value in 1000 USD
Assets	115,948
Liabilities	21,617
Expenses	59,097
Revenues	0
Stockholders Equity	94,331
Net Income	-57,557
Comprehensive Net Income	-57,568
Economic Capital Ratio	152%



RealRate

PHARMACEUTICAL 2023

Iterum Therapeutics plc
Rank 295 of 446





RealRate

PHARMACEUTICAL 2023

Iterum Therapeutics plc Rank 295 of 446



The relative strengths and weaknesses of Iterum Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Iterum Therapeutics plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Iterum Therapeutics plc is the variable Other Liabilities, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 6.7%, being 36% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	62,444
Cost of Goods Sold	0
Intangible Assets	1,719
Liabilities, Current	9,064
Liabilities, Non-Current	11,398
Other Assets	2,601
Other Compr. Net Income	-350
Other Expenses	301
Other Liabilities	18,372
Other Net Income	-13,750
Other Revenues	0
Property and Equipment	69
Research and Development	17,617
Selling, General and Administrative Expense	12,766

Output Variable	Value in 1000 USD
Assets	66,833
Liabilities	38,834
Expenses	30,684
Revenues	0
Stockholders Equity	27,999
Net Income	-44,434
Comprehensive Net Income	-44,609
Economic Capital Ratio	6.7%



PHARMACEUTICAL 2023

Entrada Therapeutics Inc.
Rank 113 of 446





RealRate

PHARMACEUTICAL 2023

Entrada Therapeutics Inc. Rank 113 of 446



The relative strengths and weaknesses of Entrada Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Entrada Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 60% points. The greatest weakness of Entrada Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 185%, being 142% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	209,875
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,972
Liabilities, Non-Current	17,530
Other Assets	34,500
Other Compr. Net Income	-2,057
Other Expenses	0
Other Liabilities	0
Other Net Income	2,632
Other Revenues	0
Property and Equipment	7,681
Research and Development	66,609
Selling, General and Administrative Expense	30,639


Output Variable	Value in 1000 USD
Assets	252,056
Liabilities	39,502
Expenses	97,248
Revenues	0
Stockholders Equity	212,554
Net Income	-94,616
Comprehensive Net Income	-95,644
Economic Capital Ratio	185%



RealRate

PHARMACEUTICAL 2023

Aptinyx Inc.
Rank 299 of 446





PHARMACEUTICAL 2023

Aptinyx Inc.
Rank 299 of 446



The relative strengths and weaknesses of Aptinyx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aptinyx Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 43% points. The greatest weakness of Aptinyx Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is 2.1%, being 41% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	64,030
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,291
Liabilities, Non-Current	22,108
Other Assets	2,622
Other Compr. Net Income	0
Other Expenses	3,019
Other Liabilities	0
Other Net Income	737
Other Revenues	0
Property and Equipment	32
Research and Development	42,748
Selling, General and Administrative Expense	19,819

Output Variable	Value in 1000 USD
Assets	66,684
Liabilities	28,399
Expenses	65,586
Revenues	0
Stockholders Equity	38,285
Net Income	-64,849
Comprehensive Net Income	-64,849
Economic Capital Ratio	2.1%



PHARMACEUTICAL 2023

Retrieve Medical Holdings Inc.
Rank 404 of 446





PHARMACEUTICAL 2023

Retrieve Medical Holdings Inc.
Rank 404 of 446


The relative strengths and weaknesses of Retrieve Medical Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Retrieve Medical Holdings Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Retrieve Medical Holdings Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 176% points.

The company's Economic Capital Ratio, given in the ranking table, is -269%, being 312% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	225
Liabilities, Non-Current	0
Other Assets	130
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	397
Other Net Income	-1.7
Other Revenues	0
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	163

Output Variable	Value in 1000 USD
Assets	130
Liabilities	622
Expenses	163
Revenues	0
Stockholders Equity	-491
Net Income	-165
Comprehensive Net Income	-165
Economic Capital Ratio	-269%





PHARMACEUTICAL 2023

Petros Pharmaceuticals Inc.
Rank 263 of 446




The relative strengths and weaknesses of Petros Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Petros Pharmaceuticals Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Petros Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is 36%, being 7.0% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	14,668
Cost of Goods Sold	2,289
Intangible Assets	12,244
Liabilities, Current	7,068
Liabilities, Non-Current	263
Other Assets	5,470
Other Compr. Net Income	0
Other Expenses	10,265
Other Liabilities	8,388
Other Net Income	474
Other Revenues	5,992
Property and Equipment	39
Research and Development	1,740
Selling, General and Administrative Expense	12,209

Output Variable	Value in 1000 USD
Assets	32,421
Liabilities	15,719
Expenses	26,504
Revenues	5,992
Stockholders Equity	16,702
Net Income	-20,038
Comprehensive Net Income	-20,038
Economic Capital Ratio	36%





RealRate

PHARMACEUTICAL 2023

Kronos Bio Inc.
Rank 135 of 446




The relative strengths and weaknesses of Kronos Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kronos Bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Kronos Bio Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 166%, being 123% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	244,291
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,486
Liabilities, Non-Current	28,953
Other Assets	37,662
Other Compr. Net Income	-753
Other Expenses	0
Other Liabilities	0
Other Net Income	3,911
Other Revenues	0
Property and Equipment	12,985
Research and Development	93,715
Selling, General and Administrative Expense	43,400

Output Variable	Value in 1000 USD
Assets	294,938
Liabilities	50,439
Expenses	137,115
Revenues	0
Stockholders Equity	244,499
Net Income	-133,204
Comprehensive Net Income	-133,580
Economic Capital Ratio	166%





PHARMACEUTICAL 2023

HUMANIGEN INC Rank 436 of 446




The relative strengths and weaknesses of HUMANIGEN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HUMANIGEN INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 133% points. The greatest weakness of HUMANIGEN INC is the variable Assets, Current, reducing the Economic Capital Ratio by 273% points.

The company's Economic Capital Ratio, given in the ranking table, is -437%, being 480% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	11,105
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	56,194
Liabilities, Non-Current	0
Other Assets	90
Other Compr. Net Income	0
Other Expenses	2,918
Other Liabilities	1,766
Other Net Income	492
Other Revenues	2,514
Property and Equipment	0
Research and Development	55,210
Selling, General and Administrative Expense	15,608

Output Variable	Value in 1000 USD
Assets	11,195
Liabilities	57,960
Expenses	73,736
Revenues	2,514
Stockholders Equity	-46,765
Net Income	-70,730
Comprehensive Net Income	-70,730
Economic Capital Ratio	-437%





The relative strengths and weaknesses of VACCINEX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VACCINEX INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 30% points. The greatest weakness of VACCINEX INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 342% points.

The company's Economic Capital Ratio, given in the ranking table, is -386%, being 430% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	7,478
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,537
Liabilities, Non-Current	247
Other Assets	310
Other Compr. Net Income	-19,815
Other Expenses	2.0
Other Liabilities	0
Other Net Income	93
Other Revenues	275
Property and Equipment	189
Research and Development	13,979
Selling, General and Administrative Expense	6,202

Output Variable	Value in 1000 USD
Assets	7,977
Liabilities	2,784
Expenses	20,183
Revenues	275
Stockholders Equity	5,193
Net Income	-19,815
Comprehensive Net Income	-29,722
Economic Capital Ratio	-386%



PHARMACEUTICAL 2023

BeiGene Ltd.
Rank 174 of 446





RealRate

PHARMACEUTICAL 2023

BeiGene Ltd.
Rank 174 of 446




The relative strengths and weaknesses of BeiGene Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BeiGene Ltd. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 30% points. The greatest weakness of BeiGene Ltd. is the variable Intangible Assets, reducing the Economic Capital Ratio by 8.6% points.

The company's Economic Capital Ratio, given in the ranking table, is 131%, being 88% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	5,207,078
Cost of Goods Sold	286,475
Intangible Assets	40,616
Liabilities, Current	1,468,528
Liabilities, Non-Current	527,407
Other Assets	285,650
Other Compr. Net Income	-95,367
Other Expenses	43,529
Other Liabilities	0
Other Net Income	-171,372
Other Revenues	1,415,921
Property and Equipment	845,946
Research and Development	1,640,508
Selling, General and Administrative Expense	1,277,852

Output Variable	Value in 1000 USD
Assets	6,379,290
Liabilities	1,995,935
Expenses	3,248,364
Revenues	1,415,921
Stockholders Equity	4,383,355
Net Income	-2,003,815
Comprehensive Net Income	-2,051,498
Economic Capital Ratio	131%






The relative strengths and weaknesses of Verona Pharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verona Pharma plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Verona Pharma plc is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 227%, being 184% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	242,996
Cost of Goods Sold	346
Intangible Assets	545
Liabilities, Current	19,029
Liabilities, Non-Current	9,973
Other Assets	15,854
Other Compr. Net Income	0
Other Expenses	253
Other Liabilities	0
Other Net Income	7,302
Other Revenues	458
Property and Equipment	73
Research and Development	49,283
Selling, General and Administrative Expense	26,579

Output Variable	Value in 1000 USD
Assets	259,468
Liabilities	29,002
Expenses	76,461
Revenues	458
Stockholders Equity	230,466
Net Income	-68,701
Comprehensive Net Income	-68,701
Economic Capital Ratio	227%





RealRate

PHARMACEUTICAL 2023

CNBX Pharmaceuticals Inc. Rank 434 of 446




The relative strengths and weaknesses of CNBX Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CNBX Pharmaceuticals Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 80% points. The greatest weakness of CNBX Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 321% points.

The company's Economic Capital Ratio, given in the ranking table, is -422%, being 465% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	198
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,443
Liabilities, Non-Current	0
Other Assets	176
Other Compr. Net Income	-669
Other Expenses	782
Other Liabilities	0
Other Net Income	13
Other Revenues	0
Property and Equipment	437
Research and Development	1,183
Selling, General and Administrative Expense	1,771

Output Variable	Value in 1000 USD
Assets	811
Liabilities	2,443
Expenses	3,736
Revenues	0
Stockholders Equity	-1,632
Net Income	-3,723
Comprehensive Net Income	-4,058
Economic Capital Ratio	-422%





The relative strengths and weaknesses of Intra-Cellular Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intra-Cellular Therapies Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Intra-Cellular Therapies Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 204%, being 161% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	737,957
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	83,236
Liabilities, Non-Current	15,474
Other Assets	14,910
Other Compr. Net Income	-3,826
Other Expenses	20,449
Other Liabilities	0
Other Net Income	7,376
Other Revenues	250,314
Property and Equipment	1,913
Research and Development	134,715
Selling, General and Administrative Expense	358,782


Output Variable	Value in 1000 USD
Assets	754,780
Liabilities	98,710
Expenses	513,946
Revenues	250,314
Stockholders Equity	656,070
Net Income	-256,256
Comprehensive Net Income	-258,169
Economic Capital Ratio	204%



RealRate

PHARMACEUTICAL 2023

Elanco Animal Health Inc
Rank 206 of 446





RealRate

PHARMACEUTICAL 2023

Elanco Animal Health Inc Rank 206 of 446



The relative strengths and weaknesses of Elanco Animal Health Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Elanco Animal Health Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 171% points. The greatest weakness of Elanco Animal Health Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is 104%, being 61% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	3,279,000
Cost of Goods Sold	1,913,000
Intangible Assets	10,835,000
Liabilities, Current	1,702,000
Liabilities, Non-Current	5,677,000
Other Assets	378,000
Other Compr. Net Income	-183,000
Other Expenses	990,000
Other Liabilities	823,000
Other Net Income	0
Other Revenues	4,411,000
Property and Equipment	999,000
Research and Development	321,000
Selling, General and Administrative Expense	1,265,000

Output Variable	Value in 1000 USD
Assets	15,491,000
Liabilities	8,202,000
Expenses	4,489,000
Revenues	4,411,000
Stockholders Equity	7,289,000
Net Income	-78,000
Comprehensive Net Income	-169,500
Economic Capital Ratio	104%



PHARMACEUTICAL 2023

BIORA THERAPEUTICS INC.
Rank 392 of 446





PHARMACEUTICAL 2023

BIORA THERAPEUTICS INC. Rank 392 of 446

The relative strengths and weaknesses of BIORA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIORA THERAPEUTICS INC. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 27% points. The greatest weakness of BIORA THERAPEUTICS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 174% points.

The company's Economic Capital Ratio, given in the ranking table, is -205%, being 248% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	38,116
Cost of Goods Sold	0
Intangible Assets	6,072
Liabilities, Current	23,305
Liabilities, Non-Current	4,696
Other Assets	7,683
Other Compr. Net Income	0
Other Expenses	-10,334
Other Liabilities	127,811
Other Net Income	13,290
Other Revenues	305
Property and Equipment	1,654
Research and Development	24,049
Selling, General and Administrative Expense	38,037

Output Variable	Value in 1000 USD
Assets	53,525
Liabilities	155,812
Expenses	51,752
Revenues	305
Stockholders Equity	-102,287
Net Income	-38,157
Comprehensive Net Income	-38,157
Economic Capital Ratio	-205%



PHARMACEUTICAL 2023

Werewolf Therapeutics Inc.
Rank 144 of 446





PHARMACEUTICAL 2023

Werewolf Therapeutics Inc.
Rank 144 of 446

The relative strengths and weaknesses of Werewolf Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Werewolf Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Werewolf Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 158%, being 115% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	140,200
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	23,989
Liabilities, Non-Current	13,919
Other Assets	11,057
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	18,647
Other Revenues	0
Property and Equipment	8,988
Research and Development	53,761
Selling, General and Administrative Expense	18,696

Output Variable	Value in 1000 USD
Assets	160,245
Liabilities	37,908
Expenses	72,457
Revenues	0
Stockholders Equity	122,337
Net Income	-53,810
Comprehensive Net Income	-53,810
Economic Capital Ratio	158%



PHARMACEUTICAL 2023

SUPERNUS PHARMACEUTICALS INC.
Rank 180 of 446





PHARMACEUTICAL 2023

SUPERNUS PHARMACEUTICALS INC. Rank 180 of 446




The relative strengths and weaknesses of SUPERNUS PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SUPERNUS PHARMACEUTICALS INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 85% points. The greatest weakness of SUPERNUS PHARMACEUTICALS INC. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 126%, being 83% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	734,151
Cost of Goods Sold	0
Intangible Assets	819,482
Liabilities, Current	687,958
Liabilities, Non-Current	44,690
Other Assets	148,875
Other Compr. Net Income	-4,749
Other Expenses	169,373
Other Liabilities	83,656
Other Net Income	14,619
Other Revenues	667,238
Property and Equipment	0
Research and Development	74,552
Selling, General and Administrative Expense	377,221

Output Variable	Value in 1000 USD
Assets	1,702,508
Liabilities	816,304
Expenses	621,146
Revenues	667,238
Stockholders Equity	886,204
Net Income	60,711
Comprehensive Net Income	58,336
Economic Capital Ratio	126%





RealRate

PHARMACEUTICAL 2023

Histogen Inc.
Rank 213 of 446




The relative strengths and weaknesses of Histogen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Histogen Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 53% points. The greatest weakness of Histogen Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 100%, being 57% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	13,456
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,234
Liabilities, Non-Current	4,379
Other Assets	5,181
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	84
Other Net Income	-1.0
Other Revenues	3,769
Property and Equipment	436
Research and Development	5,021
Selling, General and Administrative Expense	9,391

Output Variable	Value in 1000 USD
Assets	19,073
Liabilities	5,697
Expenses	14,412
Revenues	3,769
Stockholders Equity	13,376
Net Income	-10,644
Comprehensive Net Income	-10,644
Economic Capital Ratio	100%





RealRate

PHARMACEUTICAL 2023

Biofrontera Inc. Rank 207 of 446

us.com the alternative.com
PERFECT FOR AMERICAN COMPANIES AND WEBSITES TARGETING THE AMERICAN MARKET


The relative strengths and weaknesses of Biofrontera Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biofrontera Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Biofrontera Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 104%, being 61% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	43,140
Cost of Goods Sold	0
Intangible Assets	3,032
Liabilities, Current	20,894
Liabilities, Non-Current	869
Other Assets	4,508
Other Compr. Net Income	0
Other Expenses	12,150
Other Liabilities	5,243
Other Net Income	17,973
Other Revenues	28,674
Property and Equipment	204
Research and Development	0
Selling, General and Administrative Expense	35,137

Output Variable	Value in 1000 USD
Assets	50,884
Liabilities	27,006
Expenses	47,287
Revenues	28,674
Stockholders Equity	23,878
Net Income	-640
Comprehensive Net Income	-640
Economic Capital Ratio	104%



The relative strengths and weaknesses of Anebulo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anebulo Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 966% points. The greatest weakness of Anebulo Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 237%, being 194% points above the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	381
Liabilities, Non-Current	0
Other Assets	15,579
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	132
Other Net Income	5.6
Other Revenues	0
Property and Equipment	0
Research and Development	2,962
Selling, General and Administrative Expense	3,870

Output Variable	Value in 1000 USD
Assets	15,579
Liabilities	513
Expenses	6,831
Revenues	0
Stockholders Equity	15,067
Net Income	-6,826
Comprehensive Net Income	-6,826
Economic Capital Ratio	237%



PHARMACEUTICAL 2023

Skye Bioscience Inc.
Rank 399 of 446





PHARMACEUTICAL 2023

Skye Bioscience Inc.
Rank 399 of 446

The relative strengths and weaknesses of Skye Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Skye Bioscience Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 8.4% points. The greatest weakness of Skye Bioscience Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is -232%, being 275% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	8,944
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,119
Liabilities, Non-Current	0
Other Assets	80
Other Compr. Net Income	0
Other Expenses	6,212
Other Liabilities	0
Other Net Income	-1,163
Other Revenues	0
Property and Equipment	88
Research and Development	6,012
Selling, General and Administrative Expense	6,095

Output Variable	Value in 1000 USD
Assets	9,111
Liabilities	12,119
Expenses	18,318
Revenues	0
Stockholders Equity	-3,008
Net Income	-19,482
Comprehensive Net Income	-19,482
Economic Capital Ratio	-232%



PHARMACEUTICAL 2023

RespireRx Pharmaceuticals Inc.
Rank 425 of 446





PHARMACEUTICAL 2023

RespireRx Pharmaceuticals Inc.
Rank 425 of 446

The relative strengths and weaknesses of RespireRx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RespireRx Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 204% points. The greatest weakness of RespireRx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 203% points.

The company's Economic Capital Ratio, given in the ranking table, is -378%, being 421% points below the market average of 43%.


Input Variable	Value in 1000 USD
Assets, Current	23
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,729
Liabilities, Non-Current	174
Other Assets	0
Other Compr. Net Income	0
Other Expenses	604
Other Liabilities	0
Other Net Income	80
Other Revenues	0
Property and Equipment	0
Research and Development	430
Selling, General and Administrative Expense	1,150

Output Variable	Value in 1000 USD
Assets	23
Liabilities	11,903
Expenses	2,183
Revenues	0
Stockholders Equity	-11,880
Net Income	-2,103
Comprehensive Net Income	-2,103
Economic Capital Ratio	-378%



PHARMACEUTICAL 2023

Atreca Inc.
Rank 267 of 446





PHARMACEUTICAL 2023

Atreca Inc.
Rank 267 of 446




The relative strengths and weaknesses of Atreca Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Atreca Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Atreca Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is 33%, being 11% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	78,026
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,293
Liabilities, Non-Current	60,331
Other Assets	39,032
Other Compr. Net Income	0
Other Expenses	449
Other Liabilities	0
Other Net Income	817
Other Revenues	770
Property and Equipment	37,972
Research and Development	66,829
Selling, General and Administrative Expense	31,466

Output Variable	Value in 1000 USD
Assets	155,030
Liabilities	76,624
Expenses	98,744
Revenues	770
Stockholders Equity	78,406
Net Income	-97,157
Comprehensive Net Income	-97,157
Economic Capital Ratio	33%



The relative strengths and weaknesses of RAPT Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RAPT Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 87% points. The greatest weakness of RAPT Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 235%, being 192% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	252,694
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,224
Liabilities, Non-Current	6,819
Other Assets	10,976
Other Compr. Net Income	180
Other Expenses	0
Other Liabilities	0
Other Net Income	1,957
Other Revenues	1,527
Property and Equipment	2,539
Research and Development	67,082
Selling, General and Administrative Expense	20,240


Output Variable	Value in 1000 USD
Assets	266,209
Liabilities	21,043
Expenses	87,322
Revenues	1,527
Stockholders Equity	245,166
Net Income	-83,838
Comprehensive Net Income	-83,748
Economic Capital Ratio	235%



RealRate

PHARMACEUTICAL 2023

NightHawk Biosciences Inc. Rank 185 of 446





RealRate

PHARMACEUTICAL 2023

NightHawk Biosciences Inc. Rank 185 of 446



The relative strengths and weaknesses of NightHawk Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NightHawk Biosciences Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 33% points. The greatest weakness of NightHawk Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 119%, being 76% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	50,054
Cost of Goods Sold	6,401
Intangible Assets	11,971
Liabilities, Current	18,037
Liabilities, Non-Current	3,112
Other Assets	21,891
Other Compr. Net Income	547
Other Expenses	-2,210
Other Liabilities	10,811
Other Net Income	-1,462
Other Revenues	6,383
Property and Equipment	20,480
Research and Development	23,461
Selling, General and Administrative Expense	21,131

Output Variable	Value in 1000 USD
Assets	104,397
Liabilities	31,960
Expenses	48,783
Revenues	6,383
Stockholders Equity	72,437
Net Income	-43,862
Comprehensive Net Income	-43,589
Economic Capital Ratio	119%